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Yearly, around 5,000 children between the ages of 1 day and 18 years are admitted to 
one of the eight pediatric intensive care units (PICU) in the Netherlands (1). They form 
a heterogeneous group, and 45-55% present with acute, severe pathology and are 
deemed critically ill. Critically ill children often require pharmacological intervention to 
support organ function, treat underlying diseases or reduce pain and agitation, which 
easily results in polypharmacy. A study from 2001 found that children admitted to our 
PICU on average received 10 different drugs (2).
Drug dose selection in children is often a normalization of the adult dose based on the 
child’s body weight or age group (preterm, term newborns, infants, toddlers, children 
and adolescents). However, this approach does not take account of infants’ develop-
mental changes and physiological differences between adults and children. This may 
lead to unsafe or ineffective dosing in children. To date, pharmacokinetic data from 
studies in children are scarce, and the more so with regard to critically ill children data. 
This is an undesirable situation because particularly in this vulnerable population many 
other factors may influence drug disposition and response. Therefore, we are still a long 
way from evidence-based dosing in critically ill children.
Factors influencing drug disposition and response in critically ill children
The pharmacokinetic properties of a drug include the processes of absorption, distribu-
tion, metabolism and excretion of a drug, while the pharmacodynamic properties com-
prise the physiological and biological responses to the administered drug and therefore 
may represent both efficacy and safety measures. Variability in pharmacokinetic and 
pharmacodynamic processes in critically ill children can be explained by many factors, 
as shown in Figure 1.
Although children differ from each other with regard to age and weight, it is mainly the 
underlying physiological changes that explain this variability in pharmacokinetic and 
pharmacodynamic processes, or: drug disposition and response. First, the maturation 
of drug-metabolizing enzymes leads to age-related changes in clearance of drugs and 
most cytochrome P450 (CYP) enzymes show an enzyme-dependent increase in activity 
after birth (3, 4). Second, genetic differences may also result in different phenotypes, e.g. 
poor and extensive metabolizers. Relevant genetic polymorphisms have been identified 
for CYP2D6, CYP2C9, CYP2C19, CYP3A4 and CYP3A5 (5, 6). Third, the underlying disease 
state and organ failure may alter the pharmacokinetic properties of a drug and its clinical 
effect (7, 8). Hepatic and renal dysfunction are well-known to alter pharmacokinetic and 
pharmacodynamic processes, but also cardiac, respiratory and gastrointestinal dysfunc-
tion affect drug therapy (8). More specifically, animal and limited human adult studies 
suggest a profound effect of the inflammatory response, which occurs in many critically 
ill patients and patients with other inflammatory disease states, on drug metabolizing 
enzymes (9-11).
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Taken together, intrinsic factors only partially explain the pharmacokinetic and pharma-
codynamic variation in critically ill children. Differences in diet, environmental factors 
and concomitant administration of other therapeutic drugs (drug-drug interactions) 
may also contribute to this variation. For example, ketoconazole is a potent inhibitor 
of CYP2C9, CYP2C19 and CYP3A and inhibition of these enzymes leads to a reduced 
drug clearance of drugs metabolized by these enzymes (12). Specifically, in critically ill 
patients, non-drug therapies such as dialysis, cardiopulmonary bypass, extracorporeal 
membrane oxygenation (ECMO) and cooling all potentially contribute to pharmacoki-
netic and pharmacodynamic variation (13). Hence, the disposition and effect of drugs 
in critically ill children is subject to many intrinsic and extrinsic factors, leaving these 
vulnerable patients at high risk of toxicity or therapy failure.
Pharmacokinetics
Drug dose
Clinical effect
Absorption
Metabolism
Active transport
Passive diffusion
Protein binding
Extrinsic factors
Drug-drug interactions 
Medical (mal)practice
Diet
Environment
Patient factors
Age
Weight / body size
Sex
Genetics
Disease
Organ dysfunction
Inflammation
Pharmacodynamics
Receptors
Enzymes
Ion channels
Carrier molecules
Figure 1. The pharmacokinetic-pharmacodynamic relationship in critically ill children
Theoretical framework of factors explaining inter- and intra-individual variability in pharmacokinetics and 
pharmacodynamics in a critically ill child.
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To disentangle the observed inter- and intra-individual variability, it is important to 
study specific factors, preferably in the context of age-related changes, taking a systems 
approach (14). A key element of the systems approach is the distinction between drug-
specific and system-specific parameters in pharmacokinetic models. System-specific 
parameters are parameters describing physiological processes, such as organ perfusion 
and the expression/function of drug-metabolizing enzymes. Knowledge on the changes 
in the system-specific parameters characterizing the absorption, distribution, metabo-
lism and excretion of drugs, is essential for individually tailored drug dosing that takes 
all these covariates into account.
Pharmacokinetics in pediatric critical illness - midazolam as CYP3A probe
The cytochrome P450 (CYP) family is the most abundant enzyme family in the liver 
involved in the metabolism of drugs. CYP3A is the most prominent subfamily in terms 
of proportion of total CYP activity in the liver and number of substrates; it metabolizes 
more than half of all therapeutic drugs (12). Many of the drugs used in children are 
metabolized by this enzyme, such as analgesics (e.g. fentanyl and lidocaine), benzodi-
azepines (e.g. midazolam and diazepam), macrolide antibiotics, antiarrhythmics (e.g. 
verapamil and propanolol), prokinetics (e.g. domperidone) and anticancer drugs (12).
In critically ill children, the maturation of drug-metabolizing enzymes is probably 
the predominant factor accounting for variation in drug clearance (3, 4), followed by 
inflammation and organ failure. Cytokines, released during inflammation, downregulate 
drug-metabolizing enzymes by up to 70% (11). In adults, inflammation-related changes 
in drug disposition have been described for different disease states, such as infection 
and cancer (15, 16). In children with sepsis and organ failure a two- and fourfold lower 
antipyrine clearance, respectively, was found compared to children without sepsis (7). In 
addition, level of IL-6 was negatively correlated with antipyrine clearance, suggesting an 
important role of inflammation. Antipyrine is a global marker for CYP450; it is metabo-
lized by several CYP isoforms, and individual CYPs appear to be differentially regulated 
by inflammation. To better understand the impact of inflammation on individual CYPs, 
and to be able to individualize drug therapy, individual enzymes need to be studied.
Midazolam as probe of CYP3A activity
Midazolam is a short-acting benzodiazepine routinely used in pediatric patients as a 
sedative agent. Midazolam is metabolized by CYP3A4 and CYP3A5 to hydroxylated 
metabolites (1-OH-midazolam, 4-OH-midazolam and 1,4-OH-midazolam), which exhibit 
equivalent pharmacological activity to midazolam (17). These metabolites are excreted 
in the urine as glucuronide conjugates (18). 1-OH-midazolam-glucuronide appears to 
have sedative properties when concentrations are high, as has been observed in adult 
patients with renal failure (17).
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Midazolam is a validated probe for determining CYP3A activity in vivo. It has a low to 
intermediate extraction ratio implying a hepatic clearance predominantly dependent 
on CYP enzymes (19). As CYP3A is responsible for the metabolism of >50% of all clini-
cally used drugs, including several important substrates used in the PICU, the study of 
midazolam pharmacokinetics gives a unique opportunity to study CYP3A metabolism 
in critically ill children.
We therefore hypothesize that studying the pharmacokinetics of midazolam in criti-
cally ill children can provide valuable information on the relation between critical illness 
(inflammation and disease state) and clearance of midazolam as a model for CYP3A 
mediated drug metabolism.
Pharmacodynamics in pediatric critical illness – midazolam as sedative
Like pharmacokinetic data and dosing recommendations, the effect of drugs cannot be 
extrapolated from adults to children. Apart from age-related maturation in the expres-
sion and function of proteins and receptors, children have other diseases and measure-
ment of effect may be different. To illustrate this, many children are unable to express 
pain verbally, but express pain through changes in behavior.
Extrapolation from relatively healthy children to critically ill children is also not feasible, 
as pharmacokinetic processes are different in critical illness, as described above. In addi-
tion, pharmacodynamic processes may be different in critically ill children. For instance, 
a critically ill child who is less reactive due to its underlying illness will respond differ-
ently to a sedative drug from a relatively healthy and probably anxious child who re-
ceives a sedative drug as premedication before an elective procedure. Furthermore, the 
pharmacokinetic-pharmacodynamic relationship can be different in critically ill children. 
It may well be that exposure-response relationship is non-linear and changes in drug-
receptor interactions may occur as a result of illness (20, 21). Therefore, increased drug 
concentrations owing to reduced clearance do not necessarily lead to higher efficacy 
or toxicity as the pharmacodynamic processes can change concomitantly. Regrettably, 
little pharmacodynamic data on drugs administered to critically ill children are available, 
and this is a field that should be urgently explored.
Midazolam for sedation
Critically ill children who are mechanically ventilated often require sedative and/or 
analgesic drugs to diminish anxiety or pain and ensure their comfort. Moreover, a state 
of sedation facilitates synchronization with mechanical ventilation and enables invasive 
procedures to be performed. The sedative of choice in pediatric intensive care is often 
midazolam. It is usually given continuously by the intravenous route. Midazolam is a 
central nervous system depressant that exerts its clinical effect by binding to a receptor 
complex, which facilitates the action of the inhibitory neurotransmitter gamma-amino 
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butyric acid (GABA) in the brain. Through this effect, midazolam possesses sedative, 
anxiolytic, anticonvulsant, muscle relaxant and amnesic properties (22).
Adequate sedation has been described as the level of sedation at which patients are 
asleep but easily arousable (23). In ICU practice this means that a child is conscious, 
breathes in synergy with the ventilator, and is tolerant or compliant with other thera-
peutic procedures. However, the optimal level of sedation varies for each patient, de-
pending on the type of underlying disease, the severity of disease and the application 
of certain therapeutic, invasive procedures.
To achieve the optimal level of sedation in individual patients, doses of sedatives are 
titrated to effect on the guidance of observational sedation scales validated for the 
population in question, e.g. the COMFORT-behavior scale (24). It can be difficult to reach 
optimal sedation, because of variability in plasma drug levels and response. Both un-
der- and oversedation are undesirable, as these conditions may adversely affect patient 
outcomes. Oversedation delays recovery, as greater sedatives consumption is associated 
with longer duration of ventilation as well as extubation failure (25). Oversedation also 
induces tolerance and withdrawal syndrome (26, 27). Undersedation, on the other hand, 
may cause distress and adverse events such as unintentional extubation or displace-
ment of catheters. All this may lead to a longer PICU stay.
Despite the use of sedation algorithms to optimize dosing, oversedation is still com-
mon in the ICU setting. In adults, daily sedation interruption (DSI), has been proposed 
as a method of reducing the adverse effects of continuous sedation infusions, espe-
cially midazolam (28, 29). Clinical trials have shown that DSI can reduce the duration of 
mechanical ventilation, hospital stay and amount of sedatives administered, without 
compromising patient comfort or safety (28, 30). It is not known whether this holds for 
critically ill children as well. Obviously, results from adult DSI studies cannot be extrapo-
lated to children for several reasons. First, adult patients receive other sedative agents, 
such as propofol, which is contra-indicated for the prolonged sedation of children, and 
fentanyl. Second, the elimination half-life of sedatives may differ between adults and 
children. The elimination half-life of midazolam is longer in critically ill children than in 
adults (6.5-12 hours vs. 1.8-6.4 hours) (31). Third, children often cannot fully comprehend 
the situation in which they are when they wake up, and consequently may show more 
distress than adults.
Still, we hypothesize that DSI in addition to protocolized sedation improves clinical 
outcome in critically ill children.
In conclusion, many intrinsic and extrinsic factors seem to contribute to the inter- and 
intra-individual variability seen in the disposition and effect of drugs. With regard to 
critically ill children, both pharmacokinetic and pharmacodynamic data that take into 
account age and underlying disease are scarce.
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Studying the effects of critical illness on CYP3A activity, in the context of age-related 
changes and using midazolam as a surrogate marker, is an important first step to gain 
more knowledge. In addition, studying the effect of midazolam with the use of a more 
tailor-made sedation strategy can help to achieve more rational dosing in this vulnerable 
patient group. Studies of this kind serve as blueprints for an approach that considers 
pharmacotherapy in the critically ill child as a complex system which affects both drug 
disposition and effect.
Aims and outline of this thesis
The aims of this thesis are:
- To study the influence of critical illness (inflammation and disease state) on mid-
azolam pharmacokinetics, as a surrogate measure of CYP3A activity in critically ill 
children.
- To study the safety and efficacy of a new sedation strategy of daily sedation interrup-
tion in critically ill children.
In chapter 2 the current knowledge on the effect of inflammation on CYP450-mediated 
drug metabolism and drug effect in children is reviewed. Chapters 3 and 4 present 
studies on the effect of inflammation and organ dysfunction on midazolam clearance 
in critically ill children. The pilot study in chapter 3 evaluates the effect of inflammation 
and severity of illness on midazolam pharmacokinetics and pharmacodynamics in 21 
critically ill children. The prospective population pharmacokinetic study in chapter 4 
addresses the relationship of inflammation and organ failure, with midazolam clearance 
in critically ill children. This study serves as a model for the impact of inflammation and 
critical illness on CYP3A-mediated drug metabolism.
Chapter 5 deals with the reported incidences of under-, optimal, and oversedation in 
pediatric intensive care patients and the question to what extent the goal of adequate 
sedation is met. Chapter 6 describes the study protocol of a multicenter randomized 
controlled trial to compare the outcomes of daily sedation interruption plus protocolized 
sedation and protocolized sedation only in critically ill children. The results of this trial 
are presented in chapter 7. Chapter 8 concerns children’s short-term health-related 
quality of life following daily sedation interruption.
Lastly, in chapter 9, the main findings and conclusions of this thesis are discussed, and 
recommendations for future research are given.
Chapter 1
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AbsTrACT
Inflammation is associated with downregulation of the expression and activity of cyto-
chrome P450 enzymes (CYP450) involved in hepatic drug metabolism. Elevated plasma 
drug levels and increased toxicity might be the consequences of this downregulation. 
Few clinical studies have investigated these consequences of inflammation in children, 
who are prescribed many off-label or unlicensed drugs. This review describes the impact 
of inflammation on CYP450 drug metabolism and drug effect in children, with the con-
sequent implications for drug studies and clinical therapy in this group.
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INTroDuCTIoN
Pharmacokinetic and pharmacodynamic studies in children are scarce. Knowledge of 
the behavior of drugs in these patients is limited, and is based mainly on information 
derived from studies in adult healthy volunteers and patients. There are important 
differences in pathophysiology and disease spectrum between children and adults, as 
well as developmental changes that might affect the pharmacokinetics and pharmaco-
dynamics of a drug. Therefore, adult data on the disposition and effect of drugs cannot 
generally be extrapolated to children, as reviewed by Kearns et al. (1).
In critically ill children, extrapolation is even more problematic, because drug dispo-
sition and effect might be influenced by a range of other factors. Pediatric intensive 
care patients are frequently exposed to polypharmacy, and more than 70% of drugs 
prescribed are either unlicensed or off-label (2). Both factors could impose an increased 
risk of drug therapy failure or adverse drug reactions on these patients. Critical illness 
is associated with renal failure, hepatic dysfunction and cardiac failure, all leading to 
altered drug clearance (3).
A relatively unrecognized factor that can greatly affect the disposition of drugs is the 
underlying inflammation. Inflammation is common in several disease states in children, 
such as critical illness, autoimmune diseases and cancer. Numerous animal and limited 
human studies have shown that inflammation is associated with the downregulation of 
several drug-metabolizing enzymes, especially the cytochrome P450 (CYP) enzymes, as 
reviewed by several authors (4-8). Given that CYP is the major enzyme system involved 
in drug metabolism, changes in the expression or activity of these enzymes could 
have a significant impact on the clearance and clinical effect of drugs (9). Although 
understanding the effect of inflammation on drug disposition and effect in critically ill 
children and children with other inflammatory disease states could be of considerable 
clinical relevance, data are scarce. The purpose of this review is to summarize the effect 
of inflammation on CYP450-mediated drug metabolism, and drug effect in children with 
inflammatory disease.
hePATIC Drug meTAbolIsm IN ChIlDreN AND The INFlAmmATorY 
resPoNse
The CYP450 enzyme family consists of several subfamilies and these enzymes are the 
most abundant drug-metabolizing enzymes in humans. CYP3A is the most prominent 
subfamily in terms of number of substrates and proportion of total CYP in the liver, 
and it metabolizes more than half of all therapeutic drugs (10). Many of the drugs used 
in children are also metabolized by this enzyme, such as analgesics (e.g. fentanyl and 
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lidocaine), benzodiazepines (e.g. midazolam and diazepam), macrolide antibiotics, anti-
arrhythmics (e.g. nifedipine, verapamil and propanolol), prokinetics (e.g. domperidone 
and cisapride) and anticancer drugs (10).
Changes in CYP activity could have a significant impact on drug metabolism. In children, 
most CYP enzymes show an increase in activity after birth (1). Furthermore, CYP enzyme 
activity might change as a result of the concomitant administration of other drugs, 
genetic polymorphisms and concomitant diseases.
The inflammatory response, which occurs in many diseases, has also been associated 
with decreased CYP enzyme activity. The release of proinflammatory cytokines, es-
pecially interleukins (IL-1, IL-6 and IL-8), tumor necrosis factor (TNF-α) and interferon 
gamma (IFN-γ), induce the production of acute phase proteins by the liver (e.g. fibrino-
gen, α1-acid glycoprotein and C-reactive protein) and decrease the synthesis of normal 
export proteins (e.g. albumin and transferrin). The proinflammatory cytokines involved 
in the acute phase response can also alter drug-metabolizing enzyme capabilities.
The eFFeCT oF INFlAmmATIoN oN Drug meTAbolIsm
Animal studies
The effect of inflammation on CYP expression and activity has been extensively studied 
in animals and has been described in several reviews (4-6, 11, 12). These studies showed 
a downregulation of expression and activity of CYP450 enzymes after the administra-
tion of endotoxins (lipopolysaccharide (LPS)) and cytokines (TNF-α, IL-1, IL-6 and IFN-γ) 
(13). The most affected CYPs belong to the CYP1A, 2A, 2C, 2E and 3A subfamilies. The 
inflammatory response to viruses, bacteria and parasites also negatively alters CYP 
expression and function (11). Similarly, the inflammatory response to infection, injury or 
autoimmune disease negatively impact drug biotransformation in animals (14).
Consequently, the downregulation of CYP activity by inflammation leads to decreased 
drug clearance and elevated plasma drug levels. In LPS-treated rats, a reduced clearance 
is observed for several drugs, such as midazolam, chlorzoxazone, telithromycin and an-
tipyrine (12, 15). In addition, propranolol plasma concentrations are markedly elevated 
in inflammatory conditions in rats (16).
Given that a homology of proteins between human and rat CYP isoenzymes is reported, 
it could be expected that human drug metabolism is also affected by inflammation. 
However, the extrapolation of animal data to humans is hampered by interspecies dif-
ferences in CYP450 enzymes and their regulation (13).
Chapter 2
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In vitro studies in human hepatocytes
In vitro studies with primary cultured human hepatocytes have served as a model for 
the in vivo effects of cytokines on CYP activity (13). Recently, Aitken et al. reported that 
expression of CYP3A4 and CYP2C8 was downregulated by all cytokines studied (IL-1, IL-
6, TNF-α, IFN-γ and transforming growth factor-β (TGF-β)), whereas CYP2C18 expression 
was unaffected. Expression of CYP2C9 and CYP2C19 was affected by IL-6 and TGF-β, but 
not by TNF-α, IFN-γ and IL-1. CYP2B6 expression was only decreased after administration 
of IL-6 and IFN-γ (17). This study confirmed that inflammatory cytokines differentially 
regulate human CYP expression.
In addition to downregulation of expression, it was recently shown that IL-6 also medi-
ates repression of CYP3A4 protein levels and enzymatic activity (18). Given that different 
diseases have different cytokine profiles and time courses, the influence of inflammation 
on human drug metabolism might be disease and drug specific.
The eFFeCT oF INFlAmmATIoN oN humAN PhArmACokINeTICs
Adults
During the past 40 years, several clinical studies in adults have reported alterations in 
drug metabolism and the pharmacokinetics of drugs in the presence of inflammation. 
These studies have been reviewed previously (4-8, 11). Table 1 provides a summary of 
all the clinical studies we identified as looking at the effect of inflammation on drug 
metabolism.
Reduced activity is reported for CYP3A, CYP1A2, CYP2C9, CYP2C19 and, recently, for 
CYP2D6 in patients with an acute infection or inflammatory disease. This cytokine-
mediated decrease in drug metabolism can be up to 70%. Therefore, the clinical concern 
is that patients with an inflammatory disease will have an increased exposure to drugs 
because of a decreased clearance, and thereby an increased risk of adverse drug effects. 
Additionally, as inflammation can also affect the expression and activity of important drug 
transporters, the uptake and clearance of drugs can be further affected (19). For instance, 
a recent study in patients with HIV showed that not only overall CYP3A activity, but also 
P-glycoprotein activity was lower in these patients compared with healthy volunteers (20).
Furthermore, other factors that are influenced by inflammation, such as protein binding, 
capillary permeability, cardiac output and liver blood flow, also have the potential to 
influence pharmacokinetics and pharmacodynamics (21). All together, these changes 
could have important consequences in terms of pharmacokinetic and pharmacody-
namic disposition of drugs in adults.
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Critically ill adults
In 1987, it was reported that drug metabolism is altered in critically ill patients. In patients 
with septic shock, a reduced clearance of midazolam was found. This altered clearance 
was due to a reduced capability to form the 1-OH metabolite, but was reversible after 
improvement of the clinical condition (22). The reduced clearance of midazolam could 
Table 1. studies on the effect of inflammation on drug metabolism in adults
Inflammation mechanism CYP 
activity
measurement effect Correlated 
with
refs
healthy subjects
LPS Overall 
CYP
Antipyrine, theophylline 
and hexobarbital
↓ 22-35% TNF-α, IL-6 (54, 55)
CYP2E1 Chlorzoxazone ↔ (56)
IL-10 CYP3A Midazolam ↓ 12% IL-10 (57)
CYP2C9 Tolbutamide ↔ 
CYP1A2 Caffeine ↔ 
CYP2D6 Dextromethorphan ↔ 
Influenza vaccination CYP3A4 Erythromycin breath test ↓ 4% IFN-γ (58)
Inflammatory diseases
Elective surgery CYP3A4 Erythromycin breath test ↓ 20-60% IL-6 (59)
Allogeneic bone marrow 
transplantation
CYP3A4 Cyclosporine ↓ IL-6, CRP (60)
HIV CYP3A
CYP2D6
Midazolam
Dextromethorphan
↓ 18%
↓ 90%
TNF-α (61)
CYP3A
CYP2D6
Midazolam
Dextromethorphan
↓ 50%
↔
NA (20)
Hepatitis C with Helicobacter 
pylori infection
CYP3A4 Lidocaine (MEGX test) ↓ 60-70% NA (62)
Rheumatoid arthritis CYP3A4 
and 
CYP1A2
Verapamil ↓ IL-6 (63)
Infection in schizophrenia patients CYP1A2 Clozapine ↓ NA (64)
Congestive heart failure CYP1A2
CYP2C9
CYP2E1
Caffeine
Mephenytoin
Chlorzoxazone
↓
↓
↔
IL-6, TNF-α (65)
Cancer
Cancer with acute phase response CYP3A Erythromycin breath test ↓ 30% CRP, IL-6 (66)
Advanced solid tumors CYP3A Erythromycin breath test ↓ α1-acid 
glycoprotein
(67)
Advanced cancer CYP3A Midazolam ↓ Ferritin (68)
CYP2C19 Omeprazole ↓ NA (69)
CYP2C19 Omeprazole ↓ - (70)
Cancer CYP2C9 Tolbutamide ↔ - (71)
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be the result of reduced liver perfusion, as suggested by the authors but, given that 
midazolam is a medium-clearance drug, it is likely that reduced CYP3A activity is also a 
factor of influence.
During the past few years, additional studies have suggested a reduced CYP activity in 
critically ill patients with sepsis. The clearance of theophylline (CYP1A2) is reduced in pa-
tients with sepsis and multiple organ failure (23). The formation of MEGX from lidocaine, 
formed by CYP3A4, is decreased in patients with sepsis and this was not influenced by 
acute changes in hepatosplanchnic blood flow after dopamine infusion (24). In addition, 
plasma levels of atorvastatin, metabolized by CYP3A4, are high in patients with sepsis 
(25). It is likely that cytokines have an important role in the suppression of CYP activity 
in these patients. This is further supported by the results of Novotny et al., who found 
a significant decrease in overall CYP450 activity, measured by the aminopyrine breath 
test, in patients with sepsis and this reduction was inversely correlated with TNF-α 
serum levels (26). In addition, mephenytoin and chlorzoxazone (CYP2C19 and CYP2E1, 
respectively) metabolism was depressed in severely injured patients, who also display 
an intense inflammatory response (27).
Children
In children, studies on the effect of inflammation on the pharmacokinetics of drugs 
are scarce. In 1978, a reduced clearance of theophylline was described in asthmatic 
children suffering from a viral upper respiratory tract infection caused by influenza A or 
adenovirus (28). Yamaguchi et al. showed that children who have raised serum concen-
trations of C-reactive protein (>0.5 mg/dl) and fever (>37.5 °C) had a reduced clearance 
of theophylline. Although cytokines were not determined in this study, this suggests 
that the in vivo activity of CYP1A2 was suppressed by cytokines released in the process 
of acute illness (29).
Critically ill children
To the best of our best knowledge, only two studies have specifically looked at the ef-
fect of inflammation on drug metabolism in children with an inflammatory response. In 
critically ill children, one study focused on CYP activity in the presence of critical illness 
and inflammation. Antipyrine metabolism, as global marker of CYP activity, was studied 
in 51 children with sepsis and six critically ill children without sepsis. Children with 
sepsis had a two-time reduction in antipyrine clearance compared with controls (0.38 
± 0.28 vs. 0.74 ± 0.31 ml/kg/min, p<0.05) and children with multiple organ failure had a 
four-time reduction in clearance compared with controls (0.22 ± 0.15 vs. 0.74 ± 0.31 ml/
kg/min, p<0.05). The clearance of antipyrine was inversely correlated to circulating IL-6 
concentration and to the number of failing organs (30). Recently, the pharmacokinet-
ics of intravenous pantoprazole in pediatric intensive care patients was described. The 
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authors showed that the systemic inflammatory response was a significant covariate 
affecting the clearance of pantoprazole, a CYP2C19 and a CYP3A4 probe. The presence 
of the systemic inflammatory response in these children was associated with a 62.3% 
decrease in pantoprazole clearance (31). Both studies illustrate the potentially dramatic 
effects of inflammation on drug metabolism in critically ill children.
suPPorTINg eVIDeNCe From PhArmACokINeTIC sTuDIes IN ChIlDreN
As presented above, only a few studies have specifically looked at the effect of inflam-
mation on drug metabolism in children. Additional information can be inferred from 
individual pharmacokinetic and pharmacodynamic studies, comparing (relatively) 
healthy children with those with inflammatory disease.
midazolam
Midazolam is one of the most widely used drugs in pediatric intensive care for sedation. 
It undergoes extensive metabolism by the CYP3A subfamily to form a major hydroxyl-
ated metabolite (1-OH midazolam) and is an acknowledged in vivo CYP3A probe.
In children, the pharmacokinetics of midazolam has been described in several stud-
ies (Table 2). Looking at these studies, there are remarkable differences in midazolam 
clearances between the different populations. In critically ill neonates, the clearance of 
midazolam appears to be low (1.2-2.0 ml/kg/min), presumably as a result of immature 
CYP3A4/5 enzyme activity (32-35). In relatively healthy non-ventilated children, aged 
3 months to 17 years, midazolam clearance is higher and ranges from 10 to 16 ml/kg/
min (36-42). By contrast, in critically ill ventilated children, aged 2 days to 17 years, the 
reported clearance of midazolam appears to be lower than in non-ventilated children 
(2.3 to 9.1 ml/kg/min) (43-46). The overall average clearance, from the studies reported, 
is approximately 12 ml/kg/min in healthy children and approximately 7 ml/kg/min in 
critically ill children. Hence, the clearance of midazolam appears to be considerably 
lower in critically ill children compared with healthy children of the same age.
Children in the reported studies had diagnoses associated with inflammation (post-
cardiac surgery, airway infections and systemic infections). It is therefore reasonable to 
postulate inflammation as a factor contributing to the decreased midazolam clearance 
in critically ill children. This observation is supported by a study in critically ill children 
undergoing cardiac surgery. The authors showed a tendency to a reduced clearance in 
children who had undergone cardiopulmonary bypass compared with children with 
cardiac surgery without cardiopulmonary bypass (44). Given that cardiopulmonary 
bypass triggers an inflammatory response (47), it supports inflammation as a covariate 
in midazolam clearance in children.
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Unfortunately, although a logical next step, none of these studies evaluated the phar-
macodynamic consequences of the altered midazolam clearance in critically ill children 
compared with healthy children.
omeprazole
Omeprazole, an acid pump inhibitor, is frequently used to treat gastroesophageal reflux 
in children and infants. Omeprazole is primarily metabolized in humans by CYP2C19 
and, to a minor extent, by CYP3A.
In children, only a few data are available on the clearance of omeprazole (Table 3). Two 
studies have examined the pharmacokinetic parameters of intravenous omeprazole. 
Faure et al. found a median omeprazole clearance of 0.53 L/kg/h in children requiring 
intravenous omeprazole for esophagitis or an ulcer (48). Jacqz-Agrain et al. studied the 
pharmacokinetics of omeprazole in a heterogeneous group of children who needed 
omeprazole for an acute gastrointestinal disease. They found a median omeprazole 
clearance of 0.23 L/kg/h (49). In this study, systemic clearance was variable between 
individuals. When looking at the individual clearances, the lowest clearances were 
reported for patients with a disease that is most likely to be accompanied by an inflam-
matory response (e.g. Crohn’s disease, leukemia, renal and liver transplantation). Inflam-
mation could therefore also have a role in the reduced clearance. However, with only 
two studies available, one can only speculate on the role of inflammation as a reason for 
the observed difference in omeprazole clearance. If omeprazole clearance is reduced in 
critically ill children, it would be expected that low doses are needed to reach adequate 
acid-suppression. By contrast, in a large proportion of critically ill pediatric patients, acid 
suppression was inadequate with ‘therapeutic’ doses of oral omeprazole (up to 1.6 mg/
kg/d). An important limitation of this study is the lack of omeprazol plasma concentra-
tions to link exposure with (lack of ) effect (50).
Antipyrine
Antipyrine has served as a good probe drug for overall CYP activity. Antipyrine clearance 
is a useful method for evaluating drug-metabolizing capacity. In children, a few studies 
using antipyrine as a probe have been performed (Table 3). Average antipyrine clear-
ance reported in these studies was 0.9 ml/kg/min.
Interestingly, Relling et al. have demonstrated that there is an improvement in antipyrine 
clearance in children with acute lymphocytic leukemia (ALL) from before to after remis-
sion (0.65 to 0.95 ml/kg/min, p=0.007) (51). The authors hypothesize that eradication of 
hepatic leukemic infiltration by ALL remission therapy resulted in an improvement in 
the microsomal metabolism of antipyrine. Interestingly, α1-acid glycoprotein concen-
trations significantly decreased after induction therapy (211 vs. 128 mg/dl, p<0.0001). 
Given that α1-acid glycoprotein is an acute phase protein, this indicates that an inflam-
34
matory response is present in patients with ALL. This is also reported by other authors 
(52). This observation suggests a relationship between inflammation and reduced drug 
metabolism in children with cancer, as also reported in adult cancer patients (4). We 
speculate that, after therapy, when the inflammatory response diminishes, α1-acid 
glycoprotein concentrations decrease and antipyrine clearance increases.
The eFFeCT oF INFlAmmATIoN oN PhArmACoDYNAmICs
Both clinical and preclinical studies suggest that the inflammatory response alters the 
pharmacokinetics of CYP450-metabolized drugs. Reduced clearance with consequent 
increased drug concentrations might expose the patient to increased effect and toxicity. 
However, data supporting these pharmacodynamic consequences of inflammation-
mediated reduced clearance are currently limited.
For some drugs, it is shown that an increased exposure consequent to inflammation 
leads to increased toxicity (e.g. docetaxel) (4), However, for other drugs, this pharmaco-
kinetic-pharmacodynamic relationship is less clear. Inflammation might also downregu-
late receptors (e.g. cardiovascular receptors), leading to a reduced drug effect despite 
increased plasma drug concentrations as reviewed elsewhere (4, 21).
Table 3. Pharmacokinetic studies of omeprazole and antipyrine in children
Age (mean) Patients n Dose/route Clearance (l/kg/h) (sD) reference
omeprazole
4.5-27 months Children with esophagitis or 
an ulcer
9 Once a day (iv) 0.53 (0.29) (48)
0.3-19 years Heterogeneous group of 
children with an acute 
gastrointestinal disease
13 Twice a day (iv) 0.23 (0.32) (49)
Antipyrine
2-16 years
(5.3 years)
Children with acute 
lymphocytic leukemia before 
and after remission-induction 
therapy
14 Single dose (iv) Before remission: 0.65 
(0.30)
After remission: 0.95 
(0.29)
(51)
2.3-17.8 years
(7.8 years)
Children with acute 
lymphocytic leukemia in 
complete remission
50 Single dose (iv) 0.91 (72)
14.6-20.2 years 
(cystic fibrosis)
Patients with cystic fibrosis 
and patients with cancer 
treated only with surgery and 
radiation
14 Single dose (iv) 0.9 (0.1) (73)
7.2-19.4 years 
(cancer)
12 0.7 (0.09)
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Little is known about the clinical implications of these changes in the exposure-response 
relationship during inflammation. Clinical studies are lacking, and data from children relat-
ing to the pharmacokinetic-pharmacodynamic relationship in inflammation are absent.
INFlAmmATIoN AND The ImPACT oN Drug DeVeloPmeNT AND TherAPY
In vitro and in vivo adult studies have so far shown that CYP enzymes, which catalyze 
the metabolism of most drugs currently in use, are differentially downregulated by 
proinflammatory cytokines. By contrast, consequent high drug concentrations might 
not necessarily lead to higher efficacy or toxicity, as pharmacodynamics can change 
concomitantly. Preliminary studies described here have demonstrated that the inflam-
matory response in children with inflammatory diseases also appears to be associated 
with marked reduced hepatic drug metabolism, although pharmacodynamic data are 
lacking. Therefore, extrapolation of data from healthy adults and children to a pediatric 
population with inflammatory disease cannot be done automatically. The differential 
effect of inflammation on pharmacokinetics and pharmacodynamics could further com-
plicate extrapolation. Increased drug concentrations, owing to reduced clearance, could 
result in toxic levels (Figure 1b), but could also result in therapeutic, subtherapeutic or 
toxic levels owing to changed pharmacodynamics (Figure 1c-e).
Consequently, the design of pharmacokinetic and pharmacodynamic studies and, 
ultimately, of dose regimens for CYP-metabolized drugs must capture inflammation 
as a covariate to ensure adequate characterization of the disposition of drugs and the 
translation of this information into the provision of safe drug therapy for children.
Until the relationship between exposure and response is better characterized, we need 
to dose carefully for safe and effective drug therapy in children. Nevertheless, a standard 
dose decrease in children with inflammatory disease could be considered for drugs that 
are easily titrated to effect (i.e. sedative drugs). Close monitoring of the effect of drugs 
and adequate dose adjustments are needed, also when the inflammatory response 
resolves because it is unclear whether, and in what time period, the activity of drug-
metabolizing enzymes will normalize when inflammation diminishes (21).
FuTure DIreCTIoNs
There are therefore several crucial information gaps with regard to the overall impact of 
inflammation on drug metabolism and drug effect, not only in children but also in adults. 
First, more pharmacokinetic studies are needed to understand how drug disposition is 
regulated in inflammatory diseases. In children, clinical drug studies must be designed, 
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using minimal sample strategies and population pharmacokinetic modeling, to increase 
knowledge on drug disposition in this population (53). Pharmacokinetic studies alone 
will not suffice. It is imperative that the pharmacodynamic consequences of inflam-
mation are also studied. These studies in children will be challenging, as they need 
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Figure 1. Possible pharmacokinetic-pharmacodynamic relationships during inflammatory diseases
The solid black line represents the estimated plasma drug concentration, whereas the dotted lines repre-
sent the effective range of the drug (pharmacodynamic window). (a) Patient without inflammation on a 
stable drug regimen with a therapeutic drug concentration. (b) Patient with acute inflammatory disease 
only affecting pharmacokinetics, resulting in toxic plasma drug concentrations. (c)-(e) Patient with acute 
inflammatory disease affecting both pharmacokinetics and pharmacodynamics, resulting in (c) altered ef-
fect concentration with therapeutic drug concentrations; (d) altered effect concentration with sub-thera-
peutic drug concentrations; and (e) altered effect concentration with toxic drug concentrations. 
Infl.=inflammation; No infl.=no inflammation
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to incorporate not only inflammation as covariate, but also disease- and age-related 
changes. Important age-related changes in pharmacokinetics and pharmacodynamics 
occur during childhood. It is of paramount importance that children over the whole age 
range are studied, as the interplay of developmental changes and inflammation-related 
variation has yet to be determined.
In addition, there is a need to identify the most appropriate way to assess inflammatory 
status in children. During the inflammatory response, multiple cytokines are increased 
and the exact cytokine pattern responsible for the downregulation in CYP activity is 
still not known (5). Given that a correlation between loss of drug clearance and IL-6 is 
described in vitro, in animals and in humans, IL-6 appears to have an important role in 
this loss. Although the time course of changes in IL-6 levels during different diseases in 
humans is poorly known, IL-6 might be a good biomarker to use to assess inflammation. 
Alternatively, measurement of acute-phase proteins, such as C-reactive protein or α1-
acid glycoprotein, or a combination of several markers, could be useful in predicting 
the net effect of inflammation on drug pharmacokinetics (4). If a reliable biomarker of 
inflammation is available, with a time course fast enough to correlate with increase or 
reduction of inflammation, yet slow enough to be measured once daily, this biomarker 
could be measured along with drug concentrations and drug effect to characterize the 
pharmacokinetic-pharmacodynamic relationship in inflammatory diseases (9).
Finally, in addition to well-designed pharmacokinetic-pharmacodynamic studies, in-
dividual cases of increased toxicity, adverse effects or lack of efficacy of drug therapy 
in children with inflammation should be reported in the peer-reviewed literature. 
Given that many pediatric patient groups are small and/or heterogeneous, large well-
controlled studies on the effect of individual drugs are a logistical challenge or even 
impossible. Hence, reporting of individual or combined cases could aid in improving 
understanding of inflammation in relation to pediatric drug therapy.
CoNClusIoN
The inflammatory response downregulates CYP expression and activity and contrib-
utes to pharmacokinetic and probably pharmacodynamic variability in children with 
inflammation. These changes might be of clinical significance for drug studies and drug 
therapy. Investigators and clinicians must consider the impact of inflammation in the 
context of developmental changes on drug disposition and effect in both the design of 
drug studies and the provision of safe therapy to pediatric patients.
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AbsTrACT
objective: To determine the effect of inflammation and disease severity on midazolam 
pharmacokinetics (as surrogate marker of cytochrome 3A activity) and pharmacody-
namics in critically ill children.
Design: Analysis of prospectively collected pharmacokinetic and pharmacodynamic 
data from a midazolam study in critically ill children.
setting: Pediatric intensive care unit of a university hospital.
Patients: Twenty-one critically ill children who needed midazolam for sedation.
Interventions: None.
measurements and main results: We determined the relationship between inflamma-
tion (using C-reactive protein and leucocyte count as surrogate markers) and disease 
severity (Pediatric Logistic Organ Dysfunction and Pediatric Risk of Mortality scores) 
vs. the pharmacokinetics (clearance) and pharmacodynamics (COMFORT score, dose 
requirement) of midazolam. We found a significant negative correlation between 
disease severity and midazolam clearance corrected for body weight (r=-0.49, p=0.02). 
Midazolam clearance was significantly lower in children with multiple organ failure 
(defined as Pediatric Logistic Organ Dysfunction≥10, n=11) compared with children 
without multiple organ failure (Pediatric Logistic Organ Dysfunction<10, n=10) (median 
0.14 (IQR 0.11-0.23) vs. 0.28 (IQR 0.14-0.43) L/kg/h, p=0.035). No other significant correla-
tions were found.
Conclusions: Results from this pilot study suggest that increased disease severity is 
associated with reduced midazolam clearance in critically ill children, most likely as a 
result of reduced cytochrome 3A activity. In contrast, reduced midazolam clearance 
does not seem to result in decreased midazolam dose requirements.
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INTroDuCTIoN
Inflammation greatly contributes to the inter-individual variability in response to drug 
therapy. In that, the acute inflammatory response strongly affects the hepatic cyto-
chrome P450 (CYP450) enzyme system (1). In vitro, animal and limited human studies 
have demonstrated that proinflammatory cytokines, especially interleukin-6 and tumor 
necrosis factor-α, downregulate catalytic activity of CYP enzymes up to 70% (1). This 
may lead to an increase in drug exposure and increased clinical toxicity, especially for 
drugs with a narrow therapeutic window.
Inflammation resulting from infectious diseases, tissue injury, or trauma is quite common 
in critically ill children. Its effect on drug metabolism potentially exposes them to toxicity 
and adverse drug reactions. If we should be able to predict the impact of inflammation 
and disease state on disposition and effect of drugs, we could design more rational drug 
dosing guidelines for this vulnerable patient group. However, pediatric data looking at 
the effect of inflammation and disease severity on systemic exposure (pharmacokinetic) 
and response (pharmacodynamic) are scarce. We identified only one such study. Using 
a nonspecific surrogate marker for drug metabolism, the researchers showed reduced 
drug metabolism in pediatric intensive care patients with sepsis (2).
The aim of the pilot study reported here is to determine the effect of inflammation and 
disease severity on midazolam pharmacokinetics (as a marker of CYP3A activity) and 
pharmacodynamics in critically ill children.
mATerIAls AND meThoDs
This study is an analysis of prospectively collected pharmacokinetic and pharmacody-
namic data from a midazolam study in critically ill children (3). The study was approved 
by the local ethics review board. Subjects were critically ill children admitted to the in-
tensive care unit of the Erasmus MC-Sophia Children’s Hospital who needed midazolam 
for sedation. Midazolam was given as an intravenous bolus (0.1 mg/kg), after which an 
intravenous midazolam infusion was started at a rate of 0.1 mg/kg/h. Subsequently, the 
infusion rate was adjusted in a protocolized way based on predefined COMFORT scale 
cutoff points (3). The COMFORT score is a validated pediatric sedation score and consists 
of six behavioral items and two physiological dimensions of distress scored during a 
2-minutes period of observation. The total COMFORT score is the total of all item scores 
with a maximum score of 40. COMFORT scores between 17 and 26 were considered 
reflective of optimal sedation, COMFORT scores of <17 as oversedation, and scores of 
>26 as distressed, undersedated and in need for further intervention. In all patients, 
blood samples, for midazolam concentrations, were taken once daily, before and after 
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each dose change, and as washout curve after discontinuation of the drug. With these 
midazolam concentration data, a population model was developed using the nonpara-
metric expectation maximization algorithm and MW/Pharm and individual clearances 
were calculated. A detailed description of the study can be found in the original paper 
(3).
As a pharmacokinetic outcome measure, we used midazolam clearance as a surrogate 
marker for CYP3A activity (4). As a pharmacodynamic outcome measure, we used me-
dian midazolam dose (mg/kg/h) as a primary outcome measure, because midazolam 
infusion was adjusted based on the COMFORT score and thus reflects average need for 
sedation. We also used median COMFORT score as a pharmacodynamic endpoint.
In addition, we estimated disease severity using the Pediatric Risk of Mortality score 
(PRISM II) assessed at admission and the Paediatric Logistic Organ Dysfunction score 
(PELOD) assessed daily (5, 6). The PRISM score was developed to predict mortality risk 
and quantifies severity of illness. The PELOD score is an outcome measure of the severity 
of multiple organ dysfunction in pediatric intensive care patients. C-reactive protein 
(CRP) and leukocyte count served as surrogate markers for inflammation. The pharma-
codynamic, disease severity, and inflammatory parameters were all collected during the 
course of the study. The study ended when the full pharmacokinetic washout curve was 
obtained after discontinuation of midazolam.
Data were analyzed with nonparametric tests (Spearman, Mann Whitney U) because 
data were distributed nonlinearly. We used median values of each daily parameter 
(PELOD, CRP, leukocyte count, COMFORT scores), as length of stay and numbers of daily 
measurements differed between patients. Statistical analyses were done using SPSS 
(version 15.0, Chicago, IL).
resulTs
subjects
We included 21 critically ill children ranging in age from 2 days to 17 years. The clinical 
and pharmacokinetic characteristics of the subjects included in the analysis are listed in 
Table 1.
Disease severity/inflammation - pharmacokinetics
We found significant negative relationships between PELOD score and both total 
midazolam clearance and for body weight-corrected clearance (r=-0.44, p=0.045 and 
r=-0.49, p=0.02, respectively) (Figure 1). The relationship between PRISM score and total 
clearance was significant as well (r=-0.50, p=0.02), but that between PRISM score and 
clearance corrected for body weight was not (r=-0.15, p=0.53).
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Table 1. Clinical and pharmacokinetic characteristics (n=21)
Female/male (n) 9/12
PICU admission reason (n)
Congenital heart disease 4
Upper airway infection 4
Pneumonia 2
Postcardiac surgery 2
Pulmonary hypertension 2
Other 7
Median IQR
Age (years) 2.5 0.1-9.0
Weight (kg) 13.0 3.8-24.5
PELOD 10.0 1.0-11.0
PRISM 14 8-20
Length of stay PICU (days) 3 2-5
COMFORT score 18 15-20
Median Range
Total midazolam dose (mg/kg) 2.9 0.40-46.0
Midazolam dose (mg/kg/h) 0.09 0.05-0.27
Mean SD
Clearance (ml/kg/min) 5.0 3.9
PICU=pediatric intensive care unit; IQR=interquartile range; PELOD=Pediatric Logistic Organ Dysfunction; 
PRISM=Pediatric Risk of Mortality
tion of the study can be found in the original
paper (3).
As a pharmacokinetic outcome measure,
we used midazolam clearance as a surrogate
marker for CYP3A activity (4). As a pharmaco-
dynamic outcome measure, we used median
midazolam dose (mg/kg/h) as a primary out-
come measure, because midazolam infusion
was adjusted based on the COMFORT score
and thus reflects average need for sedation. We
also used median COMFORT score as the
pharmacodynamic end point.
In addition, we estimated disease severity
using the Pediatric Risk of Mortality score as-
sessed at admission and the Pediatric Logistic
Organ Dysfunction score (PELOD) assessed daily
(5, 6). The Pediatric Risk of Mortality score was
developed to predict mortality risk and quanti-
fies severity of illness. The PELOD score is an
outcome measure of the severity of multiple
organ dysfunction in pediatric intensive care
unit patients. C-reactive protein (CRP) and leu-
kocyte count served as surrogate markers for
inflammation. The pharmacodynamic, disease
severity, and inflammatory parameters were all
collected during the course of the study. The
study ended when the full pharmacokinetic
washout curve was obtained after discontinua-
tion of midazolam.
Data were analyzed with nonparametric
tests (Spearman, Mann-Whitney U) because
data were distributed nonlinearly. We used
median values of each daily parameter
(PELOD, CRP, leukocyte count, COMFORT
scores) as length of stay and numbers of daily
measurements differed between patients. Sta-
tistical analyses were done using SPSS (ver-
sion 15.0, Chicago, IL).
RESULTS
Subjects. We included 21 critically ill
children ranging in age from 2 days to 17
yrs. The clinical and pharmacokinetic
characteristics of the subjects included in
the analysis are listed in Table 1.
Disease Severity/Inflammation–Phar-
macokinetics. We found significant nega-
tive relationships between PELOD score
and both total midazolam clearance and for
body weight-corrected clearance (r 
0.44, p  .045; and r  0.49, p  .02,
respectively) (Fig. 1). The relationship be-
tween Pediatric Risk of Mortality score and
total clearance was significant as well (r 
0.50, p .02), but that between Pediatric
Risk of Mortality score and clearance cor-
rected for body weight was not (r0.15,
p  .53).
Midazolam clearance was significantly
lower in children with multiple organ
failure (defined as PELOD 10, n  11)
compared with children without multiple
organ failure (PELOD 10, n  10) (me-
dian 0.14 [interquartile range, 0.11–0.23]
vs. 0.28 [interquartile range, 0.14–0.43]
L/kg/h, p  .035).
CRP (n  17) or leukocyte count (n 
21) did not correlate with total clearance
or clearance corrected for body weight
(r  0.27, p  .30; and r  0.29, p 
.90, respectively). Because there was no
significant correlation between disease
severity and inflammation, we consider
them as independent parameters.
Disease Severity/Inflammation–Phar-
macodynamics. Relationships between
disease severity (PELOD and Pediatric
Risk of Mortality score) and the mean
administered dose of midazolam (mg/
kg/h) or mean COMFORT score were not
significant and neither were those be-
tween inflammation (CRP, leukocyte
count) and pharmacodynamic parame-
ters (Table 2). There was a small but not
significant correlation between clearance
corrected for body weight and the admin-
istered midazolam dose (mg/kg/h) (r 
0.41, p  .06).
DISCUSSION
This pilot study suggests that severity
of organ failure, as reflected by the
PELOD score, significantly correlates
Figure 1. Correlation between Pediatric Logistic Organ Dysfunction (PELOD) score and midazolam
clearance corrected for body weight (L/kg/h).
Table 1. Clinical and pharmacokinetic
characteristics (n  21)
Female/male, no. 9/12
PICU admission reason, no.
Congenital heart disease 4
Upper airway infection 4
Pneumonia 2
Postcardiac surgery 2
Pulmonary hypertension 2
Other 7
Median IQR
Age, yrs 2.5 0.1–9.0
Weight, kg 13.0 3.8–24.5
PELOD 10.0 1.0–11.0
PRISM 14 8–20
Length of stay PICU, days 3 2–5
COMFORT score 18 15–20
Median Range
Total midazolam dose, mg/kg 2.9 0.40–46.0
Midazolam dose, mg/kg/h 0.09 0.05–0.27
Mean SD
Clearance, mL/kg/min 5.0 3.9
PICU, pediatric intensive care unit; IQR, inter-
quartile range; PELOD, Pediatric Logistic Organ
Dysfunction; PRISM, Pediatric Risk of Mortality.
Table 2. Correlations disease severity/
inflammation–pharmacodynamics
Spearman’s Rho
COMFORT
Score
Administered
Midazolam,
mg/kg/h
r p r p
PELOD 0.04 .87 0.07 .77
PRISM 0.25 .27 0.11 .64
CRP 0.35 .17 0.33 .20
Leukocyte count 0.03 .91 0.35 .12
r  correlation coefficient; PELOD, Pediatric
Logistic Organ Dysfunction; PRISM, Pediatric
Risk of Mortality; CRP, C-reactive protein.
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Figure 1. Correlation between Pediatric logistic organ Dysfunction (PeloD) score and midazolam 
clearance corrected for body weight (l/kg/h)
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Midazolam clearance was significantly lower in children with multiple organ failure 
(defined as PELOD≥10, n=11) compared with children without multiple organ failure 
(PELOD<10, n=10) (median 0.14 (IQR 0.11-0.23) vs. 0.28 (IQR 0.14-0.43) L/kg/h, p=0.035).
CRP (n=17) or leukocyte count (n=21) did not correlate with total clearance or clearance 
corrected for body weight (r=-0.27, p=0.30 and r=-0.29, p=0.90, respectively). Because 
there was no significant correlation between disease severity and inflammation, we 
consider them as independent parameters.
Disease severity/inflammation - pharmacodynamics
Relationships between disease severity (PELOD and PRISM score) and the mean admin-
istered dose of midazolam (mg/kg/h) or mean COMFORT score were not significant and 
neither were those between inflammation (CRP, leukocyte count) and pharmacody-
namic parameters (Table 2). There was a small but not significant correlation between 
clearance corrected for body weight and the administered midazolam dose (mg/kg/h) 
(r=-0.41, p=0.06).
DIsCussIoN
This pilot study suggests that severity of organ failure, as reflected by the PELOD score, 
significantly correlates with midazolam clearance in critically ill children. Children with 
multiple organ failure have a significant reduced clearance compared with children 
without. This is most likely the result of reduced activity of CYP3A. Alternative explana-
tions could be altered protein binding, because midazolam is highly bound to plasma 
proteins or, less likely, reduced blood flow, because midazolam has an intermediate 
extraction ratio (7). However, decreased clearance, with expected higher drug exposure, 
is seemingly unrelated to decreased dose requirements of midazolam as a surrogate 
pharmacodynamic marker in our population.
Table 2. Correlations disease severity/inflammation-pharmacodynamics
Spearman’s Rho
COMFORT score Administered midazolam, mg/kg/h
r p value r p value
PELOD 0.04 0.87 0.07 0.77
PRISM -0.25 0.27 0.11 0.64
CRP -0.35 0.17 0.33 0.20
Leukocyte count -0.03 0.91 -0.35 0.12
r =correlation coefficient; PELOD=Pediatric Logistic Organ Dysfunction; PRISM=Pediatric Risk of Mortality; 
CRP=C-reactive protein
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Our results are supported by the study of Carcillo and colleagues (2). They studied 
antipyrine metabolism as a global marker for CYP450 activity in 51 consecutive children 
with sepsis and six critically ill children without sepsis. There was a twofold lower overall 
estimated CYP450 activity in children with sepsis and a fourfold lower overall estimated 
CYP450 activity in children with multiple organ failure.
A decrease in hepatic CYP450 activity may result in lower clearance of substrate drugs. 
The resulting higher drug exposure may raise drug efficacy and give rise to risk of toxicity. 
However, the therapeutic consequences of increased drug exposure during inflamma-
tory states are mainly unknown (8). The present study suggests that reduced clearance, 
with likely higher midazolam exposure, does not necessarily reduce dose requirements 
in critically ill children. We can only speculate on the reason for this observation. Satura-
tion of midazolam pharmacokinetics, as was observed in adult patients, may explain 
why patients with higher midazolam doses could have lower clearance rates (9).
In addition, a change in the pharmacokinetic-pharmacodynamic relation may occur as 
a result of illness. For example, gamma aminobutyric acid receptors may be downregu-
lated resulting in a reduced sedative effect; hence, sicker patients may need more drugs 
to reach the same sedation level. This speculation is in line with findings from a study 
in adult patients with rheumatoid arthritis. In this population, more severe disease (as 
reflected by increased interleukin-6 levels) was associated with decreased verapamil 
plasma clearance and higher verapamil plasma levels. However, despite higher plasma 
levels, patients with more severe inflammation showed significantly weaker dromotrop-
ic response. This observation may be explained by a direct effect of proinflammatory 
cytokines on the receptor level, resulting in its downregulation (10). This observation 
as well as our own suggest that inflammation may alter drug pharmacokinetics and 
pharmacodynamics differently.
Another reason for reduced clearance without lower dosing requirements may relate 
to one of the limitations of our study. Midazolam infusions were not always tapered 
off as dictated by the sedation protocol. Clinicians sometimes opted for maintaining a 
deeper level of sedation, e.g. in patients with pulmonary and systemic therapy resistant 
hypertension. Hence, one could speculate that sicker patients, with associated lower 
midazolam clearance, may have received higher midazolam doses to reach a relatively 
deeper level of sedation. A second limitation of our study is the small sample size for 
which CRP levels were available (n=17) coupled with the possibility that CRP might not 
be the best biomarker for inflammation in critically ill children. The exact inflammatory 
mediator responsible for the changes in CYP activity is still not known (1). Evidence exists 
that especially interleukin-6 is correlated with downregulation of CYP450; the value of 
CRP in this context is less studied (1). However, hepatic drug metabolism may be down-
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regulated also in viral infections, which are generally not associated with significantly 
increased CRP levels (11, 12). Interleukin-6 may have been a better marker to support 
our hypothesis, but because inflammation was not the primary goal of the initial studies, 
this marker was not available for this study.
CoNClusIoNs
This pilot study suggests that severity of organ failure affects the clearance of midazolam 
in critically ill children, most likely as a result of reduced activity of CYP3A. This is not 
related, however, to decreased dose requirements of midazolam as a surrogate pharma-
codynamic marker. The clinical magnitude of the impact of inflammation and disease 
state on disposition and effect may have therapeutic consequences. A prospective study 
in a larger group of patients, collecting pharmacokinetic and pharmacodynamics data 
in addition to cytokine and CRP levels, is needed to answer the questions raised in this 
pilot study.
Chapter 3
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AbsTrACT
rationale: Various in vitro, animal and limited human adult studies suggest a profound 
inhibitory effect of inflammation and disease on cytochrome P450 3A (CYP3A)-mediated 
drug metabolism. Studies showing this relationship in critically ill patients are lacking, 
while clearance of many CYP3A drug substrates may be decreased, potentially leading 
to toxicity.
objectives: To prospectively study the relationship between inflammation, organ fail-
ure and midazolam clearance, as validated marker of CYP3A mediated drug metabolism, 
in critically ill children.
methods: From 83 critically ill children (median age 5.1 months (range 0.02-202 
months)), midazolam plasma levels (n=523), cytokines (e.g. IL-6, TNF-α), C-reactive 
protein (CRP) and organ dysfunction scores (PRISM II, PIM 2, PELOD), as well as number 
of failing organs were prospectively collected. A population pharmacokinetic model to 
study the impact of inflammation and organ failure on midazolam pharmacokinetics 
was developed using NONMEM 7.3.
main results: In a two-compartmental pharmacokinetic model, body weight was 
the most significant covariate for clearance and volume of distribution. Both CRP and 
organ failure were significantly associated with clearance (p<0.01), explaining both 
inter-individual and inter-occasional variability. In simulations a CRP of 300 mg/L was 
associated with a 65% lower clearance compared to 10 mg/L and three failing organs 
were associated with a 35% lower clearance compared to one failing organ.
Conclusions: Inflammation and organ failure strongly reduce midazolam clearance, a 
surrogate marker of CYP3A-mediated drug metabolism, in critically ill children. Hence, 
critically ill patients receiving CYP3A substrate drugs may be at risk of increased drug 
levels and associated toxicity.
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INTroDuCTIoN
Critically ill patients often require life-saving polypharmacy including cardiotonics, 
antimicrobials and analgo-sedatives. Dependent on the underlying disease state, these 
patients show large variation in drug disposition and response (1). Understanding the 
underlying mechanisms contributing to this variation is of importance to ensure the 
safe and effective use of drugs in this vulnerable population.
Various in vitro, animal and limited human adult studies suggest a profound inhibitory 
effect of inflammation on drug metabolism by cytochrome P450 (CYP) enzymes. Drug-
metabolizing enzymes are downregulated by cytokines released during inflammation 
(2). Inflammation-related changes in drug disposition have been described for disease 
states such as autoimmune disease and cancer (3). In addition, hepatic drug metabolism 
may be affected through a heavy loss of hepatocytes in liver failure or through a still 
unknown mechanism in renal failure (1, 4).
In children with sepsis and organ failure a two- and fourfold lower antipyrine clearance, 
respectively, was found compared to non-septic ICU children. In addition, IL-6 was 
negatively correlated with antipyrine clearance, suggesting inflammation as regulatory 
mechanism (5). Antipyrine is a global marker of CYP450 metabolism, and individual 
CYPs appear differentially regulated by inflammation (6). Individual enzymes need to be 
studied to better understand the substantial impact of drug metabolism on individual 
CYPs and to individualize drug therapy for individual drugs.
The most abundant CYP, CYP3A4/5, is involved in the metabolism of >50% of thera-
peutic drugs, of which many are prescribed daily to critically ill patients. Studies show-
ing the relationship between inflammation and CYP3A mediated drug metabolism in 
critically ill patients are lacking, while clearance of many CYP3A drug substrates may 
be decreased, potentially leading to toxicity. The benzodiazepine midazolam is me-
tabolized by CYP3A4/5 to a major hydroxylated active metabolite (1-OH midazolam), 
and subsequently metabolized to 1-OH-midazolam-glucuronide by UGTs and renally 
excreted (7). The clearance of midazolam to 1-OH-midazolam has been validated as sur-
rogate measure of in vivo CYP3A4/5 activity (8). We therefore hypothesized that inflam-
mation is inversely related to midazolam clearance in critically ill pediatric patients. A 
previous pilot study from our group, in 21 children (not included in this study) supports 
this hypothesis (9). The aim of this study was to prospectively study the relationship 
between inflammation, organ failure and midazolam clearance in critically ill children, 
as a model for CYP3A-mediated drug metabolism. Some of the results of this study have 
been previously reported in the form of an abstract (10).
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meThoDs
subjects and setting
Patients were recruited in the context of a multicenter randomized controlled trial com-
paring daily sedation interruption plus protocolized sedation to protocolized sedation 
alone in critically ill children (11). For this pharmacokinetic study, patients from only two 
of the three participating PICUs in the Netherlands were enrolled: Erasmus MC-Sophia 
Children’s Hospital and Radboud University Nijmegen Medical Center. Approval from 
each institutional review board and written informed consent from parents or legal 
representatives was obtained. Details on this study can be found elsewhere (11). The 
sample size of the original randomized controlled trial (n=200) was calculated from the 
study’s primary outcome, the number of ventilator-free days (11). Of these 200 patients, 
we estimated to include 100 patients for this pharmacokinetic study. With variability in 
sampling and dosing times and 2 samples per subject, study power would be >80% with 
a total population of n=100 to show a 30% difference in clearance with a subpopulation 
of n=20.
Patients were eligible for the study if they were between 0 and 18 years of age, born 
at least at 37 weeks of postconceptual age, required mechanical ventilation with an 
expected duration of at least 48 hours and received sedative drugs. The following 
exclusion criteria were applied: anticipated death or withdrawal of life support within 
48 hours; impossibility of assessing level of sedation due to an underlying neurologic 
condition; neurological, respiratory or cardiac instability that may not tolerate inad-
equate sedation; therapeutic hypothermia after cardiopulmonary resuscitation; difficult 
airway; fixed duration of mechanical ventilation, admission for ECMO; already having 
been ventilated/sedated for >2 days in a transferring PICU. Midazolam was administered 
as an intravenous bolus (100 μg/kg) followed by intravenous infusion at a rate of 100 μg/
kg/h. Sedation was titrated based on COMFORT-B scores. In the sedation interruption 
group sedative infusions were interrupted daily.
measurements
Blood for midazolam concentrations was sampled using an optimized sampling strategy 
for pharmacokinetic (PK) analysis, with 4 samples per day during the first 72 hours and 
1 sample per day thereafter at different time points, for up to one week. Inflammatory 
markers (C-reactive protein (CRP), cytokines (IL-1a, IL-1b, IL-2, IL-4, IL-6, IL-10, TNF-α, 
IFN-γ, MCP-1, MIP1a, MIP1b, RANTES, IL-8, FGF-b, G-CSF, GM-CSF)), liver and kidney 
function were determined once daily, CYP3A4*1G, *22 and CYP3A5*3 single nucleotide 
polymorphisms were also determined. Detailed description of the analytical methods 
can be found in the Supplemental Methods.
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Disease severity was scored using validated organ dysfunction scores: the Pediatric Risk 
of Mortality II (PRISM II) (range 0-100%) (12) and the Paediatric Index of Mortality (PIM 2) 
(range 0-100%) (13) at admission and the Paediatric Logistic Organ Dysfunction (PELOD) 
score daily (range 0-71) (14). Since the PELOD score is a non-uniform ordered discrete 
scale, this score was also used to calculate the number of organs failing. If a patient 
scored the maximum score on an organ subscale (i.e. cardiovascular, renal, respiratory, 
hematological or hepatic), this was scored as organ failure ‘yes’. The total number of 
organ failures was counted for each measurement (ranging from 0-5).
Pharmacokinetic analysis
Midazolam concentration-time data were analysed using non-linear mixed effects 
modelling version 7.3 (ICON, Globomax LLC, Ellicott, MD, USA), complying with the 
latest FDA and EMA guidelines (15, 16). Model development was in four steps: (1) selec-
tion of a structural model, (2) selection of an error model, (3) covariate analysis and (4) 
internal validation of the model. For model selection, we used the objective function 
value to compare models. The objective function of NONMEM is a statistical criterion 
for the goodness-of-fit of the model. It is proportional to the sum of squared differences 
between the observations and values predicted by the model, and is assumed to be Chi-
square distributed. Smaller (or more negative) values represent a better fit. For example, 
when covariates are added to the model, it is expected that the model should provide a 
better fit to the data. This is assessed by the difference in successive objective function 
values between the model with the covariate and without the covariate, and which can 
be tested for statistical significance using a Chi-square table (17).
For the structural and error models, a decrease in objective function value (OFV) of 3.84 
points was considered statistically significant (p<0.05). The optimal model was selected 
using standard methodology for population PK analysis with NONMEM. The details of 
model selection and validation can be found in the Supplemental Methods.
Once the base model was selected, covariates were tested for their influence on 
pharmacokinetic parameters. The continuous covariates evaluated were age, weight, 
CRP, cytokines, PRISM II, PIM 2, PELOD, number of organ failures, creatinine, ALAT and 
albumin. Since the concentration of IL-6 covered a large range, it was log-transformed 
and as such considered as covariate in the model. Categorical covariates included sex, 
diagnosis group, co-administration of CYP3A inhibitors (i.e. clarithromycin, voricon-
azole, fluconazole, erythromycin, haloperidole, metronidazole), study center and CYP3A 
genetic polymorphisms. Potential covariates were evaluated using forward inclusion 
and backward elimination with a level of significance of <0.005 (OFV -7.9 points) and 
<0.001 (OFV -10.8 points), respectively. In addition, inclusion of a covariate in the model 
had to result in a decline in unexplained inter-individual variability or unexplained 
inter-occasion variability before it was included in the final model (18, 19). Additional 
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covariates had to reduce the objective function and unexplained variability further to 
be retained in the model. Next, the model was internally validated as described in the 
Supplement.
Dose simulations
To explore the quantitative impact of relevant covariates on midazolam clearance, 
identified from the population PK analysis, simulations were performed as follows. Us-
ing the currently recommended starting dose in children (a loading dose of 100 μg/
kg and a maintenance dose of 100 μg/kg/h for 48 hours) concentration-time profiles 
were visualized for representative critically ill children with varying body weight, CRP 
concentrations and organ failure.
resulTs
Patients and data
Midazolam concentrations were obtained from 83 children admitted to the intensive 
care unit between October 2009 and August 2014. A total of 523 plasma samples were 
available with a median of 6 (range 1-15) samples per patient. Patients were between 1 
day and 17 years old (median age 5.1 months) and body weight ranged from 2.5 to 63 
kg (median 5.6 kg). See further Table 1.
model development and covariate analysis
A two-compartmental model described the pharmacokinetics of midazolam well. 
Inter-individual variability (IIV) for clearance and volume of distribution of the central 
compartment could be estimated and adding these variability parameters improved 
the model. Then, the inclusion of inter-occasion variability (IOV) for clearance improved 
the model. A combined error model, combining a proportional and additive error, was 
superior over a proportional or additive error model. The inclusion of all these variances 
in the model resulted in lower residual unexplained errors and improved the model 
significantly (ΔOFV -119.6, p<0.01).
Body weight
The covariate analysis showed that body weight was the most significant covariate 
resulting in a 76.5 reduction in objective function (p<0.005). Using body weight as co-
variate, 32.9% and 43.9% of the IIV in clearance and volume, respectively, of the central 
compartment was explained (Table 2). Therefore, body weight was incorporated in the 
model (Figure 1a, b and Figure 2a) and with this pediatric base model other covariates 
were tested to explain more inter-individual and inter-occasion variability.
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Inflammation
The inclusion of the inflammation markers IL-6 and CRP as covariate on clearance result-
ed in a decrease in the objective function by 38.1 and 59.5 points, respectively (Table 2). 
Since IL-6 and CRP concentrations were highly correlated (Pearson, r=0.6, p<0.001), only 
CRP concentrations were included as covariate on clearance. Next to a decrease in OFV, 
incorporating CRP in the model resulted in better goodness-of-fit plots and a decrease 
in the IOV in clearance of 20.4% (Table 2, Figure 1c, d). For higher concentrations of CRP, 
midazolam clearance was lower (Figure 2b). Figure 3a shows that a CRP of 300 mg/L is 
associated with a 65.4% lower clearance than a CRP of 10 mg/L. Incorporation of other 
cytokines (e.g. IL1a, IL1b, IL2, IL4, IL8, IL10 and TNF-α) did neither improve the model 
significantly, nor explained variability in clearance any further.
Organ failure
There was no relation between clearance or volume of distribution and PRISM II or PIM 
2 scores. The PELOD score correlated negatively with clearance. Including the number 
of organ failures as covariate in the pediatric model (Figure 1e, f ) significantly improved 
Table 1. Patient characteristics
Characteristic Total
Number of patients (n) 83
Number of samples (n) 523
Samples/patient* 6 (1 – 15)
Sex (male/female, %) 48/35 (58/42%)
Age (months)* 5.1 (0.02 – 202)
Weight (kg)* 5.6 (2.5 – 63)
Reason admission ICU
Respiratory disorder# 58 (70.0%) 
Cardiac disorder## 5 (6.0%) 
Sepsis 8 (9.6%) 
Cardiac surgery 9 (10.8%) 
Non-cardiac surgery 3 (3.6%) 
CRP (mg/L)* 32 (0.3 – 385)
IL-6 (ng/L)* 25 (0.55 – 43140)
PRISM II (%)* 16.3 (0.8 – 98.4)
Predicted mortality PIM 2 (%)* 5.3 (0.25 – 33.2)
PELOD* 11 (0 – 41)
Number of failing organs* 2 (0 – 5)
* Data are in median (range); PRISM II=Pediatric Risk of Mortality; PIM 2=Pediatric Index of Mortality; 
PELOD=Pediatric Logistic Organ Dysfunction; # viral/bacterial pneumonia, ARDS and asthma; ## congenital 
heart disease and cardiomyopathy
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the model (OFV Δ-34.7 points, Table 2) and resulted in better goodness-of-fit plots. It 
lowered the IIV and IOV with 8.6% and 7.8% respectively. The clearance of midazolam 
decreased with an increasing number of organ failures (Figure 2c). Three failing organs 
was associated with a 34.7% lower clearance compared to one failing organ (Figure 3b).
Other covariates
Significant differences between study centers were not found. Fourteen patients 
received a CYP3A inhibitor; this had no effect on midazolam clearance. CYP3A polymor-
phisms, albumin, creatinine and ALAT concentrations were tested as covariates as well, 
but did neither improve the model nor explained variability in clearance or volume of 
distribution.
Final model
Incorporation of both inflammation and organ failure in the model resulted in a lower 
OFV (Table 2) and better description of the data compared to models including inflam-
mation or organ failure only (goodness-of-fit plots, Suppl. Figure E1). Figure 3c shows 
that clearance is up to 77.4% lower when patients have both increased CRP and an 
increased number of organs failing.
Table 2. results of covariate analysis for the two-compartment pharmacokinetic model of
midazolam
Covariate model relationship of covariate No. of 
structural 
parameters
ΔoFV
- Simple model (without IOV) - 8 +193.7
Body weight Pediatric base model (without 
IOV)
CLi=CL5kg•(WT/5)k1
V1i=V15kg•(WT/5)k3
10 +117.2
Body weight Pediatric base model CLi=CL5kg•(WT/5)k1
V1i=V15kg•(WT/5)k3
11 -
Organ failure Pediatric model with organ 
failure
CLi=CL5kg•(WT/5)k1 with varying CL5kg 
for varying number of organs failing
14 -34.7
IL-6 Pediatric model with 
inflammatory marker*
CLi=CL5kg•(WT/5)k1•(1+l1•(IL-6/3.2)) 12 -38.1
CRP Pediatric model with 
inflammation
CLi = CL5kg • (WT/5)k1 • (CRP/32)k2 12 -59.5
CRP and organ 
failure
Pediatric model with 
inflammation and organ 
failure
CLi = CL5kg • (WT/5)k1 • (CRP/32)k2 with 
varying CL5kg for varying number of 
organs failing
15 -75.3
*IL-6: Interleukin-6 concentrations were log transformed
ΔOFV: Difference in objective function value compared to Pediatric base model
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model evaluation
The final model was evaluated in a bootstrap analysis. Median parameter values as well 
as the 5th and the 95th percentiles were in agreement with the model estimations and 
standard errors (Table 3). Normal distribution of errors was shown in the normalized 
prediction distribution errors (NPDE), with no significant trends in NPDE versus time and 
NPDE versus predictions (Suppl. Figure E2).
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Figure 1. Variability in clearance versus the included covariates before (a,c,e) and after (b,d,f) inclu-
sion of the different covariates
(a, b) Inter-individual variability on clearance versus body weight, before and after inclusion of body weight 
as covariate on clearance. (c, d) Variability on clearance before and after inclusion of CRP concentration as 
covariate on clearance. (e, f) Variability on clearance before and after inclusion of organ failure as covariate 
on clearance. Variability (c, d, e, f ) includes inter-individual variability and inter-occasion variability.
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Dose simulations
Figure 4 shows simulated midazolam concentrations over time in the final PK model for 
patients with a body weight of 3.5, 10 and 60 kg. The simulations accounted for differ-
ent clinical scenarios of increased CRP concentrations, increased organ failures or both 
increased CRP concentrations and organ failures. At a CRP level of 300 mg/L the plasma 
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Figure 2. Post-hoc plots for clearance versus the included covariates body weight (a), inflammation 
marker CrP (b) and organ failure (c)
(a)  Clearance versus body weight. • Individual estimated clearance value for each individual, -- Population 
predicted clearance, predicted with the Pediatric base model (Table 3).
(b)  Clearance versus CRP concentration. • Individual estimated clearance value for each individual at each 
different CRP measurement in the study. Shaded grey colors indicate body weight (kg) with darker grey 
for increasing body weight. -- Population predicted clearance for an individual of 3.5 (light grey), 10 
(intermediate grey) and 60 kg (dark grey), predicted with the model with inflammation (Table 3).
(c)  Boxplot of the individual predicted clearance values for each individual on each day in the study versus 
number of organs failing. Of the 523 plasma samples, 10, 200, 209, 70 and 34 samples were taken from 
patients with 0, 1, 2, 3 and >3 organs failing, respectively.
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midazolam concentration is 2.7 fold higher than at a CRP level of 10 mg/L (Figure 4a-
c). With three organ failures the plasma concentration is 1.5 fold higher than with one 
organ failure (Figure 4d-f ). Plasma concentrations are even higher in patients with both 
increased CRP concentration and higher number of organ failures (Figure 4g-l).
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Figure 3. Post-hoc values for clearance versus body weight
Each point represents the posthoc clearance for an individual at a different time point in the study.
(a)  Different colors reflect varying CRP concentrations while the four lines represent the model predictions 
for CRP concentrations of 10, 32, 100 and 300 mg/L respectively with darker grey lines for increasing 
CRP concentrations.
(b)  Different colors reflect increasing organ failure while the four lines represent the model predictions for 
number of organs failing of 1, 2, 3 and >3 respectively with darker grey lines for increasing number of 
organs failing.
(c)  Different colors of the lines reflect different scenarios as predicted by the model. The light grey line repre-
sents the scenario when the patient has a CRP concentration of 10 mg/L and 1 organ failure (ORGF), the 
intermediate greyline indicates 3 organ failures, the dark grey line indicates a CRP concentration of 300 
mg/L and the black line indicates the scenario where both CRP and the level of organ failure are 300 mg/L 
and 3 respectively.
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Figure 4. simulations of midazolam concentration over time for three typical individuals in the study 
of 3.5, 10 and 60 kg, receiving a continuous infusion of 100 μg/kg/h for 48 hours and a loading dose 
of 100 μg/kg
(a-c) Concentration-time profiles for different CRP concentrations ranging from 10-300 mg/L. (d-f) Concen-
tration-time profiles for different levels of organ failure. (g-i) Concentration-time profiles for the combined 
effect of different CRP concentrations and levels of organ failure (ORGF). The light grey line represents the 
scenario when the patient has a CRP concentration of 10 mg/L and 1 organ failure, the intermediate grey 
line indicates 3 organ failures, the dark grey line indicates CRP concentration of 300 mg/L and the black 
line indicates the scenario where both CRP and the level of organ failure are 300 mg/L and 3, respectively.
Table 3. Parameter estimates of best models 
Parameter Pediatric base 
model
Pediatric model with inflammation and organ failure 
included as covariates
Model fit (CV%) Model fit (CV%) Bootstrap median (5th-95th percentile)
Clearance CLi = CL5kg. (WT/5)k1 CLi = CL5kg . (WT/5)k1 . (CRP/32)k2
with varying CL5kg for different number of organs failing
CL5kg (L/h) 1.11 (8%) ORGF1: 1.29 (14%) ORGF1: 1.29 (1.05-1.70)
ORGF2: 0.96 (13%) ORGF2: 0.96 (0.78-1.25) 
ORGF3: 0.84 (27%) ORGF3: 0.83 (0.54-1.30) 
ORGF>3: 0.68 (25%) ORGF>3: 0.67 (0.43-0.99) 
k1 0.828 (13%) 1.02 (13%) 1.03 (0.79-1.26)
k2 – -0.312 (21%) -0.324 (-0.42- -0.21)
Inter-compartmental clearance
Q (L/h) 1.57 (43%) 1.52 (34%) 1.37 (0.09-3.43)
Volume of distribution V1i = V15kg . (WT/5)k3 V1i = V15kg . (WT/5)k3
V15kg (L) 3.58 (43%) 3.28 (33%) 3.45 (1.79-8.20)
k3 1.32 (19%) 1.34 (17%) 1.30 (0.93-1.74)
V2 (L) 5.35 (21%) 5.44 (16%) 5.13 (0.94-6.71)
Inter-individual variability
ω2 CL 0.381 (25%) 0.345 (21%) 0.350 (0.226-0.513)
ω2 V1 1.14 (59%) 1.19 (50%) 1.07 (0.14-2.06)
Inter-occasion variability
π2 CL 0.344 (24%) 0.197 (24%) 0.175 (0.103-0.265)
residual error
Proportional 0.096 (15%) 0.098 (15%) 0.095 (0.074-0.121)
Additive (μg/L) 0.121 (18%) 0.138 (19%) 0.139 (0.015-0.210)
CL clearance (L/h), with CLi the individual predicted clearance of individual i, CL5kg the population predicted 
clearance for a median subject of 5kg, k1 exponent to relate body weight to clearance, k2 exponent to 
relate CRP concentrations to clearance, Q inter-compartmental clearance (L/h), V1 volume of distribution 
in the central compartment (L), with V1i the individual predicted volume of individual i, V5 kg the population 
predicted volume for a median subject of 5 kg, k3 exponent to relate body weight to volume of distribution, 
V2 volume of distribution in the peripheral compartment, ω2 the variance for the inter-individual variability 
of the parameter mentioned, π2 the variance for the inter-occasion variability of the parameter mentioned, 
WT body weight (kg), CRP C-reactive protein concentrations (mg/L), ORGF number of organs with organ 
failure, with failure defined by a maximum value on the PELOD score for that organ. A bootstrap was per-
formed with 500 times of resampling the dataset.
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DIsCussIoN
This prospective population PK study shows that both inflammation, as reflected by CRP, 
and disease severity, as reflected by the number of organ failures, significantly affect 
midazolam clearance in critically ill children. These data suggest that critically ill patients 
may be at an increased risk of increased drug levels and associated toxicity when receiv-
ing CYP3A substrate drugs.
Our study importantly adds to existing data. In septic critically ill children, antipyrine 
clearance, as global marker of CYP450 metabolism was related to inflammation and se-
verity of organ failure (5). By using midazolam as validated probe of CYP3A activity, our 
data may serve to predict more specifically the impact of inflammation and organ failure 
on CYP3A activity, and thereby the clearance of specific CYP3A substrates. A previous 
study found on average a lower midazolam clearance in 13 critically children than in 
children receiving midazolam for elective procedures (20). From these observations, we 
speculated that inflammation may contribute to decreased CYP activity and consequent 
reduced midazolam clearance.
Also, in a pilot study we showed that organ failure as reflected by PELOD score, but not 
CRP, was related to midazolam clearance (9). Most likely, the lack of correlation with CRP 
was due to the small sample size in this pilot study (n=17). Together, these studies sug-
gest an important effect of inflammation and/or critical illness on CYP3A-mediated drug 
metabolism in children, but did not make clear to what extent inflammation and organ 
failure affect drug metabolism and consequent clearance. Furthermore, these studies 
were restricted by number and range of patients and data. The present study includes a 
much larger cohort of critically ill children, with a heterogeneous diagnosis mix covering 
an extensive variation in age, body weight, degree of inflammation and disease severity.
In this study, we indeed showed a very strong correlation between inflammation and 
organ failure and midazolam clearance within a pediatric ICU population.
To support our hypothesis that inflammation-mediated mechanisms are related to the 
observed lower midazolam clearance, we determined cytokines and CRP. IL-6 is a princi-
pal inhibitor of CYP3A mRNA expression (21). In adult patients after elective surgery and 
bone marrow transplant, and in patients with rheumatoid arthritis and cancer, elevated 
IL-6 levels correlated with reduced CYP3A4 activity (22-25). Furthermore, inhibition of 
IL-6 by the IL-6 inhibitor tocilizumab seemed to reverse this IL-6 mediated CYP3A down-
regulation in adult rheumatoid arthritis patients (26).
Indeed, in line with these studies and as we hypothesized, higher IL-6 levels were related 
to lower midazolam clearance. Moreover, C-reactive protein levels were also negatively 
correlated with midazolam clearance. CRP is an acute phase protein whose production 
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by the liver is triggered by proinflammatory cytokines such as IL-6 (27). This is apparent 
by the strong correlation between the IL-6 and CRP serum levels. As CRP explained more 
of the variability within patients, is clinically easily available and measured frequently, 
CRP was chosen as final parameter in our pharmacokinetic model.
Next to inflammation, the number of organ failures was significantly related to mid-
azolam clearance and adding this covariate further improved the model. As midazolam 
has a low to intermediate hepatic extraction ratio, changes in hepatic clearance are 
predominantly dependent on CYP enzymes, but some impact of liver flow cannot be 
excluded (8, 28). Variation in liver flow in critically ill patients may result from changes in 
cardiac output consequent to cardiac failure and/or mechanical ventilation. Also, kidney 
failure has been associated with decreased hepatic drug metabolism (4). In contrast, in 
our study, creatinine levels, as markers of kidney function, were not significantly associ-
ated with reduced midazolam clearance, while in an adult study midazolam clearance 
was significantly lower in critically ill patients with acute kidney failure (29).
Hence, in addition to inflammation-mediated CYP3A downregulation, organ failure in it-
self may add to a reduction in midazolam clearance. This is supported by the 20% higher 
concentrations in the simulations when organ failure was added to the effect of CRP.
Apart from age and disease, genetic variation in CYP3A4/5 activity may contribute to 
variation in midazolam clearance. We could, however, not identify a significant effect 
of genetic polymorphisms of CYP3A4 and CYP3A5 on midazolam clearance. There was 
a trend but not significant lower clearance in patients with CYP3A4*22, possibly due to 
the low prevalence of this SNP in our cohort. Patients who expressed the CYP3A5*1 al-
lele, i.e. who express functional CYP3A5, did not have a higher midazolam clearance. We 
also could not confirm that functional CYP3A5 compensates for CYP3A4 suppression, 
as previously suggested (29). We did not find an effect of co-administration of CYP3A 
inhibitors on midazolam clearance, most likely due to the low incidence (n=14) and the 
use of weak inhibitors only. Although an increase in IL-6 and CRP has been described in 
children on cardiopulmonary bypass (30), there were no differences in CRP and organ 
failure range between cardiac surgical patients and the whole study population in our 
study.
Some limitations of our study should be acknowledged. First, a controlled study was 
considered not feasible in this ICU setting. Therefore, an even spread of number of 
patients per age group, per inflammation, per organ failure and with different genetic 
polymorphisms was not possible. However, the present study includes a large cohort 
of critically ill children, with a heterogeneous diagnosis mix covering an extensive 
variation in age, body weight, degree of inflammation and disease severity, which is 
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representative of the usual case mix in PICUs around the world. Second, all patients had 
at least one organ failure (the lung) as mechanical ventilation was an inclusion criterion 
of the original study. Only in a few patients we could collect data in the absence of 
organ failure (i.e. after extubation). Third, we did not determine midazolam metabolite 
pharmacokinetics, which could have further supported our hypothesis that CYP3A 
metabolism is reduced in sicker patients. Lastly, our data show an association between 
inflammation and midazolam clearance but a definite causal relationship could not be 
established due to the nature of the study.
Despite these limitations, our results strongly indicate that critically ill patients are at 
an increased risk of drug toxicity or therapy failure due to important inflammation and 
organ failure mediated variation in clearance of CYP3A substrates. As CYP2D6, CYP1A2, 
CYP2C9 and CYP2C19 also appear downregulated in response to inflammation, our 
results may have an even wider impact and warrant further study for these enzymes 
and their substrates (31-34). In daily practice, our results may support more extensive 
therapeutic drug monitoring in patients with unexplained symptoms potentially related 
to drug toxicity. Finally, similar to drug metabolizing enzymes, drug receptors may also 
be subject to changes related to critical illness and in turn alter sensitivity to the drug’s 
effect (24). Hence, further exploration of the pharmacokinetic-pharmacodynamic rela-
tionship in critical illness is recommended.
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suPPlemeNTAl meThoDs
Analytical methods
Midazolam plasma concentrations were measured using liquid chromatography-tandem 
mass spectrometry (LC-MS/MS), validated according to current ICH and FDA guidelines. 
The lower limit of quantification was 5.1 ng/ml.
Serum cytokine levels were determined using a customized Luminex Performance 
Assay (R&D Systems) containing the following analytes: MCP-1, MIP1a, MIP1b, RANTES, 
IL-8, FGF-b, G-CSF, GM-CSF, IFN-γ, IL-1a, IL-1b, IL-2, IL-4, IL-6, IL-10, TNF-α. Samples were 
prepared according to the manufacturer’s instructions, read on a BioPlex200 System, 
and analyzed in BioPlex Manager 6.0 software.
CRP was measured using an immunoturbidimetric assay (Modular analytics <P> Roche 
diagnostics, Mannheim, Germany) and values <5 mg/L were considered normal.
Genomic DNA was isolated from 200 µl EDTA blood or saliva on the MagNA Pure 
Compact System with the use of MagNA Pure Compact Nucleic Acid Isolation Kit I 
(Roche®). The genetic variants CYP3A4*1G (rs2242480), *22 (rs35599367) and CYP3A5*3 
(rs776746) were determined on the 7500 Real-Time PCR System (Applied Biosystems®) 
with the use of Taqman® SNP Genotyping Assay C__26201900_30, C__59013445_10 and 
C__26201809_30 (Applied Biosystems®), respectively.
Analysis of pharmacokinetic data
Population pharmacokinetic (PK) data analysis was performed using first-order con-
ditional estimation with interaction in NONMEM version 7.3 (ICON, Globomax LLC, 
Ellicott, MD, USA) with Pirana 2.9.0 and R version 3.1.1 for visualization of data. Of all 
measurements, 1.3% were below the limit of quantification (BLQ). BLQ observations 
were handled according to the M6 method (35), as other methods did not result in an 
improvement of the model.
model development
Model development was in four steps: (1) selection of a structural model, (2) selection 
of an error model, (3) covariate analysis and (4) internal validation of the model. For the 
structural and error models, a decrease in objective function value (OFV) of 3.84 points 
was considered statistically significant (p<0.05). Visual improvement of the goodness-
of-fit plots (observed vs. individual and population predicted concentration, conditional 
weighted residuals (CWRES) vs. time and CWRES vs. population predicted concentra-
tion) was evaluated. In addition, the confidence interval for the estimated parameters, 
the correlation matrix, η-shrinkage and the condition number (to find ill-conditioning or 
over-parameterization of the model) served to evaluate the models.
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The individual pharmacokinetic parameters (post-hoc values) of the ith subject are 
modeled by use of Eq. 1:
(1)  Pi = Ppop . eηi
where Pi is the individual value of the PK parameters of the ith individual, Ppop the popula-
tion prediction and ηi the inter-individual variability, which is assumed to be a Gaussian 
random variable with a mean zero and variance of ω2 with a log-normal distribution. 
Inter-occasion variability on the different parameters was tested for the subsequent 
days to assess changes in pharmacokinetic parameters between days. This resulted in 
the identification of inter-occasion variability (IOV) on clearance describing the changes 
in clearance within individuals during the study according to Eq. 2:
(2)  CLij = CLpop . eηi +mij
where CLij is the individual parameter estimate at the jth occasion, CLpop the population 
prediction of clearance, ηi the inter-individual variability and mij is a random variable for 
the ith individual at the jth occasion (IOV). Both ηi and mij were assumed to be indepen-
dently normally distributed with a mean of zero and variances ω2 and π2, respectively. 
The IOV represents the variability between different occasions, where every 24 hours 
after the first dose was regarded as a new occasion.
The residual unexplained variability was described with a combined error model (pro-
portional and additive error model) for all data. The observations of the jth observation 
of the ith individual are described according to Eq. 3:
(3)  Yij = Cpred,ij . (1+ ε1) + ε2
where Yij is the observed concentration, Cpred,ij the predicted concentration for the jth ob-
servation in the ith individual and ε1 and ε2 the proportional and additive error samples 
respectively from a distribution with a mean of zero and variance of σ2.
Covariate analysis
Tested covariates included patient characteristics (age, weight, sex, diagnosis group, co-
administration of CYP3A inhibitors, study center, CYP3A polymorphisms), inflammation 
markers (CRP, cytokines) and disease severity (PRISM II, PIM 2, PELOD, number of organ 
failures, creatinine, ALAT and albumin). Individual post-hoc parameters, inter-individual 
variability and conditionally weighted residuals (CWRES) were plotted against the co-
variates to evaluate possible relationships. Continuous covariates were tested in a linear 
or power function (Eqs. 4 and 5):
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where Pi and Covi are the values for the parameter and covariate, respectively, for the 
ith individual, Ppop is the population mean for parameter P and Covmedian is the standard-
ized value of the covariate. In the linear function, the slope is depicted by l. For Eq. 5, k 
represents the scaling factor in the power function. For clearance, also a body weight 
dependent exponent k was tested (36). Since the concentration of IL-6 covered a large 
range, it was log-transformed and as such considered as covariate in the model. Cat-
egorical covariates such as co-administration of CYP3A inhibitors, sex and number of 
organs failing were tested as a fraction for each category or independently estimated 
for the different categories. When a CYP3A inhibitor (i.e. clarithromycin, voriconazole, 
fluconazole, erythromycin, haloperidole, metronidazole) was administered at the same 
day as midazolam, a factor affecting clearance was estimated for that day.
Potential covariates were evaluated using forward inclusion and backward elimination 
with a level of significance of <0.005 (OFV -7.9 points) and <0.001 (OFV -10.8 points), 
respectively. In addition, inclusion of a covariate in the model had to result in a decline in 
unexplained inter-individual variability or unexplained inter-occasion variability before 
it was included in the final model (18, 19). Additional covariates had to reduce the objec-
tive function and unexplained variability further to be retained in the model.
model evaluation
The model was internally validated using bootstrap analysis in Perl-speaks-NONMEM 
(PsN version 4.2.0). Five hundred datasets were resampled from the original datasets 
and refitted to the model. Normalized prediction distribution errors (NPDE) were cal-
culated with the NPDE package in R (37). For this method, the dataset used for model 
development was simulated a thousand times with inclusion of inter-individual and 
inter-occasion variability and residual error.
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Figure e1. goodness-of-fit plots for the final model with inflammation and organ failure included as 
covariates
(a) Log observed plasma concentrations vs. log population predicted concentrations. (b) Log observed 
plasma concentrations vs. log individual predicted concentrations on a log scale. (c) Conditional weighted 
residuals (CWRES) versus log population predictions. (d) CWRES versus time after first dose.
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Figure e2. Normalized prediction distribution error (NPDe) results of the final model with inflamma-
tion and disease severity included as covariate plots
(a) Q-Q plot. (b) Histogram of the NPDE distribution. (c) NPDE versus time after first dose in hours. (d) NPDE 
versus predicted concentrations in μg/L.
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AbsTrACT
Purpose: Sedatives administered to critically ill children should be titrated to effect, 
because both under- and oversedation may have negative effects. We conducted a 
systematic review to examine reported incidences of under-, optimal, and oversedation 
in critically ill children receiving intensive care.
methods: A systematic literature search using predefined criteria was performed in 
PubMed and Embase to identify all articles evaluating level of sedation in PICU patients 
receiving continuous sedation. Two authors independently recorded: study objective, 
study design, sample size, age range, details of study intervention (if applicable), seda-
tives used, length of sedation, sedation scale used, and incidences of optimal, under- 
and oversedation as defined in the studies.
results: Twenty-five studies were included. Two studies evaluated sedation level as 
primary study outcome; the other 23 as secondary outcomes. Together, these studies in-
vestigated 1.163 children; age range 0-18 years. Across studies, children received many 
different sedative agents and sedation level was assessed with 12 different sedation 
scales. Optimal sedation was ascertained in 57.6% of the observations, undersedation in 
10.6% and oversedation in 31.8%.
Conclusions: This study suggests that sedation in the PICU is often suboptimal and 
seldom systematically evaluated. Oversedation is more common than undersedation. As 
oversedation may lead to longer hospitalization, tolerance, and withdrawal, preventing 
oversedation in pediatric intensive care deserves greater attention.
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INTroDuCTIoN
The provision of adequate sedation and analgesia to critically ill children is an important 
aspect of care in the pediatric intensive care unit. Sedatives and analgesics reduce 
anxiety, pain, and agitation, enhance synchronization with mechanical ventilation, and 
enable invasive procedures to be performed. Adequate sedation is defined as the level 
of sedation at which patients are asleep but easily arousable (1). Oversedation delays 
recovery, as greater sedatives consumption is associated with longer duration of ventila-
tion as well as extubation failure (2). Oversedation also induces tolerance and withdrawal 
syndrome (3, 4). Undersedation, on the other hand, may lead to increased distress and 
adverse events such as unintentional extubation or displacement of catheters. All this 
may also lead to a longer ICU stay.
Children are usually sedated through a combination of hypnotics (e.g. midazolam) and 
analgesics (e.g. morphine or fentanyl) (5-7). Regrettably, there is little evidence from 
randomized trials on the efficacy of these drugs for sedation in critically children (8). 
Nevertheless, efforts are being made to improve sedation management, for example 
with the use of sedation algorithms and standardized sedation management (9, 10).
To achieve the optimal level of sedation in individual patients, doses of sedatives are in-
dividually titrated to effect. This process is guided by scores on a variety of observational 
sedation scales (5). The COMFORT score or COMFORT-behavior scale and the Hartwig 
sedation scale are widely used and validated for this setting (11, 12). Other scales used 
are the Ramsay scale (13), Richmond Agitation Sedation Scale (RASS) (14), State Behavior 
Scale (SBS) (15), and the University of Michigan Sedation Scale (UMSS) (16). In addition, 
methods derived from the electro-encephalogram (EEG), such as the Bispectral Index 
(BIS) and middle latency auditory-evoked potential index (AEP), are applied, although 
their use is not validated in young children (17).
The aim of this systematic literature review is to evaluate the reported incidences of 
under-, optimal, and oversedation in pediatric intensive care patients and to determine 
to what extent the goal of adequate sedation is met (18).
meThoDs
search strategy
A systematic literature search was performed in the PubMed and Embase databases 
from inception to July 2012, using the terms sedation, child, intensive care unit, and 
sedation quality/sedation level. We used a comprehensive search strategy to identify 
all published articles evaluating the level of sedation, measured with an observational 
scale, in pediatric intensive care patients. For Embase, appropriate search terms were 
84
applied. Full details of the search strategy are presented in Appendix I. Furthermore, 
reference lists of retrieved articles were searched to identify other relevant papers that 
complied with the inclusion criteria.
selection criteria
We used the following inclusion criteria:
1) Study population of PICU patients (0-18 years) on mechanical ventilation and receiv-
ing continuous sedation.
2) Reporting level of sedation and/or the incidence of under-, over-, and optimal seda-
tion, as defined in the study.
Studies published in any language with an English language abstract were eligible for 
review. Exclusion criteria were:
1) Procedural sedation.
2) Preterm patients.
3) Patients treated with muscle relaxants, which preclude the use of sedation scores.
4) Studies using only the BIS monitor in children aged <1 year, since this method is not 
validated for this patient group (17).
Two authors (NV, EI) independently reviewed titles and abstracts of all retrieved cita-
tions to identify eligible studies. Of all included studies, the full-text articles were again 
reviewed to ensure that they met inclusion criteria. Disagreements between reviewers 
were resolved by consensus.
Data extraction
Two authors (NV, EI) each independently recorded the following data: country of origin, 
study objective, study design, study population, age of patients, sample size, details of 
study intervention (if applicable), sedatives used (drug, dose), length of sedation, seda-
tion scale used, and the incidence of optimal sedation, and under- and oversedation. 
We used the definitions for optimal sedation as used by the researchers in the individual 
studies (as percentage of number of observations, patients or time) to be able to pool 
the data, despite different sedation assessment methods (Table 1).
Quality assessment
Study quality was determined with the “Quality Assessment Tool for Quantitative Stud-
ies” by the McMaster University, School of Nursing (19) as strong, moderate or weak.
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statistical analysis
We analyzed studies separately on study design, sedation scale used and proportion of 
under-, over-, and optimal sedation. Proportion was expressed as percentage of number 
of observations, patients or time (hours). If similar outcome measures were used, the 
results of individual studies were quantitatively pooled to calculate a weighted mean, 
using descriptive statistics. The large heterogeneity in study aims and study designs 
precluded further statistical analysis.
resulTs
study selection
After filtering out duplicate studies, our search yielded 392 potentially relevant articles. 
Of these studies, 348 were excluded on the grounds of information in title and abstract 
(Figure 1). Of the remaining 44 articles, the full-text was retrieved and assessed for eligi-
bility. Nineteen studies were excluded for lack of quantitative data on sedation level or 
incidence of optimal, under-, or oversedation, or for absence of a definition of optimal 
sedation. Details of the remaining 25 studies are presented in Table 1.
study characteristics
One study was a randomized controlled trial (comparing two sedative regimens); 22 
studies were prospective observational studies; and two were retrospective studies on 
a sedative drug. Of all 25 studies, only two determined the level of sedation as primary 
study outcome (20, 21). Fifteen studies investigated one or more sedation scales or 
sedation monitoring systems (such as the BIS) (11, 12, 15, 22-33); six studies investigated 
a sedative drug (34-39); one was a pharmacokinetic-pharmacodynamic study (40); and 
one study described the effect of implementation of a sedation protocol on amount 
of sedatives administered (9). Although assessment of level of sedation was not the 
primary objective in the latter 23 studies, they reported incidences of under-, optimal-, 
and oversedation.
Since sedation practices may differ between countries, we also looked at the country of 
origin. Of the 25 studies, eight were conducted in the United States, 16 in six European 
countries, and one in Brazil.
All studies together investigated a total of 1.163 critically ill children. The most frequently 
used drugs were benzodiazepines (midazolam, in 22 studies) and opioids (morphine, in 
14 studies). Other drugs used were fentanyl, ketamine, clonidine, propofol, barbiturates, 
chloral hydrate, first-generation antihistamines, and dexmedetomidine in different 
combinations.
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Quality assessment
Only two studies had level of sedation as their primary outcome, all other studies varied 
by aim and study design. Therefore, assessment of study quality with the “Quality Assess-
ment Tool for Quantitative Studies” was not possible, and this makes direct comparison 
between the studies diffi  cult.
sedation scales
Across all studies, 12 diff erent observational sedation scores were used, of which four 
were validated for the PICU setting, i.e. the COMFORT score, the COMFORT-B scale, the 
Hartwig sedation scale, and the State Behavior Scale. Most frequently (11/25) used were 
the COMFORT score and COMFORT-behavior scale (COMFORT-B), followed by the Ram-
237 records  
identified through 
PubMed search 
330 records  
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Embase search 
392 records after 
eliminating duplicates  
392 titles / abstracts 
screened 
346 records excluded: 
146 no original studies 
118 no information sedation level 
20 procedural sedation 
19 pain measurement 
10 adult studies 
10 studies only abstract available 
7 no PICU patients/mechanical 
ventilation 
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46 full text articles 
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21 articles excluded after full-text 
review:  
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say score, the State Behavioral Scale, and the Hartwig sedation scale. Six studies (23%) 
used the BIS monitor. In 13 studies two or more sedation scales or monitors were used.
All studies defined optimal sedation in terms of cut-off values (Table 1). The definition 
of optimal sedation differed between studies, even when the same sedation scale was 
used. For example, a COMFORT score between 17 and 26 is thought to indicate adequate 
sedation (20). However, one study applied the 13-23 range to define adequate sedation 
(35). This range was chosen a priori to target a level of sedation that would produce a 
patient who was under analgesics, calm, with minimal risk of self-extubation, but able 
to maintain an appropriate cough reflex and spontaneous respiratory effort to achieve 
ventilator synchrony. Furthermore, different cut-off values for the Ramsay score were 
used: i.e. 2-3 (25); 2-4 (26); and 1-5 (28, 30). Assessment frequency also varied consider-
ably between studies; from once daily to hourly.
level of sedation
Reported incidences of optimal, under-, and oversedation are presented in Table 1.
Studies varied in the way incidence was reported (as a proportion of observations, pa-
tients or hours). Fifteen studies reported the incidence as a proportion of observations, 
as summarized in Figure 2. Optimal sedation was ascertained in 15-93% of observations, 
undersedation in 0-22%, and oversedation in 0-82% of observations. In these 15 studies, 
patients were optimally sedated in 57.6% of the observations, undersedated in 10.6% of 
the observations, and oversedated in 31.8% of the observations.
Two studies reported proportions of patients; in these two studies together, 68.6% of 
patients were oversedated at any time during admission (Figure 3).
The two studies that used both an observational score and the BIS score reported consider-
ably different results (28, 30). The incidence of oversedation measured with the BIS was lower 
than that measured with a validated observational scale (56% vs. 92.9% and 65% vs. 82%).
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Mean
Crain 2002
Twite 2005
Lamas 2009
Hartwig 1991
Playfor 2000
Curley 2006
Berkenbosch 2002
Aneja 2003
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de Wildt 2005
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Ista 2009
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Undersedation
Optimal sedation
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CSS=clinical sedation scale, CF-B=COMFORT behavior scale, CF=COMFORT score, RS=Ramsay, SBS=State Behavior Scale, BIS=Bispectral Index Monitor
Figure 2. Incidence of under-, optimal, and oversedation (% of observations)
CSS=clinical sedation scale; CF-B=COMFORT behavior scale; CF=COMFORT score; RS=Ramsay; SBS=State 
Behavior Scale; BIS=Bispectral Index Monitor
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DIsCussIoN
This review shows that the level of sedation in critically ill children is often suboptimal 
during their ICU stay, at least in ICUs that apply sedation assessment in daily practice. 
Patients are optimally sedated in only 60% of assessments. Under- and oversedation 
occur in 10% and 30% of the assessments, respectively. However, across all studies, there 
is a large variation in incidence of oversedation, i.e. from 0 to 82% of assessments. Most 
studies, however, report incidence in the range of 40 to 65%, which corresponds to that 
reported in adult ICU patients (41-43).
Our results indicate that in critically ill children oversedation is more common than 
undersedation. We suggest several reasons for the relatively high incidence of overseda-
tion. First, there may be a tendency to avoid undersedation at all cost, as this may lead 
to discomfort and potential adverse effects as self-extubation and removal of lines and 
catheters. Since children, especially preverbal infants, cannot clearly communicate their 
well-being and are often bewildered by the ICU setting, nurses and doctors may also 
tend to avoid undersedation. Second, nurses believe that mechanical ventilation is un-
comfortable and stressful, and this perception might lead to higher sedation level than 
necessary (42, 44). Third, sedation protocols are not fully adhered to, so that sedatives 
are not tapered off when possible (45). These tendencies are unwanted, as oversedation 
may be even more detrimental to patients.
Continuous sedation as such is an independent predictor of prolonged mechanical 
ventilation in adults, and consequently leads to longer ICU and hospital stay (46). 
Oversedation, in addition, is also associated with tolerance, withdrawal, and delirium. 
Especially longer duration of use and high drug doses are risk factors for development 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Mean
Triltsch 2005
Amigoni 2012
% of patients
Undersedation
Optimal sedation
Oversedation
CF-B
CF
CF-B=COMFORT behavior scale, CF=COMFORT score
Figure 3. Incidence of under-, optimal, and oversedation (% of patients)
CF-B=COMFORT behavior scale; CF=COMFORT score
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of withdrawal symptoms in children (4). Moreover, longer use of sedatives has been 
associated with symptoms of depression and post-traumatic stress symptoms in adults 
(47). In a study in children, almost one-third of children reported delusional memories, 
and these were the children with the longest duration of administration of opiates/
benzodiazepines and the highest risk of posttraumatic stress (48). The administration 
of sedatives to children may also be associated with adverse neurodevelopmental out-
comes at later age, probably by inducing neuroapoptosis (49-51).
The implementation of sedation algorithms aimed at less sedation has led to shorter 
duration of mechanical ventilation, ICU stay, and hospital stay in adults (52). Also, daily 
sedation interruption significantly improved short- and long term outcomes in adults 
(53). A more recent “no-sedation” protocol is even more promising in this respect (54). All 
evidence indicates that the use of sedative drugs should be reduced. In children, daily 
sedation interruption seems feasible and safe, but effectiveness needs to be demon-
strated in large trials (55).
This review also shows a great variety of assessment instruments used in clinical prac-
tice. No more than four of the 12 observational sedation scores have been validated 
for PICU patients, i.e. the COMFORT score, the COMFORT-B scale, the Hartwig sedation 
scale, and the State Behavior Scale. This is remarkable, as there is consensus that the 
level of sedation should be assessed and documented using a validated sedation as-
sessment scale (5). The reliability of the other scales is questionable. Furthermore, six 
studies used the BIS monitor. There is insufficient evidence, however, to support the use 
of the BIS monitor, or any other neurophysiological sedation scoring technique, such as 
auditory evoked potentials, in children below the age of 6 months (56). The suitability of 
the adult-derived EEG algorithm to assess children’s BIS values is doubted. Furthermore, 
pre-awakening BIS values in children aged <1 year are lower than in older children (57). 
This could explain why in some pediatric studies BIS monitoring resulted in a lower 
incidence of oversedation than did application of the COMFORT score (28, 30).
In all studies the authors defined optimal level of sedation. Remarkably, different studies 
applied different cut-off values of the COMFORT score and Ramsay score (25, 26, 28, 30). 
This variation may be explained by the uncertainty in what constitutes optimal sedation, 
but may also be the result of patient-specific factors. For example, a deeper level of seda-
tion is often aimed for in patients with pulmonary hypertension, traumatic brain injury 
or difficult airway. Playfor et al. (21) used a clinical sedation score based on the response 
to tracheal suction, categorizing the response on a five-point scale. A score of 1 (no 
response to tracheal suction) was considered as the desired level of sedation for children 
with severe head injury; a score of 2 for children receiving a high level of intensive care 
with frequent invasive procedures, and a score of 4 for children prior to extubation.
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In addition, the relatively high incidence of suboptimal sedation shown in this review 
reflects the fact that titrating the correct amount of sedation for each child can be 
complex. There may be several reasons for this. First, PICU populations are quite hetero-
geneous with respect to disease type and severity, age, and neurodevelopmental stage, 
so optimal sedation management may differ widely. Second, pharmacokinetics and 
pharmacodynamics, largely insufficiently studied, may be unpredictable, particularly in 
patients with multiorgan failure (58). Dosing regimens are often based on healthy adult 
volunteers and do not take into account factors such as altered protein binding, distri-
bution, and clearance in critically ill children. Also, sedation requirements may change 
over the course of illness (59).
With the risks of oversedation and the difficulties of reaching adequate sedation in 
mind, a critical appraisal of sedation strategies in critically ill children is needed. Optimal 
sedation could perhaps be achieved with the use of validated sedation scales and stan-
dard sedation protocols and by studying promising interventions such as daily sedation 
interruption. These studies are needed in pediatric intensive care.
CoNClusIoNs
This review shows that optimal sedation for critically ill children remains challenging for 
health professionals. These children are often oversedated and consequently run the 
risk of adverse outcomes. It is high time to find conclusive evidence on optimal sedation 
strategies in the PICU setting.
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APPeNDIx I. seArCh sTrATegY
Pubmed
(child*[tw] OR infan*[tw] OR pediatr*[tw] OR paediatr*[tw])
AND
(intensive car*[tw] OR critical car*[tw] OR critically ill*[tw] OR ICU[tw] OR PICU[tw])
AND
(sedat*[tw] OR midazolam[tw] OR lorazepam[tw] OR diazepam[tw] OR benzodiazepin*[tw] 
OR fentanyl[tw] OR remifentanyl[tw] OR morphine[tw] OR ketamine[tw] OR clonidine[tw] 
OR pentobarbital[tw] OR opioid*[tw] OR propofol[tw])
AND
(sedation qualit*[tw] OR quality of sedation[tw] OR sedation level*[tw] OR level of 
sedation[tw] OR sedation score*[tw] OR sedation scale*[tw] OR sedation assess*[tw] OR 
assessing of sedation[tw] OR sedation protocol*[tw] OR sedation guideline*[tw] OR se-
dation algorithm*[tw] OR assessment tool*[tw] OR conscious sedation/standards[mesh] 
OR conscious sedation/methods[mesh] OR nursing assessment[mesh] OR nursing 
assess*[tw] OR nursing diagn*[tw] OR COMFORT score*[tw] OR COMFORT scale*[tw] OR 
COMFORT behavio*[tw] OR bispectral inde*[tw] OR state Behavior Scale*[tw] OR state 
behaviour scale*[tw] OR pharmacodynamic*[tiab])
embase
(child*:ti,ab,de OR infan*:ti,ab,de OR pediatr*:ti,ab,de OR paediatr*:ti,ab,de) AND (((in-
tensive OR critical*) NEAR/2 (car* OR ill*)):ti,ab,de OR ICU:ti,ab,de OR PICU:ti,ab,de) AND 
(sedat*:ti,ab,de OR midazolam:ti,ab,de OR lorazepam:ti,ab,de OR diazepam:ti,ab,de 
OR benzodiazepin*:ti,ab,de OR fentanyl:ti,ab,de OR remifentanyl:ti,ab,de OR 
morphine:ti,ab,de OR ketamine:ti,ab,de OR clonidine:ti,ab,de OR pentobarbital:ti,ab,de 
OR opioid*:ti,ab,de OR propofol:ti,ab,de) AND ((sedation NEAR/2 (qualit* OR level* OR 
score* OR scale* OR assess* OR protocol* OR guideline* OR algorithm*)):ti,ab,de OR (as-
sess* NEAR/2 tool*):ti,ab,de OR ‘conscious sedation’:de OR ‘nursing assessment’/exp OR 
(nurs* NEAR/2 (assess* OR diagn*)):ti,ab,de OR (COMFORT NEAR/1 (score* OR scale* OR 
behavio*)):ti,ab,de OR (bispectral NEAR/1 inde*):ti,ab,de OR ((‘state Behavior’ OR ‘state 
behaviour’) NEAR/1 scale*):ti,ab,de OR pharmacodynamic*:ti,ab)
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AbsTrACT
background: In adult patients who are critically ill and mechanically ventilated, daily 
interruption of sedation (DSI) is an effective method of improving sedation manage-
ment, resulting in a decrease of the duration of mechanical ventilation, the length of 
stay in the intensive care unit (ICU) and the length of stay in the hospital. It is a safe 
and effective approach and is common practice in adult ICUs. For critically ill children 
it is unknown if DSI is effective and feasible. The aim of this multicenter randomized 
controlled trial is to evaluate the safety and efficacy of daily sedation interruption in 
critically ill children.
methods/Design: Children between 0 and 18 years of age who require mechanical ven-
tilation, with an expected duration of at least 48 hours and need for sedative infusion, 
will be included. After enrollment patients will be randomly assigned to DSI in combina-
tion with protocolized sedation (intervention group) or protocolized continuous seda-
tion (control group). A sedation protocol that contains an algorithm for increasing and 
weaning of sedatives and analgesics will be used. The sedative infusion will be restarted 
if the patient becomes uncomfortable or agitated according to the sedation protocol. 
The primary endpoint is the number of ventilator-free days at 28 days.
Trial registration: NTR2030
Chapter 6
103
bACkgrouND
Critically ill children are often sedated in order to prevent discomfort or anxiety and 
to facilitate care. The sedative drug of choice for the majority of critically ill children 
is midazolam, often given together with analgesics such as morphine or fentanyl (1). 
Doses are individually titrated, based on sedation assessments, to reach the optimal 
level of sedation. Both inadequate and excessive sedation may have deleterious effects. 
Oversedation delays recovery, promotes tolerance and leads to distressing symptoms 
on withdrawal of the drugs (2). Undersedation may result in increased distress and 
increased adverse events, such as unplanned extubation, accidental displacement of 
catheters and fighting the ventilator.
Despite the use of sedation algorithms, excessive sedation is a common problem in 
critically ill children receiving continuous sedation (3). In adults, the administration of 
sedatives by continuous infusion is an independent predictor of a longer duration of 
mechanical ventilation as well as a longer stay in the intensive care unit (ICU) and in the 
hospital overall (4).
In adults, daily sedation interruption (DSI) improves clinical outcome. Every day, 
sedative drug infusions are interrupted and patients are allowed to ‘wake up’ from their 
medicine-induced sleep. During this period, patients are assessed for neurological re-
covery and readiness for extubation, or re-sedated if required (5). In adult intensive care 
patients, DSI resulted in a significant decrease in the duration of mechanical ventilation, 
the length of stay in the ICU and the length of stay in the hospital (6). DSI is also a safe 
approach: self-extubation and removal of catheters did not occur more frequently in 
patients treated with DSI. Follow-up studies showed that DSI reduces the incidence of 
complications associated with mechanical ventilation and reduced symptoms of post-
traumatic stress disorder (7, 8). In the last few years, some studies have confirmed the 
safety and efficacy of DSI (9, 10), while other studies did not find a positive effect of DSI 
on clinical outcome (11,12). Nevertheless, DSI is now routine practice in adult ICUs (5, 
13). An even more drastic approach of no sedative drugs at all has also been shown to 
improve clinical outcome in adult intensive care patients (14).
For critically ill children, it is unknown if DSI is effective, feasible and safe. Data from adult 
ICU studies cannot be automatically extrapolated to children. Important differences in 
the use of sedative drugs between children and adults have been described. In adult 
ICU patients, propofol and remifentanyl are the drugs of choice, besides midazolam, 
morphine or fentanyl. In children, propofol is contraindicated for prolonged (>24 hours) 
sedation because of the risk for propofol infusion syndrome (1). Another important 
difference is that the elimination half-life of many drugs varies between adults and 
children, due to age-related changes in drug metabolism and renal excretion. Also, 
the assessment of the sedative level differs between adults and children. For example, 
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to assess wakefulness adult patients are asked to perform actions on request, such as 
squeeze a hand or stick out their tongue. In most pediatric ICUs (PICUs), 80% of admis-
sions are children <3 years of age. Younger children cannot perform such instructions 
on request and the assessment of their sedation level should include other parameters, 
such as non-verbal communication. Specific instruments, such as the COMFORT scale, 
have been developed and validated for assessing sedation levels in critically ill children 
(15). Finally, since younger children cannot clearly communicate, their behavior is differ-
ent and there might be a greater intolerance of discomfort.
We identified two studies evaluating the feasibility of DSI in children. In a pilot study in 
30 ventilated children DSI was compared with standard care (16). DSI appeared feasible 
and safe (similar rate of unintended extubations and line removals) and reduced the 
amount of sedatives administered. However, this trial was not sufficiently powered 
to detect differences in clinical outcomes. The second study performed by our group 
showed that in 20 neonates on extracorporeal membrane oxygenation (ECMO), mid-
azolam and morphine could be discontinued following cannulation for a median of 10 
hours without adverse events (17).
Recently, a study was published comparing DSI with continuous sedation in children 
on mechanical ventilation (18). This study showed that DSI also improves outcomes in 
pediatric patients. The length of mechanical ventilation and duration of intensive care 
stay were significantly reduced in the interrupted sedation group (10.3 vs. 7.1 days, 
p=0.021 and 14.1 vs. 10.7 days, p=0.002, respectively). There were no differences in ad-
verse events between groups. Given the large differences in patient population and ICU 
practices between this Indian ICU and the Western setting, these results need further 
validation (19). In this Dutch multicenter study, efficacy and safety of daily interruption 
of sedation in critically ill children will be investigated.
meThoDs/DesIgN
In this multicenter randomized controlled trial, we will compare DSI combined with 
protocolized sedation with standard of care (protocolized sedation only). This study is a 
collaborative study between PICUs in The Netherlands.
study population
Patients will be recruited from five tertiary medical-surgical PICUs (Erasmus MC-Sophia 
Children’s Hospital, Radboud University Nijmegen Medical Centre, Academic Medical 
Centre of Amsterdam, Leiden University Medical Centre and University Medical Centre 
Groningen).
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Children between 0 and 18 years of age admitted to the pediatric intensive care unit, 
who require mechanical ventilation, with an expected duration of at least 48 hours, and 
need for sedative drugs can be included.
Inclusion criteria: age between 0 to 18 years, at least 37 weeks of post conceptual age, 
anticipated duration of mechanical ventilation of at least 48 hours, need for sedative/
analgesic drugs.
Exclusion criteria: anticipated death within 48 hours or withdrawal of life support, 
patients in whom level of sedation cannot be scored due to underlying neurologic con-
dition, neurological, respiratory or cardiac instability that may not tolerate inadequate 
sedation (for example, traumatic brain injury, pulmonary hypertension), therapeutic 
hypothermia after cardiopulmonary resuscitation, difficult airway, fixed duration of 
mechanical ventilation, admission for ECMO, admission to our PICU after transfer from 
another PICU where the patient is already ventilated/sedated for >2 days, withdrawal of 
informed consent.
randomization
Within 24 hours after intubation, parental informed consent will be obtained. The morning 
after enrollment, patients will be randomly assigned in a 1:1 ratio to DSI combined with 
protocolized sedation (intervention group) or protocolized sedation alone (control group).
Stratified randomization will be used in combination with random permuted blocks. 
Randomization will be stratified with regards to age in three groups, respectively 0 up 
to 30 days, 30 days up to 2 years, and 2 years up to 18 years. A biostatistician will carry 
out computer randomization in advance. During the study period, the pharmacist will 
have access to group allocation for preparation of study medication, and each assign-
ment is designated on a paper enclosed in a numbered, opaque sealed envelope. After 
informed consent is obtained, the appropriate envelope is placed in a study binder at 
the patient’s bedside.
Intervention
After enrollment, patients will be randomly assigned to one of two strategies: proto-
colized continuous sedation combined with daily interruption of infusion of sedatives 
beginning 24 hours after start of infusion (intervention group) or protocolized continu-
ous sedation alone (control group).
Protocolized sedation / standard of care
All study centers use a standardized sedation protocol that contains an algorithm for 
increasing and weaning of sedatives and analgesics. It standardizes sedation man-
agement and allows nurses to adapt medication based on validated sedation scores 
(COMFORT-behavior scale (COMFORT-b), Nurse Interpretation of Sedation Score (NISS)). 
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The COMFORT-b is an adapted version of a scale that was originally developed by Am-
buel and colleagues in 1992 for the assessment of distress in paediatric patients, except 
for premature neonates and children with neurological diseases and limited motor 
function (20). It consists of six behavioral items: alertness, agitation, crying or in case 
of artificial ventilation breathing reaction, body movements, muscle tone and muscle 
tone in the face. A trained intensive care nurse observes a patient for a 2-minute period, 
during which all items are assessed on a five-point numerical scale (scored 1 to 5). The 
most distressed behavior during the 2-minute period is scored. The total COMFORT-b 
score is the total of all item scores, with a minimal score of 6 and a maximal score of 30. 
The cut-off points for sedation scores were established (21). In all participating PICUs, 
nurses have been trained to use this scale. Interobserver variability was satisfactory, with 
Cohen’s κ >0.65 for all nurses.
Upon admission to the ICU patients are evaluated for the need of sedatives and an-
algesics according to standard medical treatment protocols. In this protocol, initially, 
midazolam is titrated (up to 300 µg/kg/h) according to predefined COMFORT-b scores. 
Adequate sedation is defined as a COMFORT-b score ≥11 and ≤22. A COMFORT-b score 
of <11 implies oversedation, a score >22 undersedation. When sedation is considered 
insufficient, morphine (up to 30 µg/kg/h) is given in addition to midazolam. In cases 
of continuing distress and where sedation is still inadequate, other drugs, such as ket-
amine, clonidine, fentanyl, lorazepam, propofol, and alimemazine are added. When pain 
is also suspected, as defined by a high numeric rating scale score (NRS≥4), additional 
morphine is given. All study centers use this protocol, with only local differences in the 
choice of additional agents to midazolam and morphine (Appendix 1).
Intervention group
After the first 24 hours of mechanical ventilation, the patient is assessed for a safety 
screen every morning at 10.00 AM, after routine care. This safety screen ensures that 
interruption of sedation is safe for the patient. If the patient passes the screen, the 
sedative/analgesic infusions will be discontinued immediately; this can be delayed 
for planned procedures. Analgesics needed for active pain will be continued (for ex-
ample, pleural drain, <24 hours after surgery). A patient passes the screen unless: he/
she receives a sedative infusion for active seizures, receives escalating sedative doses 
due to ongoing agitation, receives neuromuscular blockers, has evidence of increased 
intracranial pressure or if there is cardiorespiratory instability. Patients who fail the test 
will be reassessed after 24 hours (Figure 1).
During interruption, the patient may wake up, and therefore, patients will be monitored 
frequently. Patient comfort will be assessed routinely every 2 hours using the COMFORT-
b/NISS and NRS scores and at any time the patient appears distressed. The COMFORT-b 
score will be used to assess the level of sedation/wakefulness.
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The sedative infusion will be started again: (a) if the patient becomes uncomfortable or 
agitated, according to the sedation protocol; or (b) if deemed necessary by the clinical 
team for instability in cardiorespiratory parameters, defined as the need to increase the 
ventilatory support or cardiovascular treatment (inotropes/fluid bolus), not associated 
with the underlying disorder.
After a loading dose of midazolam (0.1 mg/kg, intravenously), the sedative infusions 
will be restarted at half the previous dose and then titrated according to the sedation 
protocol by the nurse to achieve adequate sedation.
Control group
In the control patients, following the safety screen, a blinded infusion will be started 
at the same rate and dose as the patient was receiving. The level of sedation will be 
assessed in a manner similar to the interruption group. When assessments indicate dis-
tress, the study infusion will be ceased and replaced by the sedative infusion at a similar 
rate as before the interruption.
Figure 1. Flowchart of study design
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Blinding
Complete blinding after randomization was considered unsafe. It would mean blinded 
multiple infusion concentration/rate changes over time, leaving patients prone to drug 
dosing mistakes. However, during interruption, all patients will receive one or more 
blinded infusions (placebo in the intervention group and current sedation in the control 
group) prepared by the study pharmacist to minimize bias. In this way the caregiving 
nurse will be blinded for placebo or current sedation during the interruption period. 
This will minimize bias in assessing the sedation level of the patient. At the end of the 
interruption period, the caregiving nurse will open the envelope that is placed in the 
study binder at the patient’s bedside to identify group allocation and sedation will be 
resumed at 50% (intervention group) or 100% (control group) of the previous intrave-
nous infusion rate. This infusion rate is visible for the caregiving nurse and is therefore 
not blinded. This procedure will be repeated on every study day.
Follow-up
Quality of life and symptoms of posttraumatic stress disorder (PTSD) will be assessed 3 
months after pediatric intensive care treatment using validated questionnaires.
Patients will be approached by telephone by the investigators. Quality of life will be 
determined using the Child Health Questionnaire (CHQ). The CHQ is a generic health 
profile measure covering physical and psychosocial domains that refer to the perceived 
health status for the collective 4 weeks prior to completing the questionnaire. Its struc-
ture and methodological approach are similar to those of the Short Form 36 (SF-36), the 
most used quality of life measure in adults. We will ask the parents to complete the CHQ 
for patients aged 2 months to 18 years. Patients aged 12 to 18 years will also be asked to 
complete the CHQ by themselves.
Symptoms of posttraumatic stress will be measured with the Dutch Children’s Responses 
to Trauma Inventory (CRTI). This is a 26-item self-report questionnaire for children aged 8 
to 18 years. The questionnaire covers three subscales (intrusion, avoidance, hyperarous-
al) according to the diagnostic symptoms as per the Diagnostic and Statistical Manual 
of Mental Disorders, fourth edition (DSM-IV) for PTSD and one subscale for non-specific 
reactions. The total score of symptoms of PTSD can be used as an overall index of a 
child’s stress reaction following a stressful event.
endpoints
The main study endpoint is the number of ventilator-free days at 28 days, defined as the 
number of days a patient breathes without mechanical assistance for at least 48 hours 
consecutively from day 1 to day 28 after randomization.
Secondary outcomes are: total and average dose of midazolam and morphine admin-
istered (mg/kg); number of COMFORT behavior scores <11 (oversedation) and >22 
Chapter 6
109
(undersedation); use of additional sedative or analgesic drugs during ventilation; total 
number of safety screen assessments and number and reason for failure to pass; total 
number and reasons for protocol deviations; adverse events (auto-extubation and 
reintubation, accidental displacement of catheters and feeding tubes, pain, changes in 
blood pressure, heart rate, respiratory rate or alarms in those parameters (bradycardia/
apneas) that need medication or adjustments in ventilator settings, need for soft wrist 
restrainers); incidence of withdrawal symptoms (Sophia Observation withdrawal Symp-
toms (SOS) scale); length of stay in the intensive care unit (days); length of stay in the 
hospital (days); organ failure free days, defined as the number of days from day 1 to day 
28 in which the patient is without clinically significant organ dysfunction (the Paediatric 
Logistic Organ Dysfunction score (PELOD) will be used to define pediatric organ dys-
function); 30-day mortality; costs at 28 days; quality of life at 3 months, assessed by the 
Child Health Questionnaire; and incidence of PTSD at 3 months.
statistical methods
Sample size calculation
Our institutional admission data from 2008 showed that 168 children were mechanically 
ventilated for at least 48 hours in our pediatric intensive care unit with mean ventilator-
free days of 16.5 days (SD 9.9). Using these data, we calculated that a sample size of 
100 patients per group is sufficient to detect a clinically significant difference of 25% in 
ventilator-free days (that is, mean 20.6 days in the intervention group versus 16.5 days in 
the control group), with a power of 80%, based on a two-tailed Mann-Whitney test with 
a significance level of 5%.
Final evaluation
Data will be analyzed with an intention-to-treat approach.
Demographic and clinical characteristics will be described using standard statistical 
analysis methods. Descriptive data will be presented as percentages, means ± SD for 
normally distributed variables, and medians ± interquartile ranges for non-normally 
distributed variables.
We will use chi-square tests or Fisher’s exact tests to compare the distribution of cat-
egorical variables between the study groups, and the Mann-Whitney test to compare 
continuous variables, including the primary outcome ventilator-free days.
The number of ventilator-free days will also be compared with correction for baseline 
variables (age, sex, PELOD score and type of disease), using multiple linear regression 
analysis.
To compare the effects of the two treatment protocols on length of stay in the intensive 
care unit and in the hospital, time-to-event analysis will be used. Kaplan-Meier analysis 
and the log-rank test will be used to assess the effect of the treatment protocols. These 
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tests will also be used to assess the effect of the treatment on 30-day mortality. Cox pro-
portional hazards analysis will be used to assess differences between the study groups 
after adjustment for the baseline variables mentioned previously.
All statistical tests will be two-tailed and the significance level will be set at 0.05.
ethical considerations
The study protocol has been evaluated and approved by the institutional review board of 
Erasmus Medical Centre, Rotterdam and by the local ethics committees of all participat-
ing centres: Radboud University Nijmegen Medical Centre, Academic Medical Centre of 
Amsterdam, Leiden University Medical Centre and University Medical Centre Groningen.
Written parental consent will be obtained from participants. The study will be con-
ducted according to the principles of the declaration of Helsinki (version 2004) and in 
accordance with the Medical Research Involving Human Subjects Act (WMO).
This trial is registered in the Dutch Trialregister, located at http://www.trialregister.nl, 
under number NTR2030.
Data and safety monitoring board (Dsmb)
All adverse events reported spontaneously by the subject or observed by the investigator 
or staff will be recorded. A continuous evaluation on adverse effects will be performed 
by an independent DSMB. Adverse events are defined as any undesirable experience oc-
curring to a subject during the clinical trial. If it appears that a disproportionate number 
of adverse events occur in the intervention group, the DSMB can decide that the study 
must be terminated.
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APPeNDIx 
sedation protocol
  
Sedation protocol 
basic scheme 
COMFORT score each 8 hrs 
(2-10-18 hr) and/or at distress/ 
increased restlessness 
CF 
11-22 and 
NISS =2 
CF 6-10 or 
CF 11-22 
and NISS =3 
CF 23-30 
CF 
11-22 and 
NISS =1 
 
 
 
 
  
  
 
  
 
 
 
  
 
 1. Melatonine (oral) 
2.5 mg <1 yrs, 5 mg >1 yrs 
2. Lorazepam (oral) 
0.05 mg/kg 
 
Repeat COMFORT score 
after 1 hour 
CF 11-22 
and NISS =2 
Nursing interventions and 
medical therapy applied to 
satisfaction 
Follow weaning scheme: 
- Midazolam     
- Midazolam +  Morphine 
- Midazolam  >5 days 
(go to page 6) 
No 
intervention 
 
 
Restlessness/ distress 
because of difficulty 
falling asleep 
Consider other 
strategies 
No Yes 
Coming from pages 3-8 
CF = COMFORT behavior score 
Follow sedation algorithm 
 
ventilated patient 
a. sedation protocol, basic scheme
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Algorithm sedation of ventiltated patient  
 
Medical therapy to be performed by 
nurses independently. 
CAVE: 
Do not perform in neonates with 
gestational age < 37 weeks, 
traumatic brain injury,  
status epilepticus, 
Reduce distress by nursing 
interventions. 
Midazolam * (iv): 
0.1 mg/kg shot + 
100 mcg/kg/h infusion 
Repeat COMFORT score 
after 30 min. 
CF 11-22 
and NISS =2 
Midazolam * (iv): 
Increase to max. 300 mcg/kg/h 
in steps of 100 mcg/kg/h 
+ shot 0.1 mg/kg per 
step (= 30 min.) 
Add Morphine (iv): 
100 mcg/kg shot + 
10 mcg/kg/u infusion 
Repeat COMFORT score 
after 30 min. 
CF 11-22 
and NISS =2 
Morphine (iv): 
Increase to max. 30 mcg/kg/h 
in steps of 10 mcg/kg/h 
+ shot of 50 mcg/kg per 
step (= 30 min.) 
COMFORT score each 8 hrs 
(2-10-18 hr) and/or  at 
distress/increased restlessness 
To page 2 
"interventions 
to satisfaction" 
Consider other medication (physician's responsibility): 
- Ketamine (iv): 0.5 mg/kg shot; 0.5 mg/kg/h infusion. 
- Clonidine (iv): 2 mcg/kg shot; 0.2-2 mcg/kg/u infusion of oral: 1-5 mcg/kg a time 
3-4 dd. 
- Propofol (iv): 1 mg/kg shot; 1 mg/kg/h infusion (cave: not in children below 12 
years of age, for long-term infusion). 
- Fentanyl (iv): 1-2 mcg/kg shot; 1-3 mcg/kg/h infusion (instead of morphine). 
- Long-term infusion (> 7days ) of midazolam , consider switching to lorazepam 
(stable and/or long term ventilation). 
- Alimemazine , 1mg /kg (oral) 
* Evaluation of hemodynamics  is essential after 
start midazolam 
Yes 
Yes 
No 
No 
No, and midazolam max (300 mcg/kg/h) 
No 
b. sedation protocol, increasing decision tree
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AbsTrACT
Purpose: To compare daily sedation interruption plus protocolized sedation (DSI+PS) to 
protocolized sedation only (PS) in critically ill children.
methods: In this multicenter randomized controlled trial in three pediatric intensive 
care units in the Netherlands, mechanically ventilated critically ill children with need for 
sedative drugs were included. They were randomly assigned to either DSI+PS or PS only. 
Children in both study arms received sedation adjusted on the basis of validated seda-
tion scores. Provided a safety screen was passed, children in the DSI+PS group received 
daily blinded infusions of saline; children in the PS group received blinded infusions of 
the previous sedatives/analgesics. If a patient’s sedation score indicated distress, the 
blinded infusions were discontinued, a bolus dose of midazolam was given and the 
‘open’ infusions were resumed: DSI+PS at half of infusion rate, PS at previous infusion 
rate. The primary endpoint was the number of ventilator-free days at day 28. Data were 
analyzed by intention to treat.
results: From October 2009 to August 2014, 129 children were randomly assigned to 
DSI+PS (n=66) or PS (n=63). The study was terminated prematurely due to slow recruit-
ment rates. Median number of ventilator-free days did not differ: DSI+PS 24.0 days (IQR 
21.6-25.8) versus PS 24.0 days (IQR 20.6-26.0); median difference 0.02 days (95% CI -0.91 
to 1.09), p=0.90. Median ICU and hospital length of stay were similar in both groups: 
DSI+PS 6.9 days (IQR 5.2-11.0) versus PS 7.4 days (IQR 5.3-12.8), p=0.47, and DSI+ PS 13.3 
days (IQR 8.6-26.7) versus PS 15.7 days (IQR 9.3-33.2), p=0.19, respectively. Mortality at 
30 days was higher in the DSI+PS group than in the PS group (6/66 versus 0/63, p=0.03), 
though no causal relation to the intervention could be established. Median cumulative 
midazolam dose did not differ: DSI+PS 14.1 mg/kg (IQR 7.6-22.6) versus PS 17.0 mg/kg 
(IQR 8.2-39.8), p=0.11.
Conclusion: In critically ill children, daily sedation interruption in addition to proto-
colized sedation did not improve clinical outcome and was associated with increased 
mortality compared with protocolized sedation only.
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INTroDuCTIoN
Commonly, mechanically ventilated critically ill children are sedated to enhance their 
comfort and safety. Moreover, a state of sedation facilitates synchronization with me-
chanical ventilation and enables invasive procedures to be performed.
Although sedation is helpful in the care of critically ill children, it has numerous nega-
tive effects. Especially, oversedation should be avoided, as it is associated with longer 
duration of ventilation, longer hospital stay and adverse patient outcomes, such as with-
drawal, delirium and long-term psychological morbidity in adults (1-4). In recent years, 
efforts have been made to improve sedation management in children, for example 
with the use of sedation algorithms and protocols (5-7). Nonetheless, optimal sedation 
remains challenging and oversedation is common in pediatric intensive care (8).
In adults, daily sedation interruption (DSI) was found to be an effective method of improv-
ing sedation management. Clinical trials have shown that DSI can reduce the duration 
of mechanical ventilation, hospital stay and amount of sedatives administered, without 
compromising patient comfort or safety (9). Several later studies have confirmed this 
beneficial effect (10), whereas other studies, in different settings, found no benefit (11, 12).
For critically ill children, it is unknown if DSI will improve outcome. Two studies showed 
that DSI in children is feasible, but these studies were not sufficiently powered to detect 
differences in clinical outcomes (13, 14). In a recent study from India comparing DSI 
with continuous sedation in children, DSI led to improved clinical outcomes, including 
shorter durations of mechanical ventilation and ICU stay (15). However, given the dif-
ferences in patient population and ICU practices between the Indian and the Western 
setting, these results need further verification (16). Furthermore, it is unknown if the 
combined use of DSI and protocolized sedation is beneficial in children, as this appears 
not the case in adults (11). We hypothesized that mechanically ventilated children man-
aged with DSI combined with protocolized sedation have more ventilator-free days at 
day 28 than patients managed with protocolized sedation alone.
meThoDs
Patients
We recruited patients from three tertiary medical-surgical PICUs in the Netherlands: Eras-
mus MC-Sophia Children’s Hospital, Radboud University Nijmegen Medical Center and 
Academic Medical Center Amsterdam. Approval from each institutional review board 
and written informed consent from parents or legal representatives was obtained. The 
trial has been registered in the Dutch Trial Register (http://www.trialregister.nl/trialreg/
index.asp), no. NTR2030.
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Eligible patients were children between 0 and 18 years of age, and at least 37 weeks 
of postconceptual age, requiring mechanical ventilation with an expected duration 
of at least 48 hours and need for sedative drugs. Exclusion criteria were: anticipated 
death or withdrawal of life support within 48 hours; impossibility of assessing level of 
sedation due to an underlying neurologic condition; neurological, respiratory or cardiac 
instability that may not tolerate inadequate sedation; therapeutic hypothermia after 
cardiopulmonary resuscitation; difficult airway; fixed duration of mechanical ventilation 
(e.g., until planned operation); admission for ECMO; already having been ventilated/
sedated for >2 days in a transferring PICU; and no informed consent.
study design
The study design of this randomized controlled trial has previously been described in 
detail (17). In short, within 24 hours after intubation, informed consent was obtained 
and, the morning after enrollment, the patient was assigned to either DSI combined 
with protocolized sedation (DSI+PS group) or protocolized sedation only (PS group).
Randomization and blinding
Patients were randomly assigned in a 1:1 ratio to either DSI+PS or PS, using blocked 
randomization with stratification by center and age group (0-30 days, 30 days-2 years, 
and 2-18 years). An independent biostatistician carried out computer randomization in 
advance.
In both groups, the syringes containing sedatives/analgesics were replaced each 
morning with blinded syringes, provided a safety screen was passed. The pharmacist 
had access to group allocation to be able to prepare blinded infusions. In the DSI+PS 
group, the infusions were replaced with saline infusions, in the PS group, the infusions 
were replaced with blinded infusions containing the same sedative and analgesic drug 
concentrations. In this way, the caregiving nurse was blinded for group allocation, so as 
to minimize bias in assessing the sedation level. If a patient’s sedation score indicated 
distress, the blinded infusions were discontinued, a bolus dose midazolam was given 
and the original ‘open’ infusions were restarted at 50% of the rate for the DSI+PS group 
and at the original rate for the PS group. This infusion rate was visible for the caregiving 
medical team. For restart of the ‘open’ infusions, the bedside nurse opened an enve-
lope placed in the study binder at the patient’s bedside to identify group allocation. 
The envelope was then closed again and returned to the study binder. This procedure 
was repeated on every study day. Effectively, only the first start of the blinded infusions 
resulted in a complete blinding of treatment for the medical team. After the first restart, 
they could be aware of the patient’s allocation, if they deduced that the full or 50% 
resumption of the infusion rate the day before indicated group assignment. For safety 
reasons, complete blinding was deemed not to be feasible.
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Protocolized sedation
All study centers used a standardized sedation protocol for adjustment of sedatives and 
analgesics, based on scores on validated instruments for this population (COMFORT be-
havior scale (COMFORT-B), Nurse Interpretation of Sedation Score (NISS), numeric rating 
scale (NRS)) (18, 19). All nurses had been trained to use these instruments. Inter-observer 
variability was satisfactory, with κ > 0.65 for all nurses. Adequate sedation was defined 
as a COMFORT-B score ≥11 and ≤22. A COMFORT-B score of <11 implied oversedation, 
a score >22 implied undersedation. Upon a patient’s admission to the PICU, the need 
of sedation was assessed. If sedation was needed, midazolam was initiated and titrated 
up to a maximum of 300 μg/kg/h. When sedation was still considered insufficient, mor-
phine (up to 30 μg/kg/h) was added to the midazolam treatment. If a patient remained 
distressed and sedation still seemed inadequate, other sedative drugs were added ac-
cording to local standard practice (see Figure 1a, b).
Intervention group (DSI+PS)
After having been on mechanical ventilation for 24 hours, a patient was assessed for a 
safety screen daily at 1000 h, after routine care. A patient passed the screen unless he/she 
received a sedative infusion for active seizures, escalating sedative doses due to ongoing 
agitation, neuromuscular blockers, had evidence of increased intracranial pressure or in 
cases of cardiorespiratory instability as judged by the bedside clinician. Patients who 
did not pass the screen were reassessed after 24 hours. If the patient passed the screen, 
all sedative and opioid infusions were replaced with blinded infusions containing saline. 
Analgesics needed for active pain were continued (e.g., pleural drain, <24 hours after 
surgery). During blinded infusions, the patient was strictly monitored and comfort was 
assessed at least every 2 hours using the COMFORT-B and NRS scores or earlier if distress 
was apparent. The sedative and opioid infusions were restarted if the patient appeared 
uncomfortable or if this was deemed necessary in view of cardiorespiratory instability. 
After a loading dose of midazolam (0.1 mg/kg, intravenously), sedative infusions were 
restarted at half the previous dose and then titrated according to the sedation protocol 
to achieve adequate sedation (Figure 2).
Control group (PS)
In the control patients, following the safety screen, blinded infusions were started at the 
same infusion rate as the patient was receiving, containing the same medication, effec-
tively continuing the sedation. Level of sedation was assessed in the same way as in the 
DSI+PS group. When assessments indicated distress, a loading dose of midazolam was 
given, and the blinded infusions were replaced with the sedative infusions at a similar 
rate as before the start of blinded infusions and subsequently titrated according to the 
sedation protocol to achieve adequate sedation.
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Sedation protocol 
basic scheme 
COMFORT score each 8 hrs 
(2-10-18 hr) and/or at distress/ 
increased restlessness 
CF 
11-22 and 
NISS =2 
CF 6-10 or 
CF 11-22 
and NISS =3 
CF 23-30 
CF 
11-22 and 
NISS =1 
 
 
 
 
  
  
 
  
 
 
 
  
 
 1. Melatonine (oral) 
2.5 mg <1 yrs, 5 mg >1 yrs 
2. Lorazepam (oral) 
0.05 mg/kg 
 
Repeat COMFORT score 
after 1 hour 
CF 11-22 
and NISS =2 
Nursing interventions and 
medical therapy applied to 
satisfaction 
Follow weaning scheme: 
- Midazolam     
- Midazolam +  Morphine 
- Midazolam  >5 days 
(go to page 6) 
No 
intervention 
 
 
Restlessness/ distress 
because of difficulty 
falling asleep 
Consider other 
strategies 
No Yes 
Coming from pages 3-8 
CF = COMFORT behavior score 
NISS = Nurse Interpretation of Sedation Score 
Follow sedation algorithm 
 
ventilated patient 
Figure 1a. sedation protocol, basic scheme
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Algorithm sedation of ventiltated patient  
 
Medical therapy to be performed by 
nurses independently. 
NOTE: 
Do not perform in neonates with 
gestational age < 37 weeks, 
traumatic brain injury,  
status epilepticus, 
Reduce distress by nursing 
interventions. 
Midazolam * (iv): 
0.1 mg/kg bolus + 
100 mcg/kg/h infusion 
Repeat COMFORT score 
after 30 min. 
CF 11-22 
and NISS =2 
Midazolam * (iv): 
Increase to max. 300 mcg/kg/h 
in steps of 100 mcg/kg/h 
+ bolus 0.1 mg/kg per 
step (= 30 min.) 
Add Morphine (iv): 
100 mcg/kg bolus + 
10 mcg/kg/u infusion 
Repeat COMFORT score 
after 30 min. 
CF 11-22 
and NISS =2 
Morphine (iv): 
Increase to max. 30 mcg/kg/h 
in steps of 10 mcg/kg/h 
+ bolus of 50 mcg/kg per 
step (= 30 min.) 
COMFORT score each 8 hrs 
(2-10-18 hr) and/or  at 
distress/increased restlessness 
To page 2 
"interventions 
to satisfaction" 
Consider other medication (physician's responsibility): 
- Ketamine  (iv): 0.5 mg/kg bolus; 0.5 mg/kg/h infusion. 
- Clonidine (iv): 2 mcg/kg bolus; 0.2-2 mcg/kg/u infusion of oral: 1-5 mcg/kg a time 
3-4 dd. 
- Propofol (iv): 1 mg/kg bolus; 1 mg/kg/h infusion (note: not in children below 12 
years of age, for long-term infusion). 
- Fentanyl (iv): 1-2 mcg/kg bolus; 1-3 mcg/kg/h infusion (instead of morphine). 
- Long-term infusion (> 7days ) of midazolam , consider switching to lorazepam 
(stable and/or long term ventilation). 
- Alimemazine , 1mg /kg (oral) 
* Evaluation of hemodynamics  is essential after 
start midazolam 
Yes 
Yes 
No 
No 
No, and midazolam max (300 mcg/kg/h) 
No 
Figure 1b. sedation protocol, increasing decision tree
124
endpoints
The primary endpoint was the number of ventilator-free days at day 28, defined as the 
number of days a patient had breathed without mechanical ventilation for at least 48 
hours continuously during a 28-day period after randomization. Patients who died dur-
ing this 28-day period were assigned zero ventilator-free days.
Secondary outcomes included: length of stay in the ICU and hospital (days); 30-day 
mortality; total and median dose of midazolam and morphine (mg/kg); number of 
COMFORT-B scores <11 and >22; use of additional sedative drugs during ventilation; 
incidence of withdrawal symptoms (Sophia Observation withdrawal Symptoms (SOS) 
scale (20)); adverse events; total number of safety screen assessments; and number and 
reason for failure to pass.
statistical analysis
The Erasmus MC institutional admission data for the year 2008 showed that 168 children 
were mechanically ventilated for at least 48 hours in our PICU with a mean number of 
Figure 2. Flowchart of study design
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16.5 (SD 9.9) ventilator-free days. On this basis, including 100 patients per group would 
be sufficient to detect a clinically significant difference of 25% in ventilator-free days (i.e. 
mean 20.6 days in the DSI+PS group versus 16.5 days in the PS group), with a power of 
80%, based on a Mann–Whitney test with a significance level of 5%.
Data were analyzed blinded, with an intention-to-treat approach. Descriptive data are 
presented as percentage, mean ± SD for normally distributed variables, and median ± 
IQR for non-normally distributed variables. Distribution of categorical variables between 
groups was compared with Fisher’s exact tests; continuous variables with Mann–Whit-
ney tests. The primary outcome was also compared between groups with correction 
for baseline variables (age, sex, Pediatric Logistic Organ Dysfunction (PELOD) score and 
type of disease), using robust multiple linear regression analysis to account for the non-
normal distribution of the model residuals. Effects of treatment on length of stay in the 
ICU and hospital were assessed with time-to-event analysis, i.e. Kaplan-Meier analysis 
and log-rank test. These tests also served to assess the effect on 30-day mortality. Penal-
ized Cox analysis was used to assess differences between the groups after adjustment 
for the baseline variables mentioned above. All statistical tests were two-tailed and the 
significance level was set at 0.05. Statistical analyses were performed using SPSS (v. 21) 
and R (v. 3.1.2) for robust regression analysis.
An interim analysis was not scheduled, but an independent data and safety monitoring 
board (DSMB) continuously evaluated possible adverse events.
resulTs
Participants
Of 1059 eligible patients, 132 patients were included in the study between October 
2009 and August 2014. Recruitment rates were lower than foreseen, and the study was 
terminated prematurely, before the recruitment of 200 patients. Three patients were ex-
cluded from the analysis because they were on mechanical ventilation for <48 hours or 
informed consent was withdrawn before the start of the study (Figure 3). Consequently, 
129 children were analyzed, 66 in the DSI+PS group and 63 in the PS group.
Eight patients (12%) in the DSI+PS group discontinued the protocol. Three of those were 
placed on ECMO, two were withdrawn by the medical team (one because of clinical 
instability and one because deeper sedation was thought necessary), two patients were 
withdrawn by parents (concerned that their child was insufficiently sedated), and one 
patient was transferred to the neonatology ward. In the PS group, four patients (6%) 
discontinued the protocol. Two of those were placed on ECMO, one was withdrawn by 
the medical team (because of clinical instability), and one was withdrawn by the parents. 
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Baseline characteristics of the two groups were similar (Table 1). Most patients (67%) 
were admitted for a non-surgical condition such as respiratory disorders.
main outcomes
Table 2 shows that the median number of ventilator-free days was 24.0 days in both groups 
(median difference 0.02 (95% CI -0.91 to 1.09), p=0.90). Adjustment for baseline variables 
gave similar results (mean difference 0.04 (95% CI -1.04 to 1.11), p=0.95). In the PS group, 
more re-intubations were needed (9 vs. 2, p=0.03). The number of accidental extubations 
was not different between groups (DSI+PS group n=1/66, PS group n=4/63, p=0.20). ICU 
and hospital length of stay did not differ significantly between the groups (Table 2).
Mortality at 30 days was significantly higher in the DSI+PS group (6 (9.1%) vs. 0 (0%), 
p=0.02 using log-rank test), also after adjustment for baseline variables. The DSMB 
reviewed the causes of mortality and could not determine a causal relation between in-
tervention and outcome for these six deaths in the DSI+PS group. The intervals between 
last blinded infusion and death were 1, 7, 20, 23 and 27 days, while one patient did not 
receive blinded infusion at all. Three of these six patients were withdrawn prematurely 
from the study because of the start of ECMO. Two others died from ongoing sepsis with 
progressive deterioration and multiple organ failure, and one patient suffered from a 
pneumonia in aplasia with critical illness neuropathy.
1059 patients assessed for eligibilty
132 randomly assigned to treatment
Erasmus MC n=94
Radboud n=22
AMC n=16
927 excluded
646 for clinical reasons
322 needed sedatives
47 status epilepticus
56 hypothermia after CPR
53 traumatic brain injury
74 congenital diaphragmatic hernia
34 respiratory instability
58 cardiac instability
28 anticipated death <48 h
52 neurological deficits
76 required ECMO
43 difficult airway
30 premature
56 fixed duration of MV
39 had been ventilated > 2 days
281 for other reasons
159 refused to participate
62 logistic reasons
32 enrolled in another trial
28 other
67 assigned to daily sedation interruption 65 assigned to protocolized sedation
66 analysed 63 analysed
1 excluded
<48 h ventilation
2 excluded
1 <48 h ventilaion
1 withdrawal informed 
consent
 
Figure 3. Flowchart of recruited patients
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sedative medication
Sedation profiles are presented in Table 3. As a reflection of the protocol, mean infusion 
rates were lower in patients treated with DSI+PS. However, cumulative dose was not 
different between the groups, as patients treated with DSI+PS received more boluses 
of midazolam (median cumulative midazolam dose (infusion+boluses) 14.1 mg/kg (IQR 
7.6-22.6) vs. 17.0 mg/kg (IQR 8.2-39.8), p=0.11). Also, for the other sedative drugs, no 
significant difference was found in cumulative dose. Median number of days of exposure 
to midazolam and number of agents received were not different. The median duration of 
blinded infusions was 25.9 hours (IQR 10.1-48.8 h) in the DSI+PS group versus 41.4 hours 
(IQR 23.8-75.7 h) in the PS group, p=0.003. In nine patients in the DSI+PS group, there was 
no need to restart sedation after the first interruption. These patients were comfortable 
without sedation for a median of 48.5 hours (range 23.5-74.5 h) until extubation.
Table 1. baseline characteristics
DsI+Ps (n=66) Ps (n=63)
Age (months) 2.8 (1.1-17.1) 2.7 (1.3-14.0)
0 – 30 days (group A) 12 (18.2%) 11 (17.5%)
30 days – 2 years (group B) 40 (60.6%) 38 (60.3%)
2 years – 18 years (group C) 14 (21.2%) 14 (22.2%)
Gender (male/female) 38/28 (57.6/42.4%) 41/22 (65.1/34.9%)
Weight (kg) 5.0 (3.7-10.0) 4.6 (3.7-11.0)
PRISM II 16.5 (13-24) 16 (11-21)
Predicted mortality PIM 2 (%) 4.3 (1.6-10.0) 3.2 (1.5-7.6)
PELOD 11 (8-20) 11 (11-20)
Diagnosis on admission:
Respiratory disordera 47 (71.2%) 40 (63.5%)
Cardiac disorderb 3 (4.5%) 4 (6.3%)
Sepsis 7 (10.6%) 6 (9.5%)
Surgery
Cardiac 7 (10.6%) 7 (11.1%)
Non-cardiac 1 (1.5%) 2 (3.2%)
Other 1 (1.5%) 4 (6.3%)
Sedation before randomization (mg/kg)c
Midazolam 3.6 (2.4-5.7) 3.1 (2.4-5.2)
Morphine 0.25 (0.12-0.43) 0.35 (0.14-0.46)
Data are in median (IQR) or n (%); PRISM II=Pediatric Risk of Mortality; PIM 2=Pediatric Index of Mortality; 
PELOD=Pediatric Logistic Organ Dysfunction; a Viral/bacterial pneumonia, ARDS and asthma; b Congenital 
heart disease and cardiomyopathy; c Cumulative dose (infusion and bolus) in the first 24 hours after intubation
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Distress assessments
Median COMFORT-B scores were slightly lower in the PS group than the PS+DSI group, 
indicating that they were more deeply sedated (12 (IQR 10-14) vs. 12 (IQR 11-15), 
p=0.048) (Table 3). The median (IQR) number of assessments per subject was not dif-
ferent between groups. Univariate analysis revealed that 824 (24.3%) of the scores in 
the DSI+PS group indicated oversedation (COMFORT-B<11), versus 998 (25.4%) of the 
scores in the PS group (p=0.27). Undersedation (COMFORT-B>22) was more frequent in 
the DSI+PS group (3.2% (n=107) vs. 2.4% (n=93), p=0.04).
All patients were oversedated at some point during the study period, whereas 62 of 129 
patients (n=34 patients in the DSI+PS group and 28 in the PS group) were undersedated 
at some point.
Median SOS scores were comparable between groups (Table 3). Total number of SOS 
assessments was significantly higher in the PS group (540 vs. 317 scores, p=0.001). In 
total, 25 patients had a SOS score of ≥4 during the study period (n=10 in DSI+PS group, 
n=15 in PS group, not significant), indicating withdrawal symptoms.
safety screen
Two-thirds of all safety screens were passed, 198 (65.6%) of 302 in the DSI+PS group and 
261 (73.7%) of 354 in the PS group. Agitation and cardiorespiratory instability were the 
main reasons for failing the safety screen (Table 4). Approximately 60% of the patients 
passed all safety screens performed (60.6% in DSI+PS group and 63.5% in PS group).
Table 2. main study outcomes
DsI+Ps (n=66) Ps (n=63) p value
Ventilator free days at 28 days (days) 24.0 (21.6-25.8) 24.0 (20.6-26.0) 0.90
Duration of mechanical ventilation (days) 5.1 (3.7-7.3) 5.2 (3.6-9.0) 0.71
Reintubation <24 h 2 (3.0%) 9 (14.3%) 0.03
Tracheostomy 1 (1.5%) 1 (1.6%) 1.00
Length of stay ICU (days) 6.9 (5.2-11.0) 7.4 (5.3-12.8) 0.47
Length of stay hospital (days) 13.3 (8.6-26.7) 15.7 (9.3-33.2) 0.19
30-day mortality 6 (9.1%) 0 (0%) 0.03
Adverse events:
Self-extubations 1 4 0.20
of which requiring reintubation 0 2 0.24
Oversedation – flumazenil 0 1 0.49
Fixation (need for soft wrist restrainers) 1 0 1.00
Data are in median (IQR) or n (%)
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Table 3. sedation profiles
DsI+Ps (n=66) Ps (n=63) p value
midazolam n=66 n=63
Cumulative dose infusion (mg/kg) 13.0 (6.9-22.3) 17.0 (8.1-39.8) 0.08
Mean infusion rate (mcg/kg/hr) 126 (59-185) 134 (90-221) 0.02
Cumulative dose bolus (mg/kg) 0.74 (0.24-1.21) 0.52 (0.20-1.19) 0.21
Total cumulative dose (mg/kg) 14.1 (7.6-22.6) 17.0 (8.2-39.8) 0.11
Number of exposure days 4.5 (3.4-6.7) 4.9 (2.8-8.7) 0.79
morphine n=54 n=52
Cumulative dose infusion (mg/kg) 0.89 (0.5-1.4) 1.15 (0.6-2.8) 0.12
Mean infusion rate (mcg/kg/hr) 9.7 (6.3-13.0) 11.9 (10.0-16.4) 0.004
Cumulative dose bolus (mg/kg) 0.15 (0.06-0.36) 0.10 (0.02-0.14) 0.03
Total cumulative dose (mg/kg) 0.92 (0.60-1.56) 1.16 (0.65-2.86) 0.17
Clonidine n=13 n=11
Cumulative dose infusion (mcg/kg) 55.2 (15.8-95.1) 92.6 (43.2-208.3) 0.04
Mean infusion rate (mcg/kg/hr) 0.56 (0.42-0.92) 0.98 (0.66-1.52) 0.01
Cumulative dose bolus (mcg/kg) 4.08 (2.24-4.73) 6.43 (3.04-10.50) 0.15
Total cumulative dose (mcg/kg) 47.4 (8.0-86.7) 75.7 (41.2-204.8) 0.10
ketamine n=9 n=17
Cumulative dose infusion (mg/kg) 15.3 (6.8-108.0) 35.8 (6.4-94.9) 0.85
Mean infusion rate (mg/kg/hr) 0.54 (0.27-1.14) 0.74 (0.30-0.97) 0.83
Cumulative dose bolus (mg/kg) 0.92 (0.50-1.89) 1.09 (0.50-3.48) 0.72
Total cumulative dose (mg/kg) 4.51 (0.52-26.20) 35.63 (3.11-56.17) 0.11
Fentanyl n=34 n=28
Cumulative dose (mcg/kg) 4.1 (2.1-12.3) 2.3 (1.2-7.9) 0.15
Propofol n=24 n=29
Cumulative dose (mg/kg) 6.5 (2.8-26.2) 10.8 (2.6-40.7) 0.57
Number of different sedatives received 2 (2-3) 2 (2-4) 0.31
Number of patients with >2 sedatives 24 (36.4%) 26 (41.3%) 0.57
ComForT-b scale
Total number of assessments 3389 3924
Median number of assessments per patient 41 (28-59) 47 (26-76) 0.45
Median COMFORT-B score 12 (11-15) 12 (10-14) 0.048
Oversedation (COMFORT-B<11), n(%) 824 (24.3%) 998 (25.4%) 0.27
Undersedation (COMFORT-B>22), n(%) 107 (3.2%) 93 (2.4%) 0.04
sos score
Number of patients 19 20
Total number of assessments 317 540
Median number of assessments per patient 9 (3-21) 16.5 (9-39) 0.07
Median SOS 1.0 (0.5-2.0) 1.0 (1.0-2.8) 0.23
SOS ≥ 4, n(%) 32 (10.1%) 66 (12.2%) 0.35
Data are in median (IQR) or n (%); n= the number of patients receiving the drug
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DIsCussIoN
This multicenter randomized controlled trial showed no difference in ventilator-free days 
and ICU or hospital length of stay for children treated with daily interruption of sedation 
combined with protocolized sedation compared with children receiving protocolized 
sedation alone. Additionally, DSI+PS was not associated with the administration of less 
sedative drugs compared with the use of PS.
These findings contradict those of two earlier studies on DSI in children, in both of which 
DSI was associated with shorter durations of mechanical ventilation, shorter ICU stays 
and less use of sedatives (13, 15).
This discrepancy can perhaps be explained as follows. First, we compared DSI in the set-
ting of a protocolized sedation strategy for all patients, the latter being standard of care 
in the participating PICUs. A nurse-driven sedation protocol is assumed to be beneficial 
to minimize sedation, although this was recently questioned in a study in critically ill 
children (6, 21). The effect of protocolized sedation itself on the clinical endpoints might 
have outweighed the effect of DSI. This is in line with an adult study in which DSI offered 
Table 4. safety screen
DsI+Ps (n=66) Ps (n=63)
median number of assessments per patient 4 (3-5) 4 (3-6)
Total number of assessments 302 354
Pass 198 (65.6%) 261 (73.7%)
Fail 69 (22.8%) 76 (21.5%)
No sedation 35 (11.6%) 17 (4.8%)
reason for failure
Active seizures 0 (0%) 3 (3.9%)
Ongoing agitation 24 (34.8%) 33 (43.4%)
Neuromuscular blockade 7 (10.1%) 24 (31.6%)
Increased ICP 0 (0%) 0 (0%)
Cardiorespiratory instability 38 (55.1%) 16 (21.1%)
No. of patients with
0 fail 40 (60.6%) 40 (63.5%)
1 fail 10 (15.2%) 8 (12.7%)
2 fail 6 (9.1%) 8 (12.7%)
3 fail 3 (4.5%) 1 (1.6%)
4 fail 3 (4.5%) 2 (3.2%)
5 fail 3 (4.5%) 2 (3.2%)
>5 fail 1 (1.5%) 2 (3.2%)
Data are in median (IQR) or n (%)
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no benefit over a nurse-driven protocol already targeting light sedation (11). Also, the 
previous pediatric pilot study used no sedation protocol and patients in the control 
group were deeply sedated (13), which could explain the beneficial effect of DSI.
Second, there are important differences between the present study and that of Gupta 
and colleagues which could explain the different study outcomes (15). In the latter, 
around 70% of the patients had neurological illnesses, while we did not include patients 
with neurological problems. Moreover, mean duration of mechanical ventilation was 
10.3 days in the continuous group, versus 5.2 days in our population. Lastly, the daily 
dose of midazolam was almost twice that in the present study (mean 11.0 vs. 6.1. mg/kg/
day in the control groups and mean 7.1 vs. 4.4 mg/kg/day in the DSI groups).
In the present study, cumulative drug doses did not significantly differ between the two 
groups. The need for intermittent bolus administration in the DSI+PS group counterbal-
anced the reduction in continuous sedation. However, in nine patients in the DSI+PS 
group, there was no need to restart sedation. It seems that there are two groups of 
patients: 1) patients who may not need sedation at all and 2) patients who become 
agitated after sedation interruption and even need more (bolus) medication to become 
comfortable again. Therefore, a continuous critical appraisal of the need to continue 
sedation is warranted. Active tapering of sedation is still needed as this may improve 
outcome, in particular in the first group.
More reintubations were needed in the PS group. Patients in the DSI+PS group were 
possibly more alert and therefore extubation may have been more successful, as also 
demonstrated in adult DSI studies (10). Overall, around a quarter of the distress assess-
ments indicated oversedation. This is somewhat lower than described in the literature 
(8), possibly due to the use of a sedation protocol. Judging from the higher number 
of SOS assessments in the PS group, these patients showed more clinical withdrawal 
symptoms, although no statistically significant difference was found in the number of 
scores ≥4, sedative drug doses, and length of exposure to midazolam between the two 
groups.
This study shows that DSI in children is feasible. Around 60% of patients passed all safety 
screens, and DSI was not related to more adverse events, in line with earlier studies. 
However, the higher mortality in the first 30 days in the DSI+PS group (9.1%) compared 
to the control group was totally unexpected, as also was the absence of mortality in the 
control group (0%). Reassuringly, overall 30-day mortality in our total patient cohort 
(6/129; 4.6%) was not higher than the reported ICU mortality in the Netherlands (22). 
Moreover, an independent DSMB could not identify a causal relationship between 
the study intervention and cause of death for individual patients. All six patients were 
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seriously ill, with a high mortality risk in advance. Furthermore, the timeframe between 
active participation in the study and death makes a causal relation unlikely.
In previously published DSI studies, mortality was never increased. In adult studies, 
reported ICU mortality was 29.8% in the DSI group and 31% in the usual care group 
(RR 0.96, 0.77-1.21) (23). Pooled adult data also demonstrated no difference in overall 
mortality (RR 0.88, 0.75-1.05) and 28-day mortality (RR 0.82, 0.5-1.12) between DSI and 
control groups (23). In children, Gupta reported a mortality of 26.1% in the DSI group 
and 26.8% in the control group (15). Both percentages are higher than our reported 
mortality due to a different ICU setting and different population, but mortality was not 
increased in DSI patients. In the pediatric pilot study, all patients survived until PICU 
discharge (13). We could not establish a theoretical framework explaining the increased 
mortality found in our study. Considering all this, and given that meta-analyses of trials 
had not previously identified an adverse mortality risk with DSI, it is highly unlikely that 
there is a relationship with DSI. Nevertheless, while our finding may be due to a type I er-
ror, we cannot exclude that the increased mortality in our study is due to an unexpected 
impact of the study protocol.
A limitation of our study is the smaller-than-planned sample size. The planned inclusion 
of 200 patients was not reached due to slow recruitment rates. The number of eligible 
patients was lower than expected and around 50% of parents declined to provide 
consent (24). The reasons for these refusals were not recorded, but it is not unreason-
able to assume that these parents found the concept of discontinuing drugs given to 
promote comfort not acceptable, as also suggested in an adult DSI trial with the same 
consent rate (25). It would probably take another 2.5 years to finish recruitment of all 
planned 200 patients. This timeframe was deemed not feasible by the study group, and 
at this point it was decided to stop the study. The decision was not influenced by interim 
results as data were still blinded at the time of the decision. Still, we believe our results 
are valuable. A post hoc power analysis resulted in a power of 62% with 129 patients, 
although the expected mean number of ventilator-free days in the sample size calcula-
tion was lower than observed in the study, likely due to the selection of relatively more 
stable patients. Since we did not even find a trend in the number ventilator-free days 
or the length of stay between both groups, it is unlikely that we would find a clinically 
meaningful difference with 200 patients. Furthermore, this study can provide useful data 
to assist others who might be planning a trial or performing a meta-analysis. Another 
consideration of the study is that, in the DSI+PS group, 22.8% of the safety screens were 
not passed, and for that day sedation was not interrupted. This could have diminished 
the differences between the two groups. However, this reflects clinical practice and is 
comparable with adult DSI studies (11). Furthermore, there may be a Hawthorne effect 
in the control group (26), as sedation practice was closely monitored in both groups 
Chapter 7
133
possibly leading to a better adherence to the sedation protocol. A strength of this study 
is the multicenter design. This reflects actual practice in different PICUs and enhances 
the generalizability of these findings.
CoNClusIoNs
Based on this multicenter study, there is no beneficial effect of daily sedation interrup-
tion in addition to protocolized sedation for critically ill children. Daily sedation inter-
ruption did not reduce the duration of mechanical ventilation, the length of stay, or 
the amounts of sedative drugs administered, but was associated with a higher 30-day 
mortality. Therefore, daily sedation interruption is not the sedation strategy of choice 
in critically ill children provided protocolized sedation is implemented in the pediatric 
intensive care.
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AbsTrACT
objective: Our earlier pediatric daily sedation interruption (DSI) trial showed that DSI in 
addition to protocolized sedation (PS) in critically ill children does not reduce duration 
of mechanical ventilation, length of stay or amounts of sedative drugs administered as 
compared with protocolized sedation only, but undersedation was more frequent in the 
DSI+PS group. We now report the preplanned analysis comparing short-term health-
related quality of life (HR-QoL) and posttraumatic stress symptoms between the two 
groups.
Design: Preplanned prospective part of a randomized controlled trial.
setting: Two tertiary medical-surgical pediatric intensive care units in the Netherlands.
Patients: Critically ill children requiring mechanical ventilation.
Interventions: None.
measurements and main results: Eight weeks after a child’s discharge from the pe-
diatric intensive care unit, HR-QoL was assessed with the validated Child Health Ques-
tionnaire and, only for children above 4 years of age, posttraumatic stress was assessed 
with the Dutch Children’s Responses to Trauma Inventory. Additionally, HR-QoL of all 
study patients was compared with Dutch normative data. Of the 113 patients from two 
participating centers in the original study, 96 patients were eligible for follow-up and 
64 patients were included (response rate 67%). No difference was found with respect 
to HR-QoL between the two study groups. None of the eight children >4 years showed 
posttraumatic stress symptoms.
Conclusions: DSI in addition to protocolized sedation for critically ill children did not 
seem to have an effect on short-term HR-QoL. Also in view of the earlier found absence 
of effect on clinical outcome, we cannot recommend the use of DSI+PS.
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INTroDuCTIoN
Critically ill children admitted to a pediatric intensive care unit (PICU) and who are 
mechanically ventilated often receive sedative drugs to ensure their comfort. It is 
common practice in many PICUs to moderately or heavily sedate children (1). There is 
a tendency to avoid undersedation, not only because this may lead to discomfort and 
potential adverse effects such as self-extubation, but also the children, especially pre-
verbal infants, otherwise may be bewildered by what is happening to them. Moreover, 
concerns have been raised that remembering such experiences may lead to adverse 
psychological outcome (2). A study from the UK found that almost one-third of children 
reported delusional memories three months after discharge from a PICU (3). Delusional 
memories were positively associated with post-traumatic stress symptoms, but the sug-
gestion that coexistence of factual memory might be protective psychologically was not 
confirmed. In addition, this study showed an association between duration of sedation 
and the presence of delusional memory, which association has also been reported in 
adults (4, 5).
Recently we conducted a multicenter randomized controlled trial to study the efficacy 
and safety of daily sedation interruption combined with protocolized sedation (DSI+PS) 
compared to protocolized sedation (PS) in mechanically ventilated critically ill children. 
Our primary hypothesis was that children treated with DSI+PS would show an improved 
clinical outcome during PICU stay, an improved short-term health-related quality of 
life (HR-QoL) and less post-traumatic stress 8 weeks after PICU discharge. Nevertheless, 
as the trial found no differences in duration of mechanical ventilation, length of PICU 
stay and amounts of sedative drugs administered between the DSI+PS group and the 
PS group the hypothesis had to be rejected regarding the clinical outcome. However, 
undersedation was more frequent in the DSI+PS group (3.2% (107 of the 3389 scores) vs. 
2.4% (93 of the 3924 scores), p=0.04). Children treated with DSI+PS had more fluctuation 
in level of sedation, while children in the PS group had a smoother course of sedation 
with the same amount of sedatives. We now report the preplanned analysis comparing 
short-term HR-QoL and posttraumatic stress symptoms between the two groups, also in 
relation to Dutch normative data.
mATerIAls AND meThoDs
setting and patients
In this preplanned prospective part of the randomized controlled trial referred to above, 
we assessed HR-QoL and post-traumatic stress disorder (PTSD) symptoms 8 weeks after 
PICU discharge (6).
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For this study, patients from only two of the three participating tertiary medical-surgical 
PICUs in the Netherlands were enrolled: Erasmus MC-Sophia Children’s Hospital and 
Radboud University Nijmegen Medical Center. Patients enrolled at Academic Medical 
Center Amsterdam were excluded as this center has a different follow-up program. Ap-
proval from each institutional review board and written informed consent from parents 
or legal representatives had already been obtained in the context of the original trial.
The following inclusion criteria applied to the original trial: age between 0 and 18 
years; at least 37 weeks of postconceptual age; requiring mechanical ventilation with 
an expected duration of at least 48 hours and need for sedative drugs. The following 
exclusion criteria were applied: anticipated death or withdrawal of life support within 48 
hours; impossibility of assessing level of sedation due to an underlying neurologic con-
dition; neurological, respiratory or cardiac instability that may not tolerate inadequate 
sedation; therapeutic hypothermia after cardiopulmonary resuscitation; difficult airway; 
fixed duration of mechanical ventilation, admission for ECMO; already having been 
ventilated/sedated for >2 days in a transferring PICU. In addition, those with insufficient 
command of the Dutch language were excluded for this substudy.
Intervention
A detailed description of the study design is provided elsewhere (6). In brief, patients 
were randomized to DSI+PS or PS only. Throughout the study, patients in both treatment 
groups were managed with protocolized sedation. All study centers used a standard-
ized sedation protocol for adjustment of sedatives and analgesics to achieve adequate 
sedation based on the scores on a validated assessment instrument (COMFORT behavior 
scale (7)). Midazolam and morphine were initiated sequentially and titrated first; other 
sedatives were added if sedation was still inadequate.
Intervention group (DSI+PS)
After having been on mechanical ventilation for 24 hours, a patient was assessed each 
morning for a safety screen. If the patient passed the screen, the sedative/analgesic infu-
sions were discontinued, either immediately or later after planned procedures had been 
performed, and replaced by a blinded saline infusion at the same pump rate. Analgesics 
needed for active pain control were continued. During interruption, patients were 
strictly monitored and comfort was assessed at least every 2 hours or earlier if distress 
was apparent. The sedative infusion was restarted if the patient became uncomfortable 
or if deemed necessary by the clinical team in view of cardiorespiratory instability. After 
a loading dose of midazolam (0.1 mg/kg, intravenously), sedative infusion was restarted 
at half the previous dose and then titrated according to the sedation protocol to achieve 
adequate sedation.
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Control group (PS)
In the control patients, following the safety screen, blinded midazolam and where ap-
plicable other analgesic/sedative infusions were started at the same rate as the patient 
was receiving. Level of sedation was assessed in the same way as in the DSI+PS group. 
When assessments indicated distress, the blinded infusion was replaced by the sedative 
infusion at a similar rate as before the interruption.
outcome assessment
Health-related quality of life
HR-QoL was assessed with the validated Child Health Questionnaire (CHQ) (8, 9). The 
CHQ is a generic health profile measure covering physical and psychosocial domains 
that refer to perceived health status for the collective 4 weeks prior to completing the 
questionnaire. Designed specifically for children, it includes valuable domains like be-
havior and the effect of the child’s health on parents. Its structure and methodological 
approach are similar to those of the SF-36, the most used HR-QoL measure in adults (10). 
The CHQ-IT97 (0-3 years) and CHQ-PF50 (4-17 years) were filled out by parents about 
their child, and the CHQ-CF87 (12-17 years) was filled out by children about themselves 
(8, 11, 12).
We assessed HR-QoL baseline status at study enrollment, and next 8 weeks after PICU 
discharge. Before discharge we told the parents that they would receive the HR-QoL 
questionnaires by regular mail in 8 weeks and invited them to complete these at home 
and return them by pre-paid envelope. The choice of respondent (mother, father or 
together) was left to the parents themselves. If the questionnaires were not returned 
within 3 weeks, we called the parents to inform whether they had received the question-
naires and if yes, kindly asked them to return them. If it appeared that parents had not 
received the questionnaire, we resent the questionnaire.
We compared HR-QoL of all study patients with normative data. Normative data were 
derived from representative samples of the general Dutch population (8, 11, 13).
Posttraumatic stress
Post-traumatic stress at 8 weeks after discharge was measured with the validated 34-
item questionnaire Dutch Children’s Responses to Trauma Inventory (CRTI), filled out by 
parents of children aged 4-18 years and by children aged 8-18 years themselves (14). 
We sent the CRTI questionnaire together with the HR-QoL questionnaire. The question-
naire covers 3 subscales (intrusion, avoidance, hyperarousal) according to the diagnostic 
DSM-IV symptoms of PTSD and one subscale for other child-specific reactions. The items 
are rated on a five-point scale. The total score, which can range from 34 to 170, can 
be used as an overall index of a child’s stress reaction following a stressful event. Total 
scores between 92 and 105 indicate subclinical PTSD possibly requiring professional 
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support); scores of 106 and higher indicate severe symptoms that can possibly fulfil the 
criteria for PTSD. Psychometric properties of the questionnaire proved to be satisfactory 
in a sample of Dutch groups of children after violence and disaster (15). The internal 
consistency (Cronbach’s alpha) was good (0.92). Convergent validity was high; the CRTI 
correlated strongly with the Children’s Impact of Event Scale (CRIES) (r=0.77) (15).
Interview by telephone
Families who returned questionnaires were contacted by phone and asked to partici-
pate in a telephone interview with one of the investigators. This interview was in a semi-
structured format using a standard questionnaire on health consequences in the weeks 
after PICU discharge. It included a total of 16 questions on healthcare consumption, 
current physical and behavioral functioning (such as fatigue, headache, pain, and sleep 
disturbances), and daily activities. Severity of complaints was scored on a 5-point scale 
(very mild to very severe).
socioeconomic status
Socioeconomic status (SES) was categorized as “low” (elementary occupations), “middle” 
(‘middle’ occupations), or “high” (‘highest’ professional occupations) (16). SES was calcu-
lated based on a combined status score of the Netherlands Institute for Social Research 
based on home address (17). The latter score consists of average income in neighbor-
hood, percentage of people with low income, percentage of less educated people, and 
percentage of people not working. A status score of 0 (±1.16 SD) was classified middle 
SES, <-1.16 was classified low SES, and >+1.16 was classified high SES.
statistical analysis
A separate power analysis for this substudy was not performed. The sample size was 
calculated from the study’s primary outcome, the number of ventilator-free days (6). 
Data were analyzed with an intention-to-treat approach; patients with follow-up data 
were analyzed in the group to which they were randomized.
Categorical data are presented as number and percentage and continuous data as 
median ± IQR.
The distribution of categorical variables between groups was compared with Fisher’s 
exact test; continuous variables with Mann–Whitney tests.
Normality of the data was examined with the Kolmogorov-Smirnov test. In case of 
normal distribution, the HR-QoL data were compared with normative data using a 
one-sample t-test. A one-sample Wilcoxon signed-rank test was used for non-normally 
distributed HR-QoL data. Effect sizes were reported with Cohen’s d (18). Baseline and 
post PICU discharge HR-QoL was compared using a paired Wilcoxon signed-rank test.
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Statistical significance was considered with 2-tailed p values of <0.05. All analyses were 
performed in SPSS 21.0 for Windows (SPSS, Inc., Chicago, IL).
resulTs
Patient sample
Of the 113 patients enrolled in the original trial from the two participating PICUs in 
this substudy, 96 patients were eligible for follow-up (44 in the DSI+PS group and 52 
in the PS group) (Figure 1). Thirty-two patients did not participate: 31 patients did not 
return the questionnaires (reason unknown) and the parents of one patient withdrew 
consent. In total, 64 families returned the questionnaires (32 patients in both groups). 
The overall response rate was 67% (64/96). Participants and non-participants did not 
differ (Supplemental Table 1).
Baseline and in-hospital characteristics of the study groups are presented in Table 1.
The median follow-up interval after PICU discharge did not differ between the two 
groups (62 days (IQR 47-105) in the DSI+PS group vs. 58 days (IQR 47-90) in the PS group, 
p=0.71).
113 patients from original study
58 assigned to daily sedation interruption 
+ protocolized sedation 55 assigned to protocolized sedation
44 patients eligible for QoL study 52 patients eligible for QoL study
32 patients included in QoL study
IT97 n=30
PF50 n=2
CF87 n=1
CRTI n=2
Interview n=8
32 patients included in QoL study
IT97 n=26
PF50 n=6
CF87 n=3
CRTI n=6
Interview n=15
Non-participants:
20 not responding
Non-participants:
11 not responding
1 withdawal consent
1 died in hospital
1 language barrier
1 withdrew from study
9 died in hospital
4 language barrier
1 withdrew from study
 
Figure 1. Flowchart of recruited patients
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Table 1. baseline and in-hospital characteristics
DsI+Ps (n=32) Ps (n=32) p value
Age (months) 1.8 (0.9-5.0) 3.1 (1.3-22.7) 0.14
0 – 30 days (group A) 8 (25.0%) 4 (12.5%)
0.2030 days – 2 years (group B) 21 (65.6%) 20 (62.5%)
2 years – 18 years (group C) 3 (9.4%) 8 (25.0%)
Gender (male/female) 18/14 (56/44%) 18/14 (56/44%) 1.00
PRISM II 16 (14-23) 19 (12-23) 0.83
Predicted mortality PIM 2 (%) 2.6 (1.5-6.3) 4.5 (2.1-8.8) 0.10
PELOD 11 (1-13) 12 (11-21) 0.03
Diagnosis on admission:
Respiratory* 22 (68.8%) 18 (56.3%)
Cardiac** 2 (6.3%) 2 (6.3%)
Sepsis 1 (3.1%) 4 (12.5%)
Surgery 0.83
Cardiac 5 (15.6%) 6 (18.8%)
Non-cardiac 1 (3.1%) 1 (3.1%)
Other 1 (3.1%) 1 (3.1%)
Duration of mechanical ventilation (days) 4.5 (3.6-5.6) 4.8 (3.4-10.0) 0.55
Length of stay PICU (days) 6.5 (5.1-9.1) 7.5 (5.4-17.3) 0.19
Length of stay hospital (days) 12.2 (8.9-17.1) 19.3 (12.1-37.2) 0.01
Sedative exposure
Midazolam n=32 n=32
Cumulative dose infusion (mg/kg) 12.9 (7.6-20.5) 15.1 (6.4-40.1) 0.23
Cumulative dose bolus (mg/kg) 0.68 (0.23-0.92) 0.40 (0.18-0.97) 0.38
Total cumulative dose (mg/kg) 13.7 (7.8-21.5) 15.8 (6.5-40.3) 0.23
Morphine n=26 n=25
Cumulative dose infusion (mg/kg) 0.77 (0.56-1.4) 1.2 (0.64-3.2) 0.21
Cumulative dose bolus (mg/kg) 0.15 (0.08-0.33) 0.12 (0.02-0.28) 0.54
Total cumulative dose (mg/kg) 0.86 (0.63-1.40) 1.17 (0.65-3.24) 0.27
COMFORT-B scale
Total number of assessments 1559 2170
Median number of assessments per patient 43 (29-60) 44 (26-93) 0.62
Oversedation (COMFORT-B<11), n(%) 325 (20.8%) 554 (25.5%) 0.001
Undersedation (COMFORT-B>22), n(%) 71 (4.6%) 44 (2.0%) <0.001
Data are in median (IQR) or n (%); PRISM II=Pediatric Risk of Mortality; PIM 2=Pediatric Index of Mortality; 
PELOD=Pediatric Logistic Organ Dysfunction; * viral/bacterial pneumonia, ARDS and asthma; ** congenital 
heart disease and cardiomyopathy
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health-related quality of life
Fifty-six parents completed the CHQ-IT97 for children 0-3 years (30 in the DSI+PS group 
and 26 in the PS group). Eight parents completed the CHQ-PF50 for children 4-17 years 
(2 in the DSI+PS group and 6 in the PS group) and 4 children (between 12 and 18 years) 
the CHQ-CF87 (1 in the DSI+PS group and 3 in the PS group).
HR-QoL in the age group 0-3 years did not differ between the two study groups (Table 
2). The older age groups were too small to compare the CHQ-PF50 and CHQ-CF87 results 
by study group. Overall, the HR-QoL scores were below the Dutch normative scores, 
indicating poorer quality of life (Table 3). Parent-reported HR-QoL scores were signifi-
cantly lower with large effect sizes on physical functioning, growth and development, 
general health perceptions, and parental impact (time), The general behavior scores 
were significantly higher than the normative scores (p=0.02). Self-report scores on the 
CHQ-CF87 (children 12-17 years; n=4) were similar to the normative scores (Table 3).
Eighteen parents (11 in the DSI+PS group and 7 in the PS group) completed the CHQ-
IT97 for children 0-3 years at baseline and after discharge. Subanalysis showed that only 
parental impact (emotional) was significantly higher after discharge (p=0.003) (Table 4).
Posttraumatic stress
The CRTI was completed for 8 of the 11 eligible patients above 4 years of age (73%, 2 in 
the DSI+PS group and 6 in the PS group); seven parents and four children completed the 
CRTI. Overall, the scores were low (median 60; range 36-78). None of the scores exceeded 
92 indicating PTSD. Due to the small numbers, we did not compare the study groups.
Table 2. health-related quality of life post discharge
DsI+Ps Ps p value
Child Health Questionnaire –
Infant Toddler 97 (0-3 yr)
n=30 n=26
Physical functioning 86.1 (65.3-100.0) 86.7 (73.8-100.0) 0.76
Growth and development 75.0 (70.0-82.5) 75.0 (62.5-85.0) 0.66
Bodily pain/discomfort 75.0 (50.0-83.3) 83.3 (66.7-100.0) 0.10
Temperament and moods 72.2 (58.0-79.9) 76.4 (66.0-87.5) 0.12
General behavior (n=4/3) 81.2 (75.3-94.2) 89.2 (77.7-..) 1.00
Getting along (n=4/3) 77.5 (72.1-81.7) 71.7 (70.0-..) 0.63
General health perceptions 44.6 (36.3-61.3) 46.7 (21.7-67.5) 0.58
Parental impact: emotional 89.3 (72.3-95.5) 92.9 (79.5-100.0) 0.11
Parental impact: time 83.3 (71.4-94.0) 85.7 (76.2-95.2) 0.62
Family cohesion 85.0 (60.0-100.0) 85.0 (60.0-96.3) 0.84
Change in health 75.0 (43.8-100.0) 87.5 (56.3-100.0) 0.42
Data are in median (IQR)
Low scores imply worse functioning
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Table 3. health-related quality of life post discharge, compared to normative data
study patients Norm p value Cohen’s d
Child Health Questionnaire – Infant Toddler 97 (0-3 yr) n=56 n=410
Physical functioning (PF) 80.7 (21.5) 97.2 (9.8) <0.001 1.40
Growth and development (GD) 74.9 (15.2) 86.5 (10.6) <0.001 1.03
Bodily pain/discomfort (BP) 73.2 (23.2) 83.8 (16.8) 0.002 0.60
Temperament and moods (TM) 72.9 (14.1) 77.2 (10.5) 0.037 0.39
General behavior (GB) 84.8 (8.7) 72.8 (12.7) 0.018 0.98
Getting along (GA) 76.4 (6.1) 71.4 (8.8) 0.062 0.59
General health perceptions (GH) 46.4 (20.4) 79.0 (14.5) <0.001 2.13
Parental impact: emotional (PE) 86.2 (13.2) 92.1 (10.5) 0.021 0.54
Parental impact: time (PT) 81.7 (16.1) 93.0 (11.0) <0.001 0.96
Family cohesion (FC) 78.9 (20.6) 75.3 (18.8) 0.178 0.19
Change in health (CH) 73.9 (29.4) 56.1 (18.4) 0.013 0.89
Child Health Questionnaire – Parent Form 50 (4-17 yr) n=8 n=353
Physical functioning (PF) 69.4 (36.9) 99.1 (4.3) 0.035 4.44
Role functioning: emotional/behavior (REB) 70.8 (36.6) 97.9 (7.2) 0.091 3.09
Role functioning: physical (RP) 56.3 (40.8) 95.8 (15.6) 0.091 2.40
Bodily pain (BP) 71.3 (22.3) 85.7 (17.2) 0.122 0.83
General behavior (GB) 77.7 (19.1) 78.5 (13.1) 0.779 0.06
Mental health (MH) 76.3 (13.8) 81.4 (12.1) 0.260 0.42
Self-esteem (SE) 73.4 (16.4) 79.2 (11.0) 0.262 0.52
General health perceptions (GH) 51.0 (27.2) 82.9 (13.4) 0.017 2.31
Parental impact: emotional (PE) 78.1 (17.2) 86.3 (15.2) 0.261 0.54
Parental impact: time (PT) 80.6 (16.5) 94.0 (13.0) 0.122 1.02
Family activities (FA) 89.1 (15.3) 91.5 (11.9) 0.887 0.20
Family cohesion (FC) 72.5 (24.2) 72.2 (19.4) 0.573 0.02
Physical summary (PHS) 35.4 (18.7) 56.4 (5.7) 0.017 3.38
Psychosocial summary (PSS) 51.0 (9.8) 53.2 (6.4) 0.674 0.34
Child Health Questionnaire – Child Form 87 (12-17 yr) n=4 n=457
Physical functioning (PF) 84.3 (24.1) 96.0 (6.9) 0.705 1.64
Role functioning: emotional/behavior (REB) 87.5 (11.5) 89.4 (17.2) 0.461 0.11
Role functioning: Physical (RP) 80.6 (14.0) 95.0 (12.9) 0.141 1.12
Bodily pain (BP) 70.0 (14.1) 73.5 (22.7) 0.713 0.15
General behavior (GB) 87.7 (7.7) 80.9 (10.6) 0.066 0.64
Mental health (MH) 79.3 (12.9) 76.5 (15.4) 0.715 0.18
Self-esteem (SE) 71.9 (14.6) 74.7 (12.2) 1.000 0.23
General health perceptions (GH) 65.9 (26.3) 73.5 (16.5) 0.715 0.46
Family activities (FA) 80.2 (16.4) 80.0 (17.7) 1.000 0.01
Family cohesion (FC) 65.0 (26.1) 70.6 (23.5) 1.000 0.24
Data are in mean (SD)
Low scores imply worse functioning
Scores on the CHQ-PF50 scale “change in health” are not presented since individual normative data were 
not available for this scale
Cohen’s d's are presented as absolute numbers. According to Cohen’s criteria, an effect size of ≤.49 is con-
sidered small, .50 - .79 medium, and ≥ .80 large
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Telephone interview
As 41 parents could not be reached by telephone, 23 of the 64 parents (36%) were inter-
viewed by telephone (8 in the DSI+PS group and 15 in the PS group).
One or more complaints were reported for 16 children (70%): fatigue (n=2 in DSI+PS 
group and n=7 in the PS group), pain (headache n=1 in the DSI+PS group; other n=1 in 
the PS group), sleep disturbances, including nightmares (n=1 in DSI+PS group and n=6 
in the PS group), behavioral/emotional problems (n=1 in DSI+PS group and n=4 in the 
PS group) and loss of appetite (n=4 in DSI+PS group and n=2 in the PS group). Seven 
parents (30%; n=3 in DSI+PS group and n=4 in the PS group) reported limitations in 
their own daily activities (e.g. job, holidays, hobbies and social visits) since their child’s 
discharge from the PICU. Overall, complaints seemed more prevalent in the PS group (12 
vs. 24 complaints); we refrained from statistical comparison due to the small numbers.
DIsCussIoN
This multicenter randomized controlled trial is the first study using validated instru-
ments to investigate the short-term outcome of DSI in critically ill children undergoing 
mechanical ventilation. We found that DSI had no effect on short-term HR-QoL. How-
ever, the parent-reported HR-QoL of their children was significantly worse compared 
with normative data.
Table 4. health-related quality of life, baseline vs. post discharge
baseline Post discharge p value
Child Health Questionnaire –
Infant Toddler 97 (0-3 yr)
n=18 n=18
Physical functioning 83.3 (80.0-93.3) 83.3 (66.3-90.0) 0.37
Growth and development 72.4 (63.8-81.5) 72.5 (65.0-90.4) 0.07
Bodily pain/discomfort 58.3 (50.0-75.0) 75.0 (58.3-83.3) 0.14
Temperament and moods 71.5 (61.7-82.3) 73.6 (57.6-79.9) 0.71
General behavior 81.2 (71.9-94.7) 81.2 (78.2-94.2) 0.27
Getting along 74.2 (66.3-78.3) 76.7 (71.7-81.7) 0.07
General health perceptions 34.0 (23.6-51.9) 34.2 (20.2-44.2) 0.91
Parental impact: emotional 73.2 (48.2-90.2) 87.5 (75.0-92.6) 0.003
Parental impact: time 83.3 (71.4-90.5) 81.0 (71.4-97.6) 0.23
Family cohesion 92.5 (60.0-100.0) 85.0 (60.0-100.0) 0.37
Change in health 50.0 (25.0-75.0) 75.0 (37.5-87.5) 0.16
Data are in median (IQR)
Low scores imply worse functioning
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Our results are in line with those from adult DSI follow-up studies. Adults managed 
with DSI reported similar cognitive, psychological, and quality-of-life outcomes after 
discharge from ICU as those managed with continuous sedation (19-21). Still, DSI was 
associated with fewer post-traumatic stress symptoms PTSD (20). The latter finding was 
also demonstrated in a study comparing light sedation with deep sedation (22).
In our original trial duration of mechanical ventilation, length of stay in the PICU and 
amounts of sedative drugs administered were similar between both study groups. In 
the adult studies, however, all these factors were lower in the intervention group. The 
lack of difference in clinical outcomes between the DSI+PS and PS group has likely 
contributed to a lack of differences in HR-QoL in the present study. Undersedation was 
more frequent in the DSI+PS group, which could have contributed to a lower HR-QoL in 
the DSI+PS group, but this was not found.
The finding of significantly worse parent-reported HR-QoL (physical scales) with large 
effect size compared with normative data is consistent with earlier studies reporting 
reduced HR-QoL and reduced mental wellbeing in children after PICU experience (23-
25). Surprisingly, parents reported better general behavior of the child compared to 
normative data. The response shift phenomenon could possibly explain this finding. Re-
sponse shift is “the change of the internal standards and values after a life-threatening 
or traumatic event” (26). If this should occur, it might result in a possibly too positive 
perception of problems. Since our results are consistent with earlier reports in children, 
this confirms that HR-QoL is reduced after pediatric critical illness. In addition, participa-
tion in a sedation study with closely monitoring of sedation levels and possibly a better 
adherence to sedation protocol does not influence HR-QoL.
As expected, 8 weeks post PICU discharge parents experienced more emotional wor-
ries/concerns than at baseline. Yet we were surprised to find no differences in the other 
HR-QoL scales. One would expect that 8 weeks after a PICU stay including mechanical 
ventilation, HR-QoL would be lower. We speculate that it is difficult for parents to objec-
tively rate their child’s HR-QoL before PICU admission, while their child is critically ill. This 
may be due to a lack of clear instructions of what is meant by ‘baseline’. Consequently, 
baseline HR-QoL results should be interpreted carefully, taking into account potential 
bias due to anxiety of parents at the time of early PICU admission.
Several limitations of this study should be addressed. First, the response rate was not 
high (67%), which reduced sample size and thereby statistical power. Still, this response 
rate is similar to that in other studies in this field of research (23, 25). As participants and 
non-participants did not differ in baseline characteristics, selection bias based on these 
characteristics is unlikely. The response rate for the telephone interview was much lower, 
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only 37%. For one thing, despite multiple attempts, it was hard to contact the parents 
by telephone. And then, once parents were contacted and agreed to participate, it was a 
challenge to receive in-depth information by telephone. This may have been due to the 
fact that the phone call had not been scheduled and parents may have been reluctant 
to recall the experiences. To overcome these challenges, we suggest to embed HR-QoL 
measurement by way of formal diagnostic instruments in a visit to the outpatient clinic 
as part of patient care. Considering the worse HR-QoL after PICU discharge compared 
with normative data in our study, routine psychological screening during standard 
follow-up visits, both short-term and long-term seems warranted to be able to provide 
families with additional care when needed.
A second limitation is the small number of patients above 4 years of age. For this reason 
we were unable to compare HR-QoL in this age group, as well as incidence of PTSD in 
the study group.
Third, patients and parents completed questionnaires only once, approximately at 8 
weeks after discharge. We planned to evaluate short-term outcome, as possible differ-
ences might resolve over time (19, 23). However, the timing of questionnaires might 
have influenced the results, reporting worse HR-QoL when compared with normative 
data, because they might not yet have fully recovered.
Fourth, the DSI+PS group had lower severity of illness, as reflected by PELOD score, and 
shorter hospital length of stay compared with the PS group. Severity of illness may be a 
predictor of health status in critically ill children, although the PELOD score, measuring 
organ dysfunction, seems not associated with worse HR-QoL (25). Whether a reduced 
hospital stay impacts HR-QoL is not clear.
CoNClusIoNs
Based on this multicenter prospective study, DSI, when added to protocolized sedation, 
is not associated with an improved health-related quality of life for critically ill children. 
Additionally, this study showed that HR-QoL of children surviving PICU is significantly 
worse compared with normative data. Also in view of the earlier found absence of effect 
on clinical outcome, we cannot recommend the use of DSI+PS in critically ill children.
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supplemental Table 1. Characteristics of participants and non-participants
Participants
(n=64)
Non-participants 
(n=32)
p value
Age (months) 2.3 (1.0-7.9) 2.5 (1.1-23.1) 0.55
0 – 30 days (group A) 12 (18.8%) 8 (25.0%)
0.5930 days – 2 years (group B) 41 (64.1%) 17 (53.1%)
2 years – 18 years (group C) 11 (17.2%) 7 (21.9%)
Gender (male/female) 36/28 (56/44%) 22/10 (69/31%) 0.27
PRISM II 17 (13-23) 17 (10-22) 0.64
Predicted mortality PIM 2 (%) -3.43 (-4.10- -2.42) -2.79 (-3.98- -2.21) 0.37
PELOD 11 (11-18) 11 (10-12) 0.23
Diagnosis on admission:
Respiratory* 40 (62.5%) 24 (75.0%)
Cardiac** 4 (6.3%) 1 (3.1%)
Sepsis 5 (7.8%) 3 (9.4%)
Surgery 0.36
Cardiac 11 (17.2%) 1 (3.1%)
Non-cardiac 2 (3.1%) 1 (3.1%)
Other 2 (3.1%) 2 (6.3%)
Duration of mechanical ventilation (days) 4.6 (3.5-7.5) 5.2 (3.8-6.6) 0.80
Length of stay PICU (days) 6.7 (5.4-12.2) 7.2 (5.3-9.9) 0.82
Length of stay hospital (days) 14.7 (10.1-26.0) 10.9 (8.0-21.4) 0.06
Sedative exposure
Cumulative midazolam dose (mg/kg) n=64
15.0 (7.7-25.0)
n=32
15.6 (6.1-32.2) 0.77
Cumulative morphine dose (mg/kg) n=51
0.94 (0.63-1.43)
n=25
1.16 (0.64-2.16) 0.47
Socioeconomic status at baseline
Level 1: low 8 (12.5%) 4 (12.5%)
Level 2: middle 39 (60.9%) 24 (75.0%) 0.27
Level 3: high 17 (26.6%) 4 (12.5%)
Data are in median (IQR) or n (%); PRISM II=Pediatric Risk of Mortality; PIM 2=Pediatric Index of Mortality; 
PELOD=Pediatric Logistic Organ Dysfunction; * viral/bacterial pneumonia, ARDS and asthma; ** congenital 
heart disease and cardiomyopathy
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research in pediatric intensive care
Pediatric intensive care is a unique and young subspecialty in medicine. The first pediat-
ric intensive care unit (PICU) was established in 1955 in Sweden, and pediatric intensive 
care was only recognized as a distinct subspecialty 30 years ago (1). Major advances in 
the treatment of critically ill children have been made since then. Not only improved care 
for major conditions such as acute respiratory distress syndrome, sepsis, and traumatic 
brain injury, but also new technologies, continuous monitoring and specialized training 
in critical care have contributed to improved outcomes and survival (1). Nevertheless, 
most clinical decision making in the PICU is not related to evidence-based medicine 
based on clinical research, but rather based on physiology and knowledge acquired 
during training and from personal experience (2).
The PICU can be an ideal environment for clinical research. A dedicated multidisciplinary 
team is immediately available, and in addition to information in the medical record, 
extensive physiological monitoring data are usually available, and samples can be ob-
tained easily from invasive devices (2). Still, the complex PICU environment also raises 
specific challenges to design and conduct of research. It may be difficult to identify good 
outcome measures due to the combination of low prevalence of major adverse events 
(e.g. severe morbidity, mortality) and small sample size (3). Second, ethical challenges 
include timely informed consent and the balance between burden and risk of research 
against the possible benefit of the trial (4). Children in the PICU generally are not able 
to participate in the decision as they are too young, too ill or too heavily sedated and 
parents or surrogates are asked to have their child participate in research under stress-
ful circumstances of admission. It is not always possible to achieve written informed 
consent before start of the study in emergency settings, and deferred consent can then 
be a good alternative (5).
To date, more than 80% of all randomized controlled trials in the PICU setting are single 
center studies (3). These are logistically easier to set up, less expensive, do not require 
prolonged negotiation for study design, and enroll a less heterogeneous population (6). 
On the other hand, generalizability of their results is limited. Furthermore, because most 
diseases in PICU can be viewed as rare diseases (7), many clinical trials have problems 
with recruitment to ensure adequate power (3).
These limitations could be overcome through collaboration in larger (inter)national PICU 
research networks, such as the Canadian Critical Care Trials Group (Pediatric Interest 
Group), the Collaborative Pediatric Critical Care Research Network, the Pediatric Acute 
Lung Injury Sepsis Investigators Network (PALISI) and in the Netherlands, the so-called 
Stichting Kinder Intensive Care (SKIC). Collaborative research efforts will over time identify 
the best practices to improve PICU outcomes. Yet, the mindset in every academic PICU 
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should be that we can learn from every individual patient. Ideally, each patient admitted 
to the PICU participates in one or more research protocols.
Although heterogeneity of patients in the PICU is large, one common denominator 
is safe and effective drug therapy, which is the focus of the research presented in this 
thesis.
Drug research in critically ill children
Drug research is essential for determining the efficacy and safety of medications in 
children. Without this type of research, we need to resort to extrapolation from adult 
studies or off-label use for indications that have not been studied in children, with the 
inherent risk of adverse effects.
Major changes in pharmacokinetics and pharmacodynamics occur with increasing age 
due to changes in body composition, ontogeny of drug metabolism and transport and 
renal function (8). The relative lack of knowledge on drug disposition in children can 
lead to therapy failure (9) or adverse effects (10, 11). Extrapolation from adult data has 
caused harm in the past, for example the grey baby syndrome in neonates treated with 
chloramphenicol (12).
Similarly, drug dosing for critically ill children cannot always be derived from research 
in the general pediatric population. Both critical illness (e.g. shifts in body fluid, inflam-
mation, liver, renal and heart failure) and its treatment modalities (e.g. mechanical 
ventilation, extra-corporeal membrane oxygenation (ECMO) (13), hypothermia (14, 15), 
continuous renal replacement therapy (16)) are likely to influence pharmacokinetics 
and pharmacodynamics of drugs. In addition, oral drug absorption is often altered in 
critically ill children (17), making the intravenous administration route preferred. As all 
medications are often given via the same intravenous catheter, this may give rise to drug 
interactions, which are hardly taken into account in daily practice.
Therefore, drug dosing for critically ill children, is a real challenge. The effects of factors 
such as inflammation, disease and therapy on both pharmacokinetics and its relation to 
pharmacodynamics need to be studied across the pediatric age range.
To better understand the interplay of different covariates in relation to drug therapy, 
a ‘systems’ pharmacology approach may be helpful. A key element of the systems ap-
proach is the distinction between ’drug-specific’ and ’system-specific’ parameters in 
pharmacokinetic models to describe variation in drug disposition and response. Sys-
tem-specific parameters relate to parameters describing physiological processes, such 
as organ perfusion and the expression/function of drug-metabolizing enzymes and 
transporters. Knowledge of the changes in the system-specific parameters characteriz-
ing the absorption, distribution, metabolism and excretion of drugs, such as maturation 
or inflammation-related changes, may aid to predict the disposition of drugs (8, 18, 19). 
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This knowledge can be obtained by analyzing changes in the pharmacokinetics of a 
paradigm compound cleared by this specific pathway. The drug metabolizing enzyme 
cytochrome P450 3A (CYP3A), for example, has been studied in this way. The maturation 
of CYP3A was modeled using the clearance of midazolam as its biological marker (20). 
Another successful example of systems pharmacology is pharmacogenomics, where 
variation in drug response has been mapped to single nuclear polymorphisms in drug 
metabolism genes, leading to clinical useful predictions (21).
Pharmacokinetics in pediatric critical illness - midazolam as CYP3A probe
Clinical studies in adults have reported reduced activity for CYP3A, CYP1A2, CYP2C9, 
CYP2C19 and CYP2D6 in patients with an acute infection or inflammatory disease (22-
26). This cytokine-mediated decrease in drug metabolism can be up to 70%. Two studies 
in critically ill children have demonstrated a significant effect of inflammation on drug 
metabolism. In children with sepsis and organ failure the antipyrine clearance, as global 
marker of CYP activity, was two- and fourfold lower, respectively, than in non-septic ICU 
children (27). In addition, interleukin-6 (IL-6) was negatively correlated with antipyrine 
clearance, suggesting an important role of inflammation. In a cohort of 20 PICU pa-
tients, the presence of the systemic inflammatory response was associated with a 62% 
decrease in pantoprazole clearance, a CYP2C19 and CYP3A4 substrate (28). Supporting 
evidence was found from pharmacokinetic studies of midazolam. Average midazolam 
clearance in critically ill children was considerably lower than in healthy children of the 
same age (7 ml/kg/min vs. 12 ml/kg/min). We speculated that this large difference can 
be explained by inflammation (chapter 2).
To further study the interplay of developmental changes, inflammation-related and 
disease-related variation, a systems pharmacology approach was applied. The pharma-
cokinetics of midazolam, as a surrogate marker for CYP3A activity, and the influence of 
covariates such as age, inflammation, disease severity, genetics and drug interactions 
were prospectively studied (chapter 4). In addition to body weight, both inflammation 
(IL-6 and C-reactive protein (CRP)) and organ failure significantly affected midazolam 
clearance in these critically ill children: simulations show a 65% lower clearance at a CRP 
concentration of 300 mg/L compared to 10 mg/L. Also, three failing organs were associ-
ated with a 35% lower midazolam clearance as compared to one failing organ. Together, 
midazolam clearance can be up to 77% lower in the presence of both increased CRP and 
multi-organ failure. This effect is most likely due to IL-6 mediated downregulation of 
CYP3A activity, possibly heightened by reduced hepatic blood flow.
The complex mechanism of inflammation-mediated downregulation of drug metabo-
lism is hardly investigated yet and far from elucidated. For most CYP enzymes studied, 
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the decrease in CYP450 protein expression are preceded or accompanied by a decrease 
in mRNA, implicating transcription as a primary mechanism. However, there are multiple 
post-transcriptional effects as well, including regulation of catalytic activity and desta-
bilization of proteins (19, 29).
The mediators include multiple proinflammatory cytokines (IL-6 and TNF-α), eico-
sanoids, and histamine, which also regulate acute phase proteins (e.g. CRP). Animal and 
preclinical human hepatocyte models have described cytokine-induced changes in CYP 
since the 1980s, but the translation to the clinical setting is challenging and the ability to 
predict changes following inflammation has been limited. This may be due to the high 
cytokine concentrations used in the models. Furthermore, the clinical effects of multiple 
pro- and anti-inflammatory cytokine changes have not been fully assessed. Even in 
sepsis, a leading cause of mortality, the complexity of the inflammatory response, con-
sidered as a ‘cytokine storm’, makes it difficult to predict outcome or develop therapies 
by blocking the inflammatory cascades (30, 31).
Of all cytokines and CYPs investigated, both in models and in humans the strongest 
relation was found between IL-6 and CYP3A4 activity. This link is supported by clini-
cal studies of the IL-6 inhibitor tocilizumab. Inhibition of IL-6 by tocilizumab seems to 
reverse the IL-6 mediated CYP3A downregulation in adult rheumatoid arthritis patients 
(32). Our results also support a regulatory role of IL-6, in view of the substantially de-
creased midazolam clearance, as marker of CYP3A, with increasing IL-6 levels in critically 
ill children. Other cytokines (e.g. IL1a, IL1b, IL2, IL4, IL8, IL10 and TNF-α) were not related 
to midazolam clearance (chapter 4). Nonetheless, IL-6 levels may also increase during an 
acute exercise-induced inflammatory reaction (33), making IL-6 a less specific marker.
It is not known yet whether inflammation also affects other CYP isozymes to this extent, 
such as CYP2C9 and CYP2D6, and whether this impact is also present in non-critically ill 
children with inflammatory conditions such as cancer and autoimmune disease.
In addition to inflammation, our study showed that organ failure affects midazolam 
clearance in critically ill children. The impact of organ failure is logically dependent on 
the organ type and the relative involvement of a specific organ in a drug’s metabolism 
and clearance. Hepatic, renal and respiratory failure may all affect a drug’s disposition in 
a complex interactive manner. For example, the mechanism by which liver disease im-
pacts on drug clearance is determined by the extraction ratio of the drug. Hepatic drug 
clearance will depend on the rate of delivery of drug to the liver (determined by the 
hepatic blood flow) and on the efficiency of drug removal from the blood (the extrac-
tion ratio). As midazolam has a low to intermediate extraction ratio, changes in hepatic 
clearance are predominantly dependent on drug metabolism, but some impact of liver 
flow cannot be excluded (34, 35). Variation in liver flow in critically ill patients may result 
from changes in cardiac output subsequent to cardiac failure or restricted filling of the 
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right ventricle because of elevated intrathoracic pressure due to mechanical ventilation. 
The impact of acute liver failure on drug metabolism is more difficult to predict because 
it does not correlate well with the measured indices of liver function or damage (e.g. 
clotting factors, transaminases, bilirubin, albumin) (36). Therefore, drug metabolism can 
be altered in patients with apparently normal liver function.
Another consideration is the effect of renal failure on hepatic drug metabolism. Kidney 
disease does not only alter the renal elimination of drugs and metabolites, but also 
the non-renal disposition of metabolized drugs. Chronic kidney disease, but also acute 
kidney injury, which is common in critically ill children (37), may impact hepatic drug 
metabolism (38, 39). In critically ill adults with renal failure a reduced hepatic clearance 
of metamizol, a highly metabolized drug, was shown (40). Also, midazolam clearance 
was significantly lower in critically ill adults with acute kidney injury (41). Although 
the underlying mechanism is not well-characterized, accumulated uremic toxins and 
inflammatory cytokines (IL-6) may modulate drug metabolizing enzymes either directly 
or by inhibiting gene expression (38, 39). In our cohort of critically ill children, creatinine 
levels, as marker of kidney function, were not significantly associated with midazolam 
clearance (chapter 4), but children with increased creatinine levels were few. Further-
more, urinary NGAL and KIM-1, recently emerged biomarkers, may be more accurate 
than creatinine for the early detection of acute kidney injury (42).
In addition to age and disease, genetic variation in CYP3A4/5 activity may contribute 
to variation in midazolam clearance. We could, however, not identify a significant effect 
of genetic polymorphisms of CYP3A4 and CYP3A5 on midazolam clearance (chapter 4). 
There was a non-significant trend towards lower clearance in patients with CYP3A4*22, 
lacking true significance possibly due to the low prevalence of this SNP in our cohort. 
Patients in our population who express the CYP3A5*1 allele, i.e. who have functional 
CYP3A5 activity, did not have a higher midazolam clearance. We also could not confirm 
that functional CYP3A5 compensates for inflammation mediated CYP3A4 suppression, 
as previously suggested (41), but sample size was small.
We did not study the impact of treatment modalities on the pharmacokinetics of 
midazolam in critically ill children. Cardiopulmonary bypass, extracorporeal membrane 
oxygenation, dialysis and hypothermia may impact on drug disposition and response. 
For example, volume of distribution is often increased in ECMO-patients and clearance 
is altered either way (13). Hypothermia leads to changes in volume of distribution due 
to redistribution of blood flow and lower clearance due to lower drug metabolizing 
enzyme activity (14, 15).
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Since midazolam is a validated probe for determining CYP3A activity in vivo, the results 
of our pharmacokinetic study can serve as a proof of principle. The ’system-specific’ 
information of the influence of inflammation and organ failure on midazolam clearance 
in critically ill children can be used to predict variation in the clearance of other drugs 
metabolized by the same enzyme (43). As CYP3A is responsible for the metabolism of 
more than half of all clinically used drugs, this approach is promising. However, future 
studies need to confirm whether the effect of critical illness also holds for other CYP3A 
metabolized drugs and, next, for other CYP enzymes and their substrates.
The next question that arises is if reduced clearance and potential higher plasma levels 
will also result in increased effect and risk of toxicity. Drug receptor activity may also 
be subject to critical illness related changes and hence cause altered sensitivity to the 
drug’s effect. For example, in rheumatoid arthritis patients, more active inflammation 
(increased IL-6 levels) was associated with decreased verapamil clearance and higher 
verapamil plasma levels. However, despite higher plasma levels, these patients showed 
significantly weaker dromotropic response (22), thereby protecting them from toxicity. 
In a pilot study we found that decreased midazolam clearance in critically ill children 
was seemingly unrelated to lower dose requirements as a surrogate pharmacodynamic 
marker (chapter 3). However, this study included only 21 patients and dose requirements 
may not be a good pharmacodynamic endpoint, especially since some sicker patients 
were more deeply sedated for clinical reasons and may have received higher midazolam 
doses. Pharmacokinetic-pharmacodynamic modeling may be a better approach, using 
the COMFORT-behavior scale as validated pharmacodynamic endpoint. To achieve 
predictable efficacy and safety in all critically ill children, the next steps will be to study 
variability in pharmacodynamics, to explore the pharmacokinetic-pharmacodynamic 
relationship in critical illness across the pediatric age range, and more specifically, the 
effect of inflammation and organ failure on pharmacodynamics.
Conclusions and recommendations:
1. In addition to body weight, inflammation and organ failure significantly affect mid-
azolam clearance in critically ill children.
2. Most likely, this effect is due to IL-6 mediated downregulation of CYP3A activity, 
which may be emphasized by reduced hepatic blood flow.
3. The effect of acute kidney injury in relation to hepatic drug metabolism should be 
elucidated.
4. One of the future goals is to examine if extrapolation of the inflammation-related 
changes in the clearance of the CYP3A substrate midazolam to other CYP3A sub-
strates is valuable.
Chapter 9
165
5. The effect of inflammation should be studied in children with other inflammatory 
conditions, such as cancer and autoimmune diseases, and for other individual CYP 
enzymes.
6. The effect of critical illness in relation to the pharmacokinetic-pharmacodynamic 
relationship of CYP3A drugs needs to be studied.
7. A system approach, studying the ’system-specific’ parameters in critically ill children 
constitutes an innovative approach to the study of pharmacokinetics and pharmaco-
dynamics in this special patient population.
Pharmacodynamics in pediatric critical illness – midazolam as sedative
Midazolam is one of the most widely used drugs in pediatric intensive care for seda-
tion. Adequate sedation has been described as the level of sedation at which patients 
are asleep but easily arousable (44). Although it is recommended to individually titrate 
sedatives, adequate sedation is often not obtained in clinical practice. In a systematic 
review critically ill children were optimally sedated in 57.6%, undersedated in 10.6% and 
oversedated in 31.8% of the assessments (chapter 5).
There are several possible reasons for the oversedation observed in clinical practice. 
First, deeper sedation levels are perceived as acceptable or considered clinically needed 
due to underlying disease. Also, there may be a tendency to sedate children more 
deeply at night. Adherence to systematic assessment of sedation and associated change 
in sedation medication might be lower during night shift. Second, there may be a role 
for pharmacokinetic and pharmacodynamic factors that influence sedative response in 
critically ill children. In addition to the factors described in the section above, kidney 
failure can contribute to a prolongation of effect, due to accumulation of the metabolite 
1-OH-midazolam-glucuronide, as described in adults (45). Also, pharmacodynamic 
changes may occur as a result of illness. In critically ill adults, severity of illness particu-
larly influenced the pharmacodynamics and to a minor degree the pharmacokinetics of 
propofol. Patients who were sicker were more likely to have a deeper level of sedation, 
and these patients need downward titration of propofol (46).
Inadequate sedation may have a detrimental impact. Undersedation may lead to in-
creased distress and adverse events such as unintentional extubation or displacement 
of catheters. Oversedation may delay recovery, as greater sedatives consumption is 
associated with longer duration of ventilation as well as extubation failure in children 
(47). Oversedation also induces tolerance and withdrawal syndrome (48, 49). All these 
factors may lead to a longer PICU stay.
In view of the negative consequences of prolonged, deep sedation a shift from deep to 
light sedation was recommended in adults (50). An important first step was the intro-
duction of protocolized sedation, targeting patient-specific sedation levels. In adults, 
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protocolized sedation has been associated with improved outcomes (e.g., shorter 
duration of mechanical ventilation and a shorter length of ICU stay) in a variety of ICU 
populations (51-56). In children, the benefits of protocolized sedation are less clear. A 
recent, large randomized controlled trial in mechanically ventilated children comparing 
protocolized sedation with usual care did not show improved clinical outcome in the 
protocolized sedation arm (57).
Another approach to avoid the negative effects of oversedation, and especially the 
adverse effects of continuous benzodiazepine use, may be daily sedation interruption 
(DSI). Clinical trials in adults have shown that DSI can reduce the duration of mechanical 
ventilation, hospital stay and amount of sedatives administered without compromising 
patient comfort or safety (58). Several later studies have confirmed this beneficial effect 
(59), whereas other studies, in different settings, showed no benefit (60, 61).
In critically ill children, a pilot study showed that DSI is feasible, but this study was 
not sufficiently powered to detect differences in clinical outcome (62). In a study from 
India comparing DSI with continuous sedation in children, DSI led to improved clinical 
outcomes, including shorter durations of mechanical ventilation and PICU stay (63). 
Patient characteristics in this study differed widely from those usually seen in the West-
ern setting, e.g. a high incidence of neurotrauma, longer mean duration of mechanical 
ventilation, and more sedatives and neuromuscular blockers administered. The ability to 
extrapolate the results of this study to PICU practice in the Western world has therefore 
been questioned (64).
In our study, DSI combined with protocolized sedation did not improve clinical outcomes 
such as duration of mechanical ventilation, length of stay, or the amounts of sedative 
drugs administered, but rather was associated with a higher 30-day mortality (chapter 
7). In addition, this approach did not seem to have an effect on short-term health-related 
quality of life for critically ill children (chapter 8). The effect of protocolized sedation itself 
on the clinical endpoints might have outweighed the effect of DSI, as also demonstrated 
in adults (60).
The higher mortality in the first 30 days in the DSI group compared to the control group 
was totally unexpected. An independent data and safety monitoring board could not 
identify a causal relationship between the study intervention and cause of death for the 
individual patients and the long time interval between active participation in the study 
and death for most patients renders causality unlikely. In addition, overall mortality in 
our total patient cohort was not higher than the reported ICU mortality in the Neth-
erlands. Also, in previously published DSI studies, mortality was never increased (65). 
Therefore, it is highly unlikely that there is a relationship with DSI. We concluded that 
DSI is not the sedation strategy of choice in critically ill children provided protocolized 
sedation is implemented in the pediatric intensive care.
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Several steps can be taken to further improve sedation management in critically ill 
children. For one, the use of non-benzodiazepine medications in critically ill children 
must be studied. As especially the continuous administration of benzodiazepines, 
such as midazolam, is associated with prolonged mechanical ventilation (66), the use 
of alternative medications that cause minimal respiratory depression, e.g. clonidine or 
dexmedetomidine, could improve outcome. Clonidine and dexmedetomidine are cen-
trally acting α2-agonists. Clonidine has been shown a viable alternative to midazolam 
in critically ill children, without substantial safety issues (67). However, whether the use 
of clonidine improves clinical effectiveness is not yet known, a study is currently under-
taken (NCT02509237). For dexmedetomidine, some retrospective studies have shown 
favorable results in critically ill children, although adverse events such as hypotension, 
bradycardia and withdrawal syndrome are not excluded (68-70). Overall, the evidence is 
weak and randomized controlled trials are needed to examine if these medications are 
better alternatives.
Drug ‘cycling’ or ‘rotation’ may be another approach to decrease the adverse effects of 
continuous sedation (71). This strategy is aimed at preventing tachyphylaxis and toler-
ance by cycling drug combinations. For example, an opioid and benzodiazepine regi-
men can be changed to ketamine and promethazine, followed by clonidine and chloral 
hydrate, all on a weekly basis. However, evidence supporting the beneficial effects of 
cycling is lacking.
In adults, a strategy of no sedation is suggested to further improve clinical outcome. No 
sedation during mechanical ventilation resulted in a lower number of days on ventilation 
and a shorter ICU stay, compared to DSI (72). Interestingly, delirium was more frequent 
in the no sedation strategy. As yet, a strategy of no sedation may not be recommended 
for critically ill children. Often unable to comprehend in what situation they are when 
they are awake for a longer period, they may show more distress than adults, with pos-
sibly higher risk of adverse events such as unintentional extubation.
The role of sedatives on short- and long term neurological outcome needs to be clarified. 
There is emerging evidence that sedatives, and especially midazolam, are a risk factor 
for development of delirium in adults (73). Delirium is a manifestation of acute brain 
dysfunction and is an important independent predictor of negative clinical outcomes in 
adult ICU patients, including increased mortality and long-term cognitive impairment 
with a dementia-like state (74, 75).  For critically ill children, risk factors for delirium 
are probably the same, but long-term consequences are unknown (76). Furthermore, 
the role of sedatives and analgesics on long term neurological outcome needs to be 
elucidated. Virtually all available sedatives and analgesic medications are neurotoxic 
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in animal models (77). Human studies are still scarce (78) and conflicting. Morphine 
administration at neonatal age was not associated with adverse long-term effects in 
a cohort of preterm newborns at 8-9 years of age (79, 80) and in a cohort of neonatal 
extracorporeal membrane oxygenation survivors at school-age (81). In contrast, opioid 
administration was associated with adverse neuropsychological outcome in meningo-
coccal septic shock survivors (82).
Although sedation studies have focused primarily on brain-related outcomes, other 
organ systems, such as the kidneys, may also be affected. A no sedation strategy in me-
chanically ventilated adult patients decreased the incidence of acute kidney injury (83). 
A decrease in the microcirculation within the kidneys following sedation could partly 
explain this finding. Although methodological limitations preclude firm conclusions 
regarding mechanisms underlying this association, this study generates the hypothesis 
that sedation may harm organs other than the brain during critical illness (84).
Sedatives may also affect the immune system, as studies suggest that sedatives have 
anti-inflammatory effects and may increase susceptibility to infection (85). For example, 
both midazolam and propofol impair multiple aspects of the innate immune response, 
for example by reducing macrophage chemotaxis and phagocytosis, suppressing nitric 
oxide production and limiting production of interferon, tumor necrosis factor and vari-
ous interleukins (85). The possible exception is the α2-agonist class of drugs (e.g. dexme-
detomidine), which may improve immune function and outcomes, including mortality in 
sepsis (85). Human studies are limited, but supportive of immunomodulatory effects of 
sedatives with a possible increased risk of infections (86, 87). Clinical studies are needed 
to determine whether these data are relevant in the clinical setting and if consideration 
of the immune effects may play a role in sedative selection in the far future.
Conclusions and recommendations
1. Sedation in PICU is often suboptimal and oversedation is common.
2. There is no beneficial effect of daily sedation interruption in addition to protocolized 
sedation for critically ill children.
3. Other sedative regimes, like drug cycling, and other sedatives, like clonidine and 
dexmedetomidine, may add to optimal sedation and need further study in well-
designed multicenter clinical trials.
4. The influence of sedatives on short- and long term neurological outcome, as well as 
potentially systemic effects, need to be clarified.
Although widely prescribed, the safety and efficacy of drugs administered to critically 
ill children is hardly studied in this population. In addition to age-related maturation 
of drug-metabolizing enzymes and renal function, critical illness (inflammation and 
Chapter 9
169
organ failure) severely affects the clearance of (CYP3A metabolized) drugs. This may 
lead to an increased risk of drug toxicity or therapy failure, but further exploration of 
the pharmacokinetic-pharmacodynamic relationship in critical illness is necessary. Until 
then, physicians should ‘be awake’ and consider the influence of critical illness on drug 
therapy and, if possible, use therapeutic drug monitoring in patients with unexplained 
symptoms potentially related to drug toxicity or therapy failure.
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summArY
On average, a critically ill child admitted to a pediatric intensive care unit receives tendif-
ferent drugs. The safety and efficacy of most of these drugs have hardly been studied in 
this population and yet they are widely prescribed. Dose recommendations are often 
empirical, based on body weight and an extrapolated adult dose. In view of the mostly 
non-linear developmental changes in young children as well as the physiological differ-
ences between adults and children, empirical dosing can lead to over- or underdosing.
Drug dosing in critically ill children poses an extra challenge. In addition to the age-
related maturation of drug-metabolizing enzymes and renal function, acute illness and 
its treatment modalities may also impact drug disposition and response. More evidence-
based dosing regimens can be derived only if the effect of factors such as inflammation, 
disease state and genetics on pharmacokinetics as well as pharmacodynamics is known.
The aims of this thesis were: 
1.   To study the influence of critical illness (inflammation and disease state) in children 
on midazolam pharmacokinetics, as a surrogate measure of CYP3A activity. 
2.  To study the safety and efficacy of daily sedation interruption in critically ill children.
Pharmacokinetics in pediatric critical illness - midazolam as CYP3A probe
Previous studies on the effect of inflammation on drug metabolism and drug effect are 
discussed in chapter 2. This review showed that in vitro, animal and few human studies 
have reported alterations in drug metabolism and the pharmacokinetics of drugs in the 
presence of inflammation. Two studies in critically ill children demonstrated a significant 
effect of inflammation on drug metabolism, with a decrease in drug clearance of up 
to 75%. Pharmacokinetic studies of midazolam showed that average midazolam clear-
ance is considerably lower in critically ill children compared with healthy children of the 
same age. It is speculated that this large difference can be explained by inflammation-
mediated downregulation of CYP3A metabolism, which largely determine midazolam 
clearance. Little is known on the clinical implications of these changes for drug dosing, 
and pharmacodynamic data in children are lacking.
The pilot study described in chapter 3 suggests that severity of organ failure in criti-
cally ill children, as reflected by the Pediatric Logistic Organ Dysfunction (PELOD) score, 
affects the clearance of midazolam, most likely as a result of reduced activity of CYP3A. 
This severity is not related, however, to decreased dose requirements of midazolam as a 
surrogate pharmacodynamic marker.
These observations prompted the study presented in chapter 4, a prospective popula-
tion pharmacokinetic study on the effect of critical illness in 83 children. We found that, 
in addition to body weight, both inflammation, as reflected by C-reactive protein or 
180
interleukin-6, and organ failure significantly affected midazolam clearance. Simulations 
show that a C-reactive protein of 300 mg/L in comparison to 10 mg/L is associated with 
a 65% lower clearance and that three failing organs is associated with a 35% lower clear-
ance compared to one failing organ. The combination of increased C-reactive protein 
and multiple failing organs can even lead to up to 77% lower midazolam clearance. 
Most likely this effect is due to inflammation-mediated downregulation of CYP3A activ-
ity, which may be amplified by critical illness related reduced hepatic blood flow. These 
observations are of concern as they suggest that critically ill children are at increased 
risk for toxicity by CYP3A metabolized drugs given at normal doses.
Pharmacodynamics in pediatric critical illness – midazolam as sedative
The provision of adequate sedation to critically ill children is an important aspect of care 
in the pediatric intensive care unit. To achieve optimal sedation in individual patients, 
doses of sedatives are titrated to effect. However, this endpoint if often not obtained. 
The systematic review presented in chapter 5 showed that critically ill children are un-
dersedated in 10.6% of the assessments and oversedated in 31.8% of the assessments.
Both under- and oversedation may have negative effects. Oversedation delays recovery, 
as greater sedatives consumption is associated with longer duration of ventilation as 
well as extubation failure. Oversedation also induces tolerance and withdrawal syn-
drome. Undersedation, on the other hand, may lead to increased distress and adverse 
events such as unintentional extubation or displacement of catheters. This may also 
lead to a longer ICU stay. With the risks of oversedation and the difficulties of reaching 
adequate sedation in mind, the question was raised whether daily sedation interruption 
in critically ill children might be beneficial. Chapter 6 describes the study protocol of 
a multicenter randomized controlled trial to compare daily sedation interruption plus 
protocolized sedation to protocolized sedation only. The results of this study are pre-
sented in chapters 7 and 8. Daily interruption of sedation did not reduce the duration 
of mechanical ventilation, length of stay, or the amounts of sedative drugs administered, 
but was associated with a higher 30-day mortality. In addition, daily sedation interrup-
tion did not seem to have an effect on the children’s short-term health-related quality 
of life. Therefore, we concluded that daily sedation interruption in critically ill children 
cannot be recommended.
In chapter 9 the results of our studies are discussed and recommendations for future re-
search are given. We conclude that besides body weight, inflammation and organ failure 
significantly affect midazolam clearance in critically ill children and that they are at an 
increased risk of drug toxicity or therapy failure when receiving CYP3A substrate drugs. 
Future studies need to confirm whether the effect of critical illness can also be applied 
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to other CYP3A metabolized drugs and, next, to other CYP enzymes and their substrates. 
Also, the effect of critical illness in relation to the pharmacokinetic-pharmacodynamic 
relationship of CYP3A drugs needs to be studied. We also conclude that there is no 
short term or long term beneficial effect of daily sedation interruption in addition to 
protocolized sedation for critically ill children.
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sAmeNVATTINg
Een ernstig ziek kind dat op een intensive care afdeling ligt, krijgt gemiddeld tien ver-
schillende medicijnen toegediend. Ondanks het veelvuldig gebruik, is de werkzaamheid 
en veiligheid van deze medicijnen bij kinderen vaak niet goed onderzocht. Doseerad-
viezen zijn doorgaans empirisch, waarbij de dosering voor het kind is afgeleid van de 
dosering voor volwassenen. Hierbij wordt geen rekening gehouden met de groei en 
ontwikkeling van het kind en de fysiologische verschillen tussen kinderen en volwasse-
nen. Deze methode kan daarom leiden tot over- of onderdosering van geneesmiddelen.
Het bepalen van de juiste dosering voor ernstig zieke kinderen is een extra uitdaging. 
Naast de leeftijdsafhankelijke veranderingen in geneesmiddelmetabolisme en nierfunc-
tie, hebben de ziekte zelf en de gegeven therapie ook invloed op de farmacokinetiek en 
werking van een geneesmiddel. Over het effect van factoren als inflammatie en ziekte 
op de farmacokinetiek en farmacodynamiek is nog weinig bekend. Meer kennis daarvan 
is nodig om tot een juiste dosering bij ernstig zieke kinderen te komen.
In dit proefschrift hebben we het volgende onderzocht:
1. het effect van inflammatie en ziekte op de farmacokinetiek van het slaapmedicijn 
midazolam, waarbij de omzetting van midazolam een surrogaat is voor de activiteit 
van het enzym CYP3A.
2. de veiligheid en effectiviteit van het dagelijks onderbreken van sedatie (slaapmedi-
catie) bij ernstig zieke kinderen.
Farmacokinetiek bij ernstig zieke kinderen – midazolam als CYP3A probe
hoofdstuk 2 geeft een overzicht van de literatuur op het gebied van inflammatie en 
geneesmiddel metabolisme. Hieruit blijkt dat in vitro-, dier- en enkele studies in mensen 
een afname laten zien van de activiteit van metaboliserende enzymen en een verande-
rende farmacokinetiek ten tijde van inflammatie. Bij ernstig zieke kinderen zijn twee stu-
dies verricht die laten zien dat de klaring van een geneesmiddel tot 75% is afgenomen 
wanneer er sprake is van inflammatie. Farmacokinetiek studies van midazolam laten 
zien dat de gemiddelde midazolam klaring veel lager is bij ernstig zieke kinderen dan 
bij relatief gezonde kinderen van dezelfde leeftijd. Wij veronderstellen dat dit verschil 
wordt veroorzaakt door een afname van CYP3A metabolisme. Er is niet veel bekend over 
de klinische gevolgen hiervan en farmacodynamische studies ontbreken.
Het onderzoek beschreven in hoofdstuk 3 laat zien dat bij ernstig zieke kinderen, de 
ernst van orgaanfalen, welke beschreven wordt met de Pediatric Logistic Organ Dysfunc-
tion (PELOD) score, invloed heeft op de klaring van midazolam. Meest waarschijnlijk komt 
dit door een afname van de activiteit van het enzym CYP3A. De ernst van orgaanfalen 
is echter niet gerelateerd aan een afname in de hoeveelheid midazolam die nodig was.
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Deze bevindingen waren de aanleiding voor de studie beschreven in hoofdstuk 4. In 
dit hoofdstuk bespreken we een prospectieve populatie farmacokinetiek studie naar 
het effect van ernstige ziekte bij 83 kinderen. We vonden dat inflammatie (weerspiegeld 
door het ontstekingseiwit C-reactief proteïne of interleukine-6) en orgaanfalen, naast 
het lichaamsgewicht, de klaring van midazolam sterk beïnvloeden. Simulaties laten zien 
dat wanneer een kind een C-reactief proteïne van 300 mg/L heeft, dit geassocieerd is 
met een 65% lagere klaring in vergelijking met een C-reactief proteïne van 10 mg/L. Als 
een kind drie falende organen heeft, is dit geassocieerd met een 35% lagere klaring in 
vergelijking met één falend orgaan. De combinatie van een verhoogd C-reactief pro-
teïne en meerdere falende organen kan leiden tot een 77% lagere midazolam klaring. 
Meest waarschijnlijk is dit het gevolg van een inflammatie-gemedieerde afname van 
CYP3A activiteit, welke versterkt wordt door een verminderde bloedstroom in de lever 
tijdens ernstige ziekte. Deze observaties zijn van belang, omdat ernstig zieke kinderen 
bij de nu gebruikte dosering mogelijk een verhoogd risico hebben op bijwerkingen van 
geneesmiddelen die door CYP3A gemetaboliseerd worden.
Farmacodynamiek bij ernstig zieke kinderen – midazolam als sedativum
Ernstig zieke kinderen die op een intensive care liggen, krijgen regelmatig kalmerende 
middelen (sedativa, zoals midazolam) om discomfort en onrust te voorkomen. Adequate 
sedatie is heel belangrijk. Om optimale sedatie te bereiken, wordt de dosering individu-
eel aangepast en wordt gekeken naar het effect (diepte van sedatie). Desalniettemin 
wordt ‘optimale sedatie’ vaak niet bereikt. In hoofdstuk 5 laten we zien dat in 10.6% van 
de observaties een kind onvoldoende gesedeerd is (ondersedatie) en in 31.8% van de 
observaties een kind te diep gesedeerd is (oversedatie).
Zowel over- als ondersedatie kan leiden tot complicaties. Oversedatie vertraagt het 
herstel; het geven van meer sedatie is geassocieerd met een langere beademingsduur. 
Oversedatie kan ook tolerantie en ontwenningsverschijnselen veroorzaken. Daarente-
gen kan ondersedatie leiden tot discomfort en ongewenste gebeurtenissen, zoals het 
uittrekken van een beademingsbuis, infuus of katheter met als mogelijk gevolg ook een 
langere ligduur op de intensive care. Met de risico’s van oversedatie in gedachte, kwam 
de vraag op of het dagelijks onderbreken van sedatie bij ernstig zieke kinderen beter 
zou zijn.
In hoofdstuk 6 beschrijven wij het onderzoeksprotocol voor een multicenter gerando-
miseerd onderzoek waarin het dagelijks onderbreken van sedatie in combinatie met 
geprotocolleerde sedatie wordt vergeleken met geprotocolleerde sedatie alleen. De 
resultaten van dit onderzoek staan beschreven in hoofdstuk 7 en 8. Dagelijkse onder-
breking van sedatie heeft niet geleid tot een kortere beademingsduur, ligduur op de 
intensive care of een afname in de hoeveelheid gegeven sedatie, maar was geassocieerd 
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met een verhoogde mortaliteit op 30 dagen. Hiernaast had het dagelijks onderbreken 
van sedatie geen effect op de kwaliteit van leven van de kinderen na twee maanden. 
Daarom bevelen wij het dagelijks onderbreken van sedatie bij ernstig zieke kinderen 
niet aan.
In hoofdstuk 9 worden de resultaten van onze studies bediscussieerd en aanbevelingen 
gedaan voor toekomstig onderzoek. We concluderen dat inflammatie en orgaanfalen, 
naast lichaamsgewicht, van invloed zijn op de klaring van midazolam bij ernstig zieke 
kinderen. Hierdoor ontstaat een verhoogd risico op bijwerkingen of het falen van de 
therapie bij het geven van geneesmiddelen die via CYP3A worden gemetaboliseerd. 
Toekomstige onderzoeken moeten laten zien of het effect van ziekte ook geldt voor 
andere CYP3A-gemetaboliseerde medicijnen en, vervolgens, ook voor geneesmiddelen 
die via andere CYP enzymen worden omgezet. Ook moet onderzocht worden wat het 
effect van ziekte is op de farmacokinetiek-farmacodynamiek relatie.
We concluderen ook dat er geen gunstige korte en langere termijn effecten zijn van 
het dagelijks onderbreken van sedatie als toevoeging op geprotocolleerde sedatie bij 
ernstig zieke kinderen.
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